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The antibody Fc region is critical for the therapeutic potency by virtue of its role 
in recruiting and activating the cytotoxic pathways of immune cells, complement 
activation and its role in antibody homeostasis (a process mediated by the pH dependent 
binding to the neonatal receptor FcRn). Bacterially produced antibodies lack of 
glycosylation at Asn297 and therefore do not bind to the surface FcγRs on effector innate 
immune cells, nor can they activate complement. This dissertation describes the 
engineering of aglycosylated bacterially expressed antibodies for binding to a specific 
FcγR and therefore eliciting therapeutically relevant effector functions. Aglycosylated Fc 
mutants that bind to desired Fc binding ligands were isolated by a new E. coli 
homodimeric Fc display system coupled with high throughput flow cytometry. Two 
amino acids mutation in the CH3 domain (Fc5) conferred selectively high binding 
affinity of aglycosylated Fc domains to the FcγRI receptor. Flow cytometry screening 
from a randomized Fc5 library resulted in the isolation of Fc mutants exhibiting higher 
  
viii 
affinity binding to FcγRI receptor than the Fc5. Aglycosylated FcγRI specific IgG 
containing the variable regions of the clinically important anti-Her2 antibody trastuzumab 
elicited dendritic cell-mediated ADCC in sharp contrast to the clinical grade trastuzumab 
(Herceptin) or the glycosylated coutreparts of the engineered antibodies, neither of which 
could potentiate target cell lysis with dendritic cells as effectors. In separate studies, a 
system was developed for the screening of periplasmically anchored E. coli libraries and 
the isolation of clones expressing antibodies that are specific to insoluble antigens or to 
cell surface markers. Following three rounds of flow cytometric screening, spheroplasts 
expressing specific scFvs were enriched 950-fold from a large excess (1,000x) of 
spheroplasts expressing nonspecific antibodies. 
 
  
ix
Table of Contents 
List of Tables .................................................................................................................. xiv 
List of Figures .................................................................................................................. xv 
Chapter 1: Introduction and Background ...................................................................... 1 
1. 1 Introduction ........................................................................................................... 1 
1. 2 Background ........................................................................................................... 3 
1.2.1 Structure and function of immunoglobulin and Fc ...................................... 3 
1.2.2 Human Fc receptors ..................................................................................... 7 
1.2.2.1 Human FcγR ...................................................................................... 7 
1.2.2.2 Human FcRn ..................................................................................... 9 
1.2.3 Engineering of monoclonal antibodies ...................................................... 10 
1.2.3.1 Engineering the Fc domain for improved antibody dependent 
cellular cytotoxicity (ADCC) ...................................................................... 10 
1.2.3.2 Engineering of the Fc domain for improved pharmacokinetics ...... 13 
1.2.4 Antibody display systems for directed evolution ...................................... 15 
1.3 Research objectives ............................................................................................. 16 
Chapter 2: Engineered, Bacterially Expressed, IgG Antibodies Displaying Selective 
Binding to Effector FcγRI Receptors ............................................................................ 19 
2.1 Introduction .......................................................................................................... 19 
2.2 Materials and methods ......................................................................................... 22 
2.2.1 Molecular biology techniques ................................................................... 22 
2.2.2 FACS analysis and library screening ........................................................ 24 
  
x
2.2.3 Expression and purification of Fc proteins ................................................ 26 
2.2.4 Preparative expression and purification of IgG ......................................... 26 
2.2.5 ELISA assays ............................................................................................. 28 
2.2.6 BIAcore analysis for Fc mutants and Herceptin IgG1 Fc mutants ............ 29 
2.3 Results.................................................................................................................. 33 
2.3.1 Bacterial display of aglycosylated functional homodimeric Fc domains .. 36 
2.3.2 Isolation of mutants aglycosylated Fc fragments exhibiting FcγRI binding
 ............................................................................................................................ 43 
2.3.3 Expression of homodimeric Fc domains in E. coli and characterization of 
affinity to FcγRI ................................................................................................. 46 
2.3.4 Expression of aglycosylated trastuzumab in E. coli .................................. 52 
2.4 Discussion ............................................................................................................ 55 
Chapter 3: Engineering of Aglycosylated Fc5 for Improved Effector Functions ..... 55 
3.1 Introduction .......................................................................................................... 55 
3.2 Materials and methods ......................................................................................... 57 
3.2.1 Error prone PCR library for engineering aglycosylated IgG-Fc5 ............. 57 
3.2.2 Construction of upper CH2 region randomization library ........................ 58 
3.2.3 Spheroplasting and flow cytometry screening for affinity maturation of 
Fc5 ...................................................................................................................... 60 
3.2.4 Expression and purification of aglycosylated trastuzumab antibodies ...... 60 
3.2.5 BIAcore analysis for aglycosylated trastuzumab antibodies to FcγRI ...... 62 
3.2.6 ELISA analysis to measure the affinity of trastuzumab antibodies to Fc 
receptors ............................................................................................................. 63 
  
xi
3.2.7 Preparation of human monocyte-derived dendritic cells (mDCs) ............. 64 
3.2.8 ADCC assays ............................................................................................. 65 
3.3 Results.................................................................................................................. 68 
3.3.1 Isolation of aglycosylated Fc mutants exhibiting higher affinity to FcγRI 
binding compared to Fc5 .................................................................................... 68 
3.3.2 Characterization of aglycosylated trastuzumab-Fc601 in E. coli .............. 76 
3.3.3 mDC mediated tumor cells killing by aglycosylated trastuzumab-Fc5 and 
trasutuzumab-Fc601 ........................................................................................... 81 
3.3.4 Isolation of aglycosylated Fc mutants exhibiting higher affinity to FcγRI 
binding than Fc5 with retaining pH dependent FcRn binding ........................... 84 
3.3.5 Characterization of aglycosylated trastuzumab-Fc701 ............................. 88 
3.4 Discussion ............................................................................................................ 92 
Chapter 4: Development of high-throughput antibody screening system for 
immobilized antigen ........................................................................................................ 95 
4.1 Introduction .......................................................................................................... 95 
4.2 Materials and methods ......................................................................................... 99 
4.2.1 Reagents .................................................................................................... 99 
4.2.2 Construction of plasmids for anchored antibody and GFP ....................... 99 
4.2.3 Digoxigenin immobilization onto beads ................................................. 100 
4.2.4 Culture conditions ................................................................................... 101 
4.2.5 Preparation of spheroplasts and FC analysis ........................................... 101 
4.2.6 Spheroplast enrichment onto beads with immobilized digoxigenin ........ 102 
4.3 Results................................................................................................................ 105 
  
xii
4.3.1 Display of scFv antibodies on E. coli inner membrane ........................... 105 
4.3.2 Binding of spheroplasts on the antigen immobilized beads .................... 108 
4.3.3 Enrichment of 26-10 scFv anchoring spheroplasts ................................. 110 
4.4 Discussion .......................................................................................................... 112 
Chapter5: Conclusion and Recommendations ........................................................... 116 
5.1 Conclusion ......................................................................................................... 116 
5.2 Recommendations .............................................................................................. 118 
Appendix 1: Bacterally Expressed Aglycosylated Fc Receptors .............................. 121 
A1.1 Introduction ..................................................................................................... 121 
A1.2 Materials and methods .................................................................................... 122 
A1.2.1 Construction of plasmids for the expression of FcγRs ......................... 122 
A1.2.2 Expression and purification of of FcγRs .............................................. 123 
A1.2.3 ELISA analysis ..................................................................................... 123 
A1.3 Results ............................................................................................................. 127 
A1.3.1 Expression of aglycosylated FcγRs in E. coli ....................................... 128 
A1.3.2 Purification and of refolding FcγRs ...................................................... 131 
A1.3.3 Affinity of aglycosylated FcγRs ........................................................... 132 
A1.4 Discussion ....................................................................................................... 134 
Appendix 2: Development of covalently anchored full length IgG display system 134 
A2.1 Introduction ..................................................................................................... 134 
A2.2 Materials and methods .................................................................................... 136 
A2.2.1 Solube expression and purification of homodimeric wild type Fc and 
Fc2a fragments ................................................................................................. 136 
  
xiii 
A2.2.2 Production and purification of full length aglycosylated trastuzumab 
IgG1 and aglycosylated trastuzumab-Fc2a ...................................................... 137 
A2.2.3 ELISA analysis ..................................................................................... 139 
A2.2.4. Construction of plasmids for covalently anchored full length IgG display 
system ............................................................................................................... 140 
A2.2.5 Preparation of spheroplasts and FACS analysis ................................... 141 
A2.3 Reuslts ............................................................................................................. 145 
A2.3.1 Affinity of Fc2a (S298G/T299A) and trastuzumab-Fc2a to human 
FcγRIIa ............................................................................................................. 145 
A2.3.2 FACS analysis for the covalently anchored full length IgG display 
system to engineer IgG heavy chain ................................................................. 147 
A2.4 Discussion ....................................................................................................... 152 
Appendix 3: E. coli 2 Hybrid Systems for Engineering of Aglycosylated Antibody Fc
......................................................................................................................................... 154 
A3.1 Introduction ..................................................................................................... 154 
A3.2. Materials and methods ................................................................................... 155 
A3.2.1 Reagents ................................................................................................ 155 
A3.2.2 Construction of plasmids for the display of homodimeric IgG-Fc ....... 155 
A3.2.3 Culture conditions for two plasmids system ......................................... 158 
A3.3 Results ............................................................................................................. 162 
A3.4 Discussion ....................................................................................................... 167 
Bibliography .................................................................................................................. 168 
Vita ................................................................................................................................. 181 
  
xiv
List of Tables 
Table 2-1. Plasmids used in this study…………………………………………………..31 
Table 2-2. Primers used in this study …………………………………………………...32 
Table 2-3. Kinetic rates and equilibrium dissociation constants of isolated Fc mutants 
determined by BIACore analysis..………......…………………………………………...46 
Table 2.4. Kinetic rates and equilibrium dissociation constants of trastuzumab antibodies 
determined by BIACore analysis..……………………………………………………….49 
Table 3-1. Plasmids used in this study…………………………………………………..66 
Table 3-2. Primers used in this study……………………………………………………67 
Table 3.3. Kinetic rates and equilibrium dissociation constants obtained by BIACore 
analysis for binding to FcγRI…………………………………………………………….78 
Table 3.4. Kinetic rates and equilibrium dissociation constants for trastuzumab 
antibodies obtained by BIACore analysis for binding to FcγRI…………………………89 
Table 4-1. Plasmids used in this study…………………………………………………104 
Table 4-2. Primers used in this study…………………………………………………..105 
Table 4-3. Enrichment obtained by sorting of 26-10 and M18 scFv mixture (1:1,000).111 
Table A1-1. Plasmids used in this study……………………………………………….124 
Table A1-2. Primers used in this study………………………………………………...125 
Table A2-1. Primers used in this study………………………………………………...143 
Table A2-2. Plasmids used in this study……………………………………………….144 
Table A3-1. Plasmids used in this study……………………………………………….160 
Table A3-2. Primers used in this study….......................................................................161 
  
xv
List of Figures 
Figure 1-1. Comparison of protein expression systems…………………………………..2 
Figure 1-2. Structure of IgG and Fc region of the IgG…………………………………...5 
Figure 1-3. Carbohydrate sequence linked at the Asn297………….…………………….6 
Figure 1-4. Human Fc receptors………………………………………………………….7 
Figure 2-1. Binding epitopes of FcγR proteins and C1q on IgG-Fc…………………….21 
Figure 2-2. Schematic diagram showing the display system……………………………22 
Figure 2-3. Expression cassette for periplasmic display of Fc………………………….35 
Figure 2-4. Effect of trehalose on periplasmic display of Fc…......……………………..35 
Figure 2-5. Fluorescence histogram of spheroplasted cells from different rounds of 
sorting labeled with FcγRI-FITC..……………………………………………………….37 
Figure 2-6. Fluorescence histogram of spheroplasted cells expressing either wt IgG Fc 
protein or high fluorescence mutants isolated from the fourth round……………………38 
Figure 2-7. Protein sequences of isolated Fc mutant clones exhibiting high affinity to 
FcγRI..……………………………………………………………………………………39 
Figure 2-8. Location of mutations for isolated aglycosylated Fc domains displayed FcγRI 
binding, in the 3D structure of glycosylated IgG (PBD Code: 1FC1)…………………...40  
Figure 2-9. Saturation mutagenesis of a.a. 382 and 428 and adjacent residues in Fc…...41 
Figure 2-10. Screening of the saturation library for high affinity Fcs to FcγRI..……….41 
Figure 2-11. Protein sequences of isolated Fc mutants from the saturation library..........42 
Figure 2-12. Expression cassette for DsbA leader peptide fused aglycosylated Fc…….44 
Figure 2-13. Effect of signal peptide on the soluble expression of Fc proteins…………44 
  
xvi
Figure 2-14. Preparative expression of Fc proteins in shake flasks……………………..44 
Figure 2-15. Purified wt Fc and high affinity Fc mutant proteins ....…………………...45 
Figure 2-16. ELISA result of the purified aglycosylated wild type Fc, Fc5, Fc11, and 
Fc49………………………………………………………………………………………45 
Figure 2-17. Map of plasmid pSTJ4-Herceptin IgG1…………………………………...47 
Figure 2-18. Example of fed-batch fermentation for the production of aglycosylated 
trastuzumab or aglycosylated trastuzumab-Fc5 in a 3.3 L fermentor……………………48 
Figure 2-19. Expression and purification of aglycosylated wild type or engineered 
trastuzumab antibodies…………………………………………………………………...48 
Figure 2-20. Biacore sensorgrams for aglycosylated and glycosylated trastuzumab 
antibodies…………………...............................................................................................49 
Figure 2-21. ELISA assays for binding to FcγRIIa-GST………………………………..50 
Figure 2-22. ELISA assays for binding to FcγRIIb-GST.………………………………50 
Figure 2-23. ELISA assays for pH dependent binding to FcRn. ……………………….51 
Figure 3-1. Mutation points of isolated aglycosylated Fc5 (382E and 428M) represented 
on the 3D structure of glycosylated IgG1 Fc (PBD Code: 1FC1)……………………….69 
Figure 3-2.  The location of 382E in β-sheet C and 428M in β-sheet F of CH3 domain 
represented on the crystal structure of glycosylated IgG. (PBD Code: 1FC1)…………..70 
Figure 3-3. Error prone PCR library for engineering aglycosylated Fc5 domain……….71 
Figure 3-4. Fluorescence histogram of spheroplasts labeled with FcγRI-FITC showing 
the enrichment by series rounds of FACS sorting……………………………………….71 
Figure 3-5. Protein sequences of isolated Fc mutant clones exhibiting higher affinity to 
FcγRI than Fc5…………………………………………………………………………...72 
  
xvii
Figure 3-6. Amino acid substitutions in variants Fc601-619 represented on the 3D 
structure of glycosylated IgG1 Fc (PBD Code: 1FC1)…………………………………..73 
Figure 3-7. Fluorescence histogram of spheroplasts expressing wild type Fc, Fc5, or 
Fc601 labeled with 30 nM of FcγRI-FITC……..………………………………………..74 
Figure 3-8. Amino acid substitutions in Fc601 (K338R, G341V, E382V, M428I) 
represented on the 3D structure of glycosylated IgG1 Fc (PBD Code: 1FC1)…………..75 
Figure 3-9. Map of plasmid pSTJ4-Herceptin IgG1…………………………………….77 
Figure 3-10. BIACore sensorgram for aglycosylated trastuzumab (A) and aglycosylated 
trastuzumab-Fc601 (B)…………………………………………………………………..78 
Figure 3-11. ELISA assays for binding of trastuzumab antibodies to FcγRIIa-GST…...79 
Figure 3-12. ELISA assays for binding of trastuzumab antibodies to FcγRIIb-GST…...79 
Figure 3-13. ELISA assays for binding of trastuzumab antibodies to FcγRIIIa………...80 
Figure 3-14. ELISA assays for pH dependent binding to FcRn at pH 7.4 and 6.0……...80 
Figure 3-15. Flow cytometry histogram showing the expression of CD11c on activated 
DCs…………………………………………………… ….…………………………......82 
Figure 3-16. Flow cytometry histogram showing the expression of FcγRI on activated 
DCs…………………………………………………………………………………….82 
Figure. 3-17. Antibody dependent cellular cytotoxicity (ADCC) induced by engineered 
aglycosylated Fc antibodies……………………………………………………………...83 
Figure 3-18. Library for the selection of higher affinity Fc fragments to FcγRI than Fc5 
with pH dependent FcRn binding………………………………………………………..85 
Figure 3-19. Protein sequences of isolated Fc mutant clones exhibiting higher affinity to 
FcγRI than Fc5…...............................................................................................................85 
  
xviii 
Figure 3-20. Summary of mutations in Fc701 – 709……………………………………86 
Figure 3-21. Fluorescence histogram of spheroplasted cells for wild type Fc, Fc5, Fc701, 
and Fc702 labeled with 1 nM of FcγRI-FITC….………….………………………….....86 
Figure 3-22. Fluorescence histogram of spheroplasted cells displaying wild type Fc, Fc5, 
Fc601, and Fc701 after labeling with 1 nM of FcγRI-FITC....…………………………..87 
Figure 3-23. Mutation points of isolated aglycosylated Fc701 represented on the 3D 
structure of glycosylated IgG1 Fc (PBD Code: 1FC1)…………………………………..87 
Figure 3-24. BIAcore sensorgrams of aglycosylated trastuzumab-Fc701 antibody with 
binding to FcγRI…………………………………………………………………………89 
Figure 3-25. ELISA assays for pH dependent binding to FcRn at pH 6.0 and 7.4 ..........90 
Figure 3-26. ELISA assays for binding of trastuzumab antibodies to FcγRIIa-GST…...90 
Figure 3-27. ELISA assays for binding of trastuzumab antibodies to FcγRIIb-GST…...91 
Figure 3-28. ELISA assays for binding of trastuzumab antibodies to FcγRIIIa………...91 
Figure 4-1. Selection of APEx spheroplasts via antibody-antigen interactions…………98 
Figure 4-2. Inner Membrane anchoring of scFvs display……………………………...107 
Figure 4-3. FC analysis of spheroplasts with beads containing immobilized 
antigen…………………………………………………………………………………..109 
Figure 4-4. Enrichment of 26-10 scFv clones from a 1,000 excess of M18 scFv-gp3 by 
binding to beads with immobilized digoxigenin………………………………………..111 
Figure A1-1. Gene casettes for the expression of FcγRIIa, FcγRIIb, and FcγRIIIa…...128 
Figure A1-2. Expression of FcγRIIa, FcγRIIb, and FcγRIIIa………………………….129 
  
xix
Figure A1-3. Western blot showing the expression of FcγRI depending on the codon 
optimization, the terminal tag location, and the various DE3 lysogen containing E. coli 
strains…………………………………………………………………………………...130 
Figure A1-4. SDS-PAGE showing the purified Fc receptors.………………………....131 
Figure A1-5. ELISA assays for purified FcγRs (FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa).132 
Figure A2-1. Purified wild type Fc and Fc2a proteins. ………………………………..146 
Figure A2-2. ELISA assays showing the affinity of aglycosylated Fc fragment (Fc2a) 
and aglycosylated full length trastuzumab-Fc2a to FcγRIIa……………………………146 
Figure A2-3. Covalently anchored full length IgG display system …...………………147 
Figure A2-4. Fluorescence histograms showing the binding of FcγRI using either the 2- 
plasmid system or the dicistronic system……………………………………………….149 
Figure A2-5. Fluorescence histograms showing the binding of FcγRIIa using either the 
2-plasmid system or the dicistronic system…….………………………………………150 
Figure A2-6. FACS analysis of cells displaying covalently anchored full length IgG 
expressed by 2 plasmids and bound by FcγRI………………………………………….151 
Figure A2-7. FACS analysis of cells displaying covalently anchored full length IgG 
expressed by 2 plasmids and bound by FcγRIIa ……….……………………..………..151 
Figure A3-1. Two plasmids system for the periplasmic display of Fc using cJun-cFos or 
cJun(Cys)-cFos(Cys) interaction……………………………………………………….164 
Figure A3-2. FACS analysis results of periplasmic displayed Fc homodimer using cJun-
cFos and cJun(Cys)-cFos(Cys) interaction pairs……………………………………….165 
Figure A3-3. Two plasmids system for the periplasmic display of Fc using ColE2-Im2 
interaction………………………………………………………………………………166 
  
xx
Figure A3-4. Effect of ColE2 on the expression of target proteins, M18 scFv (Lane 1-3), 
26-10 scFv (Lane 4-6), and Fc (Lane 7-9)……………………………………………...166 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
1
Chapter 1 
Introduction and Background 
1. 1 INTRODUCTION 
Currently, more than 20 monoclonal antibodies have been approved (Chames et 
al., 2009; Wang et al., 2007), and more than one hundred antibody drugs are in the 
clinical trial pipeline (Dimitrov and Marks, 2009; Reichert et al., 2005). Monoclonal 
antibodies currently constitute about a quarter of all biopharmaceutical products 
(Schrama et al., 2006). The market has expanded since the approval of the first 
monoclonal antibody product in 1986 and is forecasted to reach $26 billion in sales by 
2010 (Chames et al., 2009). 
Antibodies function by recognizing target cells through their so-called variable 
region which differs from antibody to antibody. In addition, the constant region of the 
antibody molecule binds to receptors present on a variety of immune cells. Antibodies 
bound on the surface of a target cell recruit leukocytes (white blood cells) which in turn 
destroy the target via a variety of mechanisms. The ability of antibodies to recruit cells is 
termed “the effector function” of the antibody and depends critically on the presence of a 
carbohydrate moiety attached to Asn297 in the constant region. In its absence, antibodies 
exhibit no binding to immune cells and thus do not display effector functions. 
 While antibody molecules can be expressed in different hosts (Fig. 1-1), 
expression in mammalian cells is necessary for proper glycosylation that gives desirable 
effector functions. From a production standpoint, antibodies produced in mammalian 
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cells are expensive and time consuming to produce. Also, heterogeneity of antibody 
carbohydrate structures causes loss of efficacy and problems in product quality control. 
Alternatively, expression in bacteria allows production of antibodies in a host 
cell with tractable genetics, ease of genetic manipulation, rapid expression, low cost, and 
high yield, and facile scale-up. Two major drawbacks of bacterial systems for antibody 
production are the potential for improper folding and lack of glycosylation machinery. As 
a result, use of bacterial produced antibodies is mostly limited to research or diagnostic 
purposes rather than therapeutic purposes requiring effector functions. To satisfy both 
therapeutic and industrial demands, this dissertation is focused on the development of a 
screening system for bacterial produced aglycosylated Fc domains and on the isolation of 
engineered aglycosylated IgGs showing high effector functions. 
 
 
 
Figure 1-1. Comparison of protein expression systems. Hosts for protein expression 
including mammalian cells, insect cells, transgenics, plant cells, yeast, and bacteria were 
compared in the aspect of speed, cost, glycosylation, protein folding, and drug 
registration (Cox, 2004). 
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1. 2 BACKGROUND 
 1.2.1 Structure and function of immunoglobulin and Fc  
Immunoglobulins, or antibodies, are globular glycoproteins involved in humoral 
immunity. The protein backbone of antibodies is composed of two identical heavy and 
two light polypeptide chains. The immunoglobulins found in human body fluids can be 
divided into five major classes (IgG, IgA, IgM, IgD, and IgE) based on the difference in 
amino acid sequences for the constant regions of the heavy polypeptide chains. IgG, the 
major immunoglobulin making up about 75 percent of the total serum immunoglobulin 
content (McKelvey and Fahey, 1965; Spiegelberg, 1974), recognizes, neutralizes, and 
eliminates foreign pathogens, defective human cells and soluble toxic molecules (Kaneko 
et al., 2006). Until now all of the monoclonal antibody drugs approved by US FDA have 
been of the IgG class. IgG antibodies are further categorized by four distinct subclasses 
(IgG1, IgG2, IgG3, and IgG4) that have distinguishable structural difference in the heavy 
chain polypeptides. Among the four subclasses, the most extensively studied is IgG1 due 
to its high concentration in serum and favorable immunological properties. 
Human IgG molecules (~150 kDa) have a common structure of four polypeptide 
chains comprising two identical heavy (~ 2 × 50 kDa) and two identical light chains (~ 2 
× 25 kDa) combined by inter-chain disulfide bonds (Fig. 1-2A) to form Y shaped 
structure. The heavy chains are constructed of four domains including an N-terminal 
variable domain (VH) and three constant domains CH1, CH2, and C-terminal CH3. The 
light chains are composed of two domains, a variable domain (VL) and a constant 
domain (CL). By proteolytic or functional fragmentation, IgG molecule can be also 
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divided into two identical Fabs (fragment antigen binding) and one Fc (fragment 
crystalizable) fragments. 
The Fab domain is composed of a full light chain (VL and CL) and parts of heavy 
chain (VH and CH1) bridged by a disulfide bond at the carboxy terminal ends of the 
chains. The Fc region is formed by dimerization of CH2, and CH3 domains and has a 
highly conserved amino acid composition. The major function of the Fc is to regulate 
effector functions by binding to immune components proteins such as Fcγ receptors 
(FcγRI, FcγRII, FcγRIII), the serum complement C1q protein, and the neonatal Fc 
receptors (FcRn) (Duncan and Winter, 1988; Ghetie and Ward, 2000; Jefferis et al., 
1998). The native human IgG has two N-linked biantennary oligosaccharide chains 
attached at Asn297 of each CH2 domain. The two carbohydrate chains are located 
between the CH2 domains and interact with hydrophobic parts of the Fc domains (Fig. 1-
2B). The structure of the core carbohydrate residues containing N-acetylglucosamine 
(GlcNAc) and mannose (Man) is highly conserved. Highly variable carbohydrate 
residues including terminal N-acetylneuraminic acid (NeuAc: sialic acid), galactose 
(Gal), bisecting N-acetylglucosamine (GlcNAc) and fucose (Fuc) can be appended to 
these core carbohydrate (Fig. 1-3). Glycan heterogeneity is influenced by many factors 
such as cell line, culture condition, and downstream processing (Wang et al., 2007). 
Currently about 30 different glycan structures resulting in different orientations of CH2 
domain pairing have been characterized (Burton and Dwek, 2006). Effector functions are 
largely dependent on the constituents of the oligosaccharide chains (Jefferis, 2005; 
Wright and Morrison, 1997). 
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A 
 
 
B 
 
 
Figure 1-2. Structure of IgG and Fc region of the IgG. (a) Schematic structure IgG and 
Fc region of the IgG. (b) Crystral structure of homodimeric Fc (PDB: 1FC1). 
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Figure 1-3. Carbohydrate sequence linked at the Asn297 (Jefferis, 2005). 
 
In the absence of glycosylation, the Fc domain is not recognized by the various 
proteins it normally binds to and effector functions are abolished. Lack of glycosylation 
causes reduced binding to FcγRI by 2 orders of magnitude and completely eliminates the 
normally weak binding to FcγRII and FcγRIII (Jefferis, 2005). C1q binding to 
aglycosylated antibody is also reduced by 10-fold (Lund et al., 1996). The FcRn binding 
is not significantly affected by aglycosylation (Jefferis, 2005). It has been also reported 
that the pattern of glycosylation completely determine the ability of antibodies to induce 
or modulate inflammation (Anthony et al., 2008; Kaneko et al., 2006). 
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1.2.2 Human Fc receptors 
   1.2.2.1 Human FcγR  
Human FcγRs (Fc gamma receptor) expressed in most immune cells (van de 
Winkel and Capel, 1993) bridge antibody associated humoral and cellular immune 
responses by binding to the Fc domain of IgG (Berken and Benacerraf, 1966; Ravetch 
and Bolland, 2001). The FcγRs initiate and regulate effector functions including 
phagocytosis, cytokine production, superoxide production, release of serotonin, and 
inhibition of B cell activation (Cohen-Solal et al., 2004). Currently three groups of human 
FcγRs (FcγRI, FcγRII, and FcγRIII) have been categorized based on differences in gene 
sequence, regulation, function, affinity to IgG, and expression in different cells (Ivan and 
Colovai, 2006). Human FcγRs except the FcγRIIIb are type I transmembrane 
glycoproteins (Fig. 1-4). 
 
 
Figure 1-4. Human Fc receptors.  
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FcγRs can be divided into two groups, activating FcγRs and inhibitory FcγRs.  
Activating FcγRs such as FcγRI (CD64), FcγRIIa (CD32a), and FcγRIIIa (CD16a) have 
an Immunoreceptor Tyrosine-based Activation Motif (ITAM) in their cytoplasmic tail 
and trigger activation of immune responses. On the other hand, FcγRIIb (CD32b) has an 
Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) in its cytoplasmic tail and 
downregulates immune responses and therefore it acts as the inhibitory FcγR (Ravetch 
and Bolland, 2001). FcγRI exhibits high affinity to monomeric IgG (Kd = 10-8~10-9 M) 
whereas the affinity of FcγRII and FcγRIII to monomeric IgG is low (Kd = 10-6~10-7 M) 
(Krapp et al., 2003). 
 FcγRI is expressed mainly on monocytes, macrophages, and dendritic cells. Upon 
activation by cytokines such as IFN-γ, IL-10, and G-CSF, it is also expressed on 
neutrophils and eosinophils (Schmidt and Gessner, 2005). Kacskovics proposed that 
FcγRI is important in the early stage immune response when antibody concentration is 
low (Kacskovics, 2004). The binding affinity of the FcγRI to IgG is different depending 
on IgG subclasses. It has high affinity to IgG1 and IgG3 and low affinity to IgG2 and 
IgG4. FcγRIIa found on macrophages, monocytes, dendritic cells, neutrophils, and 
eosinophils activates immune cells (Siberil et al., 2006). Conversely, FcγRIIb expressed 
on B lymphocytes mast cells, macrophages and dendritic cells suppresses immune cells 
while preventing autoimmunity (Cohen-Solal et al., 2004; Ravetch and Lanier, 2000). 
The FcγRIII receptors show low affinity to IgG and are expressed on natural killer (NK) 
cells, T-cells, macrophages, monocytes, mast cells, and dendritic cells and activates 
ADCC (Cohen-Solal et al., 2004). 
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 Among the human FcγRs, the structures for the extracellular domains of FcγRs 
including FcγRIIa [PDB code 1H9V (Sondermann et al., 2001) and 1FCG (Maxwell et 
al., 1999)], FcγRIIb [PDB code 2FCB (Sondermann et al., 1999)], and FcγRIIIb [PDB 
code 1E4J (Sondermann et al., 2000)] have been solved. The structures of FcγRIIIb 
extracellular domain bound to human Fc CH2 region [PDB code 1E4K (Sondermann et 
al., 2000), 1IIS, 1IIX, 1T83, and 1T89 (Radaev et al., 2001)] is also available. However, 
structural information for FcγRI is not available. 
 
  1.2.2.2 Human FcRn 
 The neonatal Fc receptor (FcRn) was identified during studies of neonatal rat 
absorbing maternal immunoglobulins from ingested milk (Brambell et al., 1958; Jones 
and Waldmann, 1972). It is a heterodimer composed of a transmembrane heavy FcRn α 
chain and a β2-microglobulin. The human FcRn α chain has one potential glycosylation 
site (West and Bjorkman, 2000) and is highly homologous to MHC class I α chain in 
sequence and domain structure. The light chain of FcRn, β2-microglobulin does not only 
provide structural support but also contacts the Fc domain of IgG as shown via the crystal 
structure of rat FcRn bound IgG Fc fragments [PDB code 1FRT (Burmeister et al., 
1994b) and 1I1A (Martin et al., 2001)]. 
Two FcRn molecules bind to one Fc homodimer with making 2:1 FcRn-Fc 
complex (Raghavan and Bjorkman, 1996). The binding of FcRn to the Fc domain of IgG 
is strongly pH dependent. It exhibits high affinity under slightly acidic pH condition and 
low affinity at neutral or basic pH (Ober et al., 2004a; Ober et al., 2004b; Raghavan and 
Bjorkman, 1996; Rodewald, 1976). The pH-dependent binding is critically important for 
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the regulation of serum IgG concentration by allowing pinocytosed IgGs to make strong 
IgG-FcRn complexes in acidified endosomes for recycling to blood across vascular 
endothelial cell membrane instead of degradation in lysosomes (Ghetie and Ward, 2000). 
 
 1.2.3 Engineering Fc domain of monoclonal antibodies 
Antibodies are highly specific and can bind to target molecules (antigens) with 
high affinities. Apart from antigen binding, the therapeutic efficacy and pharmacokinetics 
of the monoclonal antibodies are determined by the effector functions triggered by (i) 
binding of the Fc domain to FcγRs for ADCC (Antibody dependent cell mediated 
cytotoxicity) resulting in the elimination of antibody bound target cells by effector 
immune cells, (ii) binding of complement factors for CDC (Complement dependent 
cytotoxicity) which involves the killing of target cells by the immune complement 
system, and (iii) binding of FcRn for the regulation of serum clearance rate. Therefore, 
the effector functions of antibodies can be modulated by regulating affinity of Fc to the 
FcγRs, the complement protein C1q, and to the neonatal Fc receptor.  
 
  1.2.3.1 Engineering the Fc domain for improved antibody dependent cellular 
cytotoxicity (ADCC) 
Various methods have been used to enhance binding of antibodies to FcγRs and 
thus improve ADCC. One approach, termed glycoengineering seeks to optimize the 
composition of the carbohydrate attached to Asn297. Alternatively, protein engineering 
seeks to optimize the sequence of the Fc polypeptide for improved binding (Presta, 
2006). IgG Fc regions produced in animal cells contain an N-linked glycan at Asn297.  
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The carbohydrate sequence can be heterogeneous depending on the type of cells that 
express the antibodies (for in vitro production), culture conditions and the state of the B 
lymphocytes (in animals) (Fig. 1-3). Most of the heterogeneity is derived from terminal 
sialic acid and galactose residues. The carbohydrate structure has an essential function in 
stabilizing the IgG molecule by contributing to structural stability of CH2 and CH3 
regions (Sondermann et al., 2001). It has been reported that truncated or deglycosylated 
antibodies prevent FcγR or C1q binding (Mimura et al., 2001; Radaev and Sun, 2001; 
Simmons et al., 2002).   
Protein engineering that has been employed for the optimization of IgG Fc amino 
acid residues has been performed to improve binding to FcγR. A variety of site directed 
mutation studies showed that the lower hinge region (230-236) is critical for FcγR 
binding (Armour et al., 2003; Duncan et al., 1988; Lund et al., 1991; Shields et al., 2001). 
By making a single mutation (E235L) in mouse IgG2b, Duncan et al. showed 100-fold 
increased binding to FcγRI. Using alanine scanning mutagenesis, Shields et al. identified 
critical amino acids that interact with FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and FcRn. 
Subsequent mutations to non-alanine of some of these critical residues showed improved 
or reduced binding to specific FcγRs individually or simultaneously. Mutants with 
improved binding to activating FcγRs also exhibited enhanced ADCC (Shields et al., 
2001).  
 Lazar et al. selected mutated glycosylated Fc variants using a computational 
design algorithm followed by semi-automated high throughput screening. They isolated 
mutants (S239D/I332E/A330L) and (S239D/I332E) showing enhanced affinity to 
FcγRIIIa and reduced affinity to FcγRIIb. They also showed more than 2 orders of 
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magnitude enhanced in vitro ADCC for the selected mutants (S239D/I332E/A330L and 
S239D/I332E) and in vivo cytotoxicity for the mutant (S239D/I332E) compared to wild 
type IgG (Lazar et al., 2006). Using structure based high throughput mutagenesis, 
Richards et al. isolated a G236A Fc variant displaying selectively high affinity binding to 
FcγRIIa relative to FcγRIIb. The glycosylated Fc variants with the single mutation 
(G236A) showed significantly enhanced antibody dependent cell-mediated phagocytosis 
(ADCP) mediated by macrophages. The combination of this mutation with the previously 
isolated mutations (S239D/I332E) could further improve ADCP and NK cells mediated 
ADCC (Richards et al., 2008). 
 In addition to the structure based approach, a combinatorial screening approach 
using yeast surface displayed Fc library and FACS screening was also employed to 
isolate high affinity glycosylated Fc variants. Stavenhagen et al. used an initial round of 
negative selection of Fc libraries to FcγRIIb immobilized on magnetic beads to recover 
Fc clones not showing high binding affinity to inhibitory FcγRIIb reeptors. Following 
sequential rounds of FACS screening using tetravalent biotinylated FcγRIIIa-
streptavidin-PE (Phycoerythrin) complex, they isolated glycosylated Fc variants 
exhibiting high affinity to FcγRIIIa and low affinity to FcγRIIb. Two Fc variants 
containing either five mutations (F243L/R292P/Y300L/V305I/P396L) or three mutations 
(F243L/R292P/Y300L) showed more than about 100-fold enhanced NK cells mediated 
ADCC (Stavenhagen et al., 2007). 
 Recently, structure-based mutagenesis and, in a separate study, the screening of 
mixture of saturation libraries (amino acid residues at 296-299, 297-299, and 297-300) of 
the FcγRIIa binding epitope within the CH2 C’/E loop by yeast display were used to 
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isolate aglycosyated IgG1 variants lacking N297 or carrying mutations in residues S298 
and T299 that conferred binding to FcγRIIIa or FcγRIIa, respectively (Lazar et al., 2009; 
Sazinsky et al., 2008). However, the antibody variants, expressed in HEK293 or 293T 
cells were also found to also exhibit significant binding to the inhibitory FcγRIIb 
receptor, a result that is not unexpected given the overlap of the binding epitopes and the 
high degree of homology of FcγRIIa and FcγRIIb (Sazinsky et al., 2008). 
   
  1.2.3.2 Engineering of the Fc domain for improved pharmacokinetics 
Site directed mutagenesis, and sequence homology comparison using rodent IgG 
Fc and FcRn led to the identification of critical amino acid residues for the interaction 
between IgG and FcRn (Kim et al., 1994; Medesan et al., 1998; Medesan et al., 1997; 
Medesan et al., 1996). The critical residues (Ile253, His310, and His435) are located at 
the interface of CH2 and CH3 domains, similar to the binding site for staphylococcal 
Protein A (SpA) (Kim et al., 1994; Shields et al., 2001). X-ray crystallographic 
experiments of the rat FcRn bound rat Fc provided important amino acid residues of Fc 
for FcRn binding (Burmeister et al., 1994a; Burmeister et al., 1994b; Martin et al., 2001; 
West and Bjorkman, 2000). 
It has been suggested that engineering of Fc region of the IgG binding to FcRn 
could provide engineered monoclonal antibodies with enhanced pharmacokinetic 
properties (Medesan et al., 1998; Vaughn et al., 1997). Based on the intracellular 
trafficking and recycling mechanisms, engineered IgGs with enhanced affinity to FcRn at 
pH 6.0 while preserving pH dependent binding have been developed and shown to 
  
14
exhibit improved serum persistence (Dall'Acqua et al., 2002; Dall'Acqua et al., 2006; 
Ghetie et al., 1997; Hinton et al., 2006). 
Guided by the crystal structures of rat (Burmeister et al., 1994a) and human 
FcRn (West and Bjorkman, 2000) and by computational modeling of the rat FcRn–rat Fc 
complex (Weng et al., 1998), Hinton et al. substituted three amino acid residues (Thr250, 
Leu314, and Met428) of IgG2 to all the other 19 amino acids and then determined the 
binding to FcRn expressed on the cell surface through competitive binding assays. Two 
mutations (T250Q) and (M428L) increased affinity to FcRn. In a rhesus monkey serum 
stability model, a single mutant (M428L) showed 2-fold longer half-life and a 2.6-fold 
improvement was observed for the double mutant (T250Q/M428L) (Hinton et al., 2004). 
These two mutations were introduced into different IgG subtypes, IgG1 and IgG4. The 
IgG1 mutant (T250Q/M428L) showed ~2.5 fold improved serum half-life in the same 
rhesus monkey model (Hinton et al., 2006). 
Screening of libraries by phage display was employed for the isolation of high 
affinity Fc variants to human FcRn under slightly acidic condition (pH 6.0). A triple 
mutation (M252Y/S254T/T256E) in IgG-Fc at the CH2-CH3 interface enabled about 10-
fold increase in pH dependent FcRn affinity at pH 6.0 and about 4-fold improvement of 
serum half-life in the cynomolgus monkey model (Dall'Acqua et al., 2006; Dall'Acqua et 
al., 2002; Oganesyan et al., 2009). The N434A mutant Fc domain exhibiting increased 
affinity to human FcRn selectively at pH 6.0 could improve about 2 fold in serum half-
life. In contrast, the N434W mutant Fc domain showing improved affinity both at pH 6.0 
and pH 7.4 and did not improve the IgG pharmacokinetics highlighting the critical 
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relationship between pH dependent FcRn binding and serum half life of therapeutic 
antibodies (Yeung et al., 2009). 
 
 1.2.4 Antibody display systems for directed evolution 
 The isolation of antibodies exhibiting high affinity and specificity for target 
antigens is of great importance for numerous aspects of biotechnology ranging from 
proteomics to the development of therapeutics. Starting in the 1980s, the isolation of useful 
recombinant antibody fragments has been greatly facilitated by the introduction of display 
technologies for the screening of large libraries of antibody genes (Hoogenboom, 2005).  
Antibody display systems rely on the establishment of a physical linkage between an 
antibody gene and the antibody itself. In phage display, the first technique used for 
antibody fragment isolation from repertoire libraries, polypeptides are presented on the 
surface of filamentous bacteriophage via fusion to a phage coat protein (Smith, 1985).  
Numerous antibodies to widely diverse antigens have been isolated from either immune 
repertoires or synthetic libraries by employing sequential rounds of filamentous phage 
panning against immobilized antigen (Bradbury and Marks, 2004). Alternatively, very high 
affinity antibodies have been isolated using display on bacteria (Daugherty et al., 2000a; 
Daugherty et al., 2000b; Georgiou et al., 1997; Lofblom et al., 2005) or yeast (Boder et al., 
2000; Boder and Wittrup, 1997; Feldhaus et al., 2003) in conjuction with flow cytometric 
screening for antigen-binding clones (Mattanovich and Borth, 2006). 
Harvey et al. developed a new E. coli protein display system, called Anchored 
Periplasmic Expression (APEx) (Harvey et al., 2004). This technology relies on fusing 
the protein of interest to an inner membrane anchor such as a transmembrane segment of 
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a native inner membrane protein (Jeong et al., 2004), an anchoring motif derived from a 
lipoprotein (Pugsley, 1993; Sankaran and Wu, 1994), or an exogenous protein such as the 
M13 phage coat protein gp3 (Barbas Cf et al., 1991). Spheroplasting using EDTA and 
lysozyme is then used to remove the outer membrane allowing the inner membrane-
anchored polypeptide to interact and bind to desired ligands. The removal of the outer 
membrane eliminates the steric barrier presented by lipopolysaccharide and surface 
carbohydrates and facilitates interactions with much larger soluble ligands, compared to 
bacterial surface display (Harvey et al., 2004). Recently, our lab developed the E-clonal 
system for the display of full length aglycosylated IgG and the isolation of high affinity 
IgGs. In this system, periplasmic expressed full length assembled IgG is captured by an 
APEx displayed Protein A fragment ZZ domain that binds to the Fc region (Mazor et al., 
2007). 
1.3 RESEARCH OBJECTIVES 
 As described in the background, natural monoclonal antibodies exhibit three 
effector functions, antibody dependent cell-mediated cytotoxicity (ADCC), complement 
dependent cytotoxicity (CDC), and regulation of serum half-life. These effector functions 
are keys in determining therapeutic efficacy and pharmacokinetics of antibody drugs. I 
sought to engineer E.coli expressed, aglycosylated antibodies exhibiting high affinity and 
specificity to particular Fc receptors on effector cells. Such engineered aglycosylated 
antibodies are expected to have improved pharmacological efficacy for cancer therapy 
and other purposes and, also can be produced efficiently in bacteria at significantly lower 
costs 
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In chapter 2, a platform tool for library screening and isolation of engineered 
aglycosylated antibodies showing high affinity to Fc binding ligands was developed. The 
system allowed the display of properly folded homodimeric Fc for flow cytometry library 
screening purposes. Engineered aglycosylated Fc domains showing high affinity and 
exquisite selectivity to the extracellular domain of FcγRI were isolated using the 
developed bacterial display system and flow cytometry screening. 
In chapter 3, from a variety of combinatorial Fc mutant libraries, affinity 
maturation was performed to isolate engineered aglycosylated antibodies showing higher 
affinity to FcγRI and improved effector functions compared to the isolated clone (Fc5) 
discussed in chapter 2. The effector function of the isolated Fc engineered antibodies was 
evaluated by monocyte-derived dendritic cells mediated ADCC assays. Also, 
aglycosylated antibodies were isolated both for improved FcγRI binding and for pH 
dependent FcRn binding. 
In chapter 4, for the isolation of antibodies that bind specifically to insoluble 
antigens or receptors expressed on the surface of mammalian cells, a new cell 
(spheroplast)-based method to recognize antigens immobilized on beads was developed. 
Using the system, it was shown that cells displaying antibody specific to immobilized 
antigen can be successfully isolated from a mixture with a large excess of non-specific 
antibody displaying cells. 
To deeply investigate the interaction of FcγRs and antibody IgG, aglycosylated 
FcγRs were expressed in E. coli, purified and refolded. This additional study is described 
in appendix 1. In appendix 2, to engineer aglycosylated Fc domains as full length IgGs, a 
new full length IgG display system was developed. Optimization of expression system 
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and culture conditions enabled robust anchoring of full length IgG on E. coli inner 
membrane as well as good tetrameric assembly of antibody heavy chains and light chains. 
To develop a bacterial display system that is suitable for the isolation of effector 
functional aglycosylated antibody Fc, a variety of 2 hybrid systems were attemped. This 
additional study was described in appendix 3. 
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Chapter 2 
Engineered, Bacterially Expressed, IgG Antibodies Displaying Selective 
Binding to Effector FcγRI Receptors 
2.1 INTRODUCTION 
Fc receptors (FcRs) play an extremely important role in linking the adaptive 
immune system to the effector functions of innate cells in antigen presentation and in 
antibody homeostasis. Humans express six effector FcRs (FcγRI, FcγRIIa, FcγRIIb, 
FcγRIIc, FcγRIIIa, FcγRIIIb) whose activation by binding to immune complexes results 
in phagocytosis, cytokine production, superoxide production, release of serotonin, or 
inhibition of B cell activation (Cohen-Solal et al., 2004; Nimmerjahn and Ravetch, 2008). 
In addition, binding to the FcRn neonatal receptor mediates intracellular trafficking of 
IgG for recycling to blood across vascular endothelial cell membrane instead of 
degradation in lysosomes (Ghetie and Ward, 2000). Human FcγRs, except from 
FcγRIIIb, are type I transmembrane glycoproteins. Activating FcγRs such as FcγRI 
(CD64), FcγRIIa (CD32a), and FcγRIIIa (CD16a) have an Immunoreceptor Tyrosine-
based Activation Motif (ITAM) in their cytoplasmic tail that triggers activation of 
immune responses. On the other hand, FcγRIIb (CD32b) has an Immunoreceptor 
Tyrosine-based Inhibitory Motif (ITIM) in its cytoplasmic tail and downregulates 
immune responses and therefore it acts as an inhibitory FcγR (Ravetch and Bolland, 
2001). The affinity of FcγRII and FcγRIII to monomeric IgG is very low (Kd = 10-6~10-7 
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M) and requires immune compelxed IgG for activation. On the other hand, FcγRI 
exhibits high affinity to monomeric IgG (Kd = 10-8~10-9 M) (Krapp et al., 2003). 
Unlike FcRn, which binds at CH2-CH3 interface regions of the IgG Fc domain 
(Roopenian and Akilesh, 2007) and is not significantly affected by the glycosylation 
status of the antibody, the effector FcγRs interact with the upper CH2 and hinge region 
(Fig. 2-1) in a manner that is critically dependent on the presence and composition of the 
single N-linked glycan attached to Asn297. The glycosylation state of IgG determines its 
affinity for effector FcγRs and thus, modulates the activation of cytotoxic innate immune 
cells (Desjarlais et al., 2007; Jefferis, 2005). In turn, the destruction of target cells, or 
antibody dependent cell-mediated cytotoxicity (ADCC), is important for the clinical 
efficacy and outcomes of widely-used antibody therapeutics (Liu et al., 2008). The 
glycan composition and glycoform heterogeneity, which is intrinsic to the expression of 
antibodies in mammalian cells, has a well-documented effect on the response to widely 
used therapeutics such as Rituxan (rituximab, anti-CD20) and Herceptin (trastuzumab, 
anti-Her2) (Jefferis, 2005; Liu et al., 2008). This has led to intense efforts to generate 
improved antibodies via glycoengineering (Desjarlais et al., 2007; Jefferis, 2005; Liu et 
al., 2008). Wild type aglycosylated antibodies can be expressed at a high yield in 
bacterial cells and exhibit normal serum persistence and binding to FcRn, but completely 
lack the ability to bind to effector FcγRs (Simmons et al., 2002). 
In this chapter, we report the isolation of bacterially expressed aglycosylated IgG 
antibodies engineered to enable specific binding to FcγRI. For the engineering of E. coli 
expressed aglycosylated IgG Fc region, we developed a new display system for 
homodimeric Fcs. Optimized culture and spheroplasting allowed robust display of 
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homodimeric Fc protein, as required for high throughput flow cytometry screening, 
without either fusion of inner membrane anchoring domain or coexpression of displaying 
protein binding ligands (Fig. 2-2). Two amino acids change of CH3 region that is distal 
from the FcγR binding region (Sondermann et al., 2001) make aglycosylated IgG1 highly 
selective to FcγRI without increasing affinity significantly to other effector FcγRs 
including inhibitory FcγRIIb.  
 
 
 
 
Figure 2-1. Binding epitopes of FcγR proteins and C1q on IgG-Fc (Duncan and Winter, 
1988; Jefferis et al., 1998; Kacskovics, 2004). 
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Figure 2-2. Schematic diagram showing the display system. We hypothesize that the Fc 
protein is entrapped within the cell wall. 
 
2.2 MATERIALS AND METHODS 
2.2.1 Molecular biology techniques  
All plasmids and primers used in this chapter are described in Table 2-1 and 2-2. 
Plasmid pPelBFLAG was generated by ligating BamHI-HindIII digested skp gene from 
pMopac12 into pMopac1 (Hayhurst et al., 2003) digested with the same restriction 
endonucleases and by replacing polyhistidine tag and c-myc tag with a sequence 
encoding the FLAG tag (DYKDDDDK). Subcloning of PCR amplified and SfiI digested 
Fc gene encoding human IgG1-Fc fragment, hinge, CH2 and CH3 region of human IgG1 
heavy chain (McLean et al., 2000) (GeneBank Accession No. AF237583) into SfiI 
digested pPelBFLAG generated pPelBFLAG-Fc. SfiI digested genes from pMoPac1-
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FLAG-M18 for M18 scFv (Harvey et al., 2004) specific for the PA antigen of Bacillus 
anthracis were introduced to pPelBFLAG to generate pPelBFLAG-M18 scFv. 
To construct pTrc99A-DsbA-Fc-FLAG, firstly, 53bp of DsbA signal sequence 
(ATGAAAAAGATTTGGCTGGCGCTGGCTGGTTTAGTTTTAGCGTTTAGCGCAT
CGGCG) was introduced using the FatI restriction enzyme that is compatible with NcoI 
of pTrc99A (Amersham Biosciences, Piscataway, NJ) and with SalI restriction enzyme. 
The PCR products of Fc fragments amplified using primers STJ#144 and STJ#145 were 
ligated into the SalI and HindIII restriction enzyme sites of pTrc99A-DsbA plasmid 
(Table 2-1). 
For the construction of pSTJ4-Herceptin IgG1, E. coli codon optimized (Hoover 
and Lubkowski, 2002) VL and VH domains of humanized 4D5 (anti-p185HER2) were 
synthesized by total gene synthesis with overlap extension PCR using 12 
oligonucleotides that included 2 external primers (STJ#302 and STJ#313) and 10 internal 
primers (STJ#303-312) for VL and 14 primers total 2 external primers (STJ#314 and 
STJ#327) and 12 internal primers (STJ#315-326) for VH, respectively. The ligation of 
the amplified VL and VH into pMAZ360-M18.1-Hum-IgG1 using NcoI / NotI for VL 
and NheI / HindIII restriction endonuclease sites generated pSTJ4-Herceptin IgG1. 
For error prone PCR library construction, the standard error prone PCR method 
(Fromant et al., 1995) was employed using the wt Fc as the template with primers 
STJ#196 and STJ#197. A random 10 a.a. insertion library was constructed by PCR 
amplification using forward primer (STJ#194) encoding 10 degenerate codons and 
reverse primer (STJ#195) with the same template. The amplified PCR fragments were 
ligated into pPelBFLAG with SfiI restriction sites for error prone PCR library and SacII / 
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EcoRI restriction sites for random 10 a.a. insertion library, respectively. For the three 
sublibraries randomized around E382V and M428I, PCR products amplified using 
forward primers (both STJ#283 and STJ#284) and reverse primers (STJ#285, STJ#286, 
or STJ#287) for each three sublibrary were subcloned into SexAI / SapI digested 
pPelBFLAG-Fc. The resulting plasmids were transformed into E. coli Jude-1(F' 
[Tn10(Tetr) proAB+ lacIq ∆(lacZ)M15] mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 
∆lacX74 deoR recA1 araD139 ∆(ara leu)7697 galU galK rpsL endA1 nupG) 
(Kawarasaki et al., 2003). 
 
 2.2.2 FACS analysis and library screening  
E. coli Jude-1 were cultured overnight at 37 °C with 250 rpm shaking in Terrific 
Broth (TB) with 2% (w/v) glucose. Antibiotics, chloramphenicol (40 µg/ml) or ampicillin 
(50 µg/ml) were added as needed. Following overnight growth cells were diluted 1:50 in 
fresh TB medium with 0.5 M trehalose (Fisher Scientific, Fair Lawn, NJ) and antibiotics 
as needed. After incubation at 37 °C for 3 h cultures were transferred to 25 °C for 20 min 
with shaking at 250 rpm and protein expression was induced with 1 mM of isopropyl-1-
thio-β-D-galactopyranoside (IPTG). Protein expression in cells grown in media without 
trehalose was performed as above except that the cells were incubated for 2 h instead of 3 
h at 37 ºC before IPTG induction. 
For library screening, the extracellular domain of glycosylated FcγRI (R&D 
Systems, Minneapolis, MN) was labeled with FITC according to the manufacturer’s 
instruction (Invitrogen, Carlsbad, CA). Binding of FITC-labeled soluble FcγRI to human 
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IgG Fc was confirmed by fluorescent ELISA on plates coated with glycosylated human 
IgG-Fc (Bethyl Laboratories, Montgomery, TX). 
Cells were grown and induced with IPTG as above. 5 h after induction, an aliquot 
of the culture broth equivalent to 8 ml/OD600 was harvested by centrifugation and washed 
two times in 1 ml of cold 10 mM Tris-HCl (pH 8.0). After resuspension in 1 ml of cold 
STE solution (0.5 M Sucrose, 10 mM Tris-HCl, 10 mM EDTA, pH 8.0) the cells were 
incubated with rotating mixing at 37°C for 30 min, pelleted by centrifugation at 12,000 × 
g for 1 min and washed in 1 ml of cold Solution A (0.5 M Sucrose, 20 mM MgCl2, 10 
mM MOPS, pH 6.8). The washed cells were incubated in 1 ml of Solution A with 1 
mg/ml of hen egg lysozyme (Sigma-Aldrich, St. Louis, MO) at 37 °C for 15 min. After 
centrifugation at 12,000 × g for 1 min pelleted spheroplasts were resuspended in 1 ml of 
cold PBS. 200 µl of the spheroplast suspension was further diluted in 800 µl of PBS and 
mixed with either 0.5 µl of Protein A-FITC (5 mg/ml), 2 µl of PA-FITC (1 mg/ml) (List 
Biological Laboratories, Campbell, CA) or 2.5 µl of FcγRI-FITC (0.6 mg/ml). After 
incubation for 1 h with vigorous shaking at 25°C in the dark the spheroplasts were 
pelleted by centrifugation at 12,000 × g for 1 min and resuspended in 1 ml of PBS. A 100 
µl of this suspension was diluted in 1 ml of PBS and analyzed on a BD FACSort 
instrument (BD Bioscience, San Jose, CA). Spheroplasts prepared as above were sorted 
on a MoFlo droplet deflection flow cytometry (Dako Cytomation, Fort Collins, Colorado) 
using a 488 nm Argon laser for excitation and detection through a 530/40 band pass filter. 
Sorted cells were resorted immediately after initial sorting. The Fc mutant genes in the 
resorted spheroplasts rescued by PCR using two specific primers STJ#16 and STJ#220 
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were cloned into SfiI digested pPelBFLAG vector, and transformed in electrocompetent 
E. coli Jude-1 cells. The resulting transformants were subjected to the next round sorting 
and resorting. 
 
 2.2.3 Expression and purification of Fc proteins  
E. coli Jude-1 cells harboring pTrc99A-DsbA-Fc-FLAG encoding either wild type 
or mutant Fc domains were cultured in 2 L flasks with 500 ml working volume of TB 
media at 37 °C. The shake flasks were transferred to 30 °C and 15 minutes later 1 mM 
IPTG (OD600 approximately 0.6) was added. 8 h after induction the cells were harvested 
and the expressions of soluble Fc proteins was detected by Western blot using Rabbit 
anti-ECS antibody peroxidase conjugate (Bethyl Laboratories, Montgomery, TX). 
Culture supernatant from the induced cells was separated by centrifugation at 7,000 rpm 
for 30 min filtered through a 0.22 µm filter and 400 ml were loaded onto a column 
packed with 1 ml of Immobilized Protein A agarose (Pierce Biotechnology, Rockford, 
IL) by gravity flow. The column was washed with 75 ml of 20 mM sodium phosphate 
buffer (pH 7.0) and with 50 ml of 40 mM sodium citrate (pH 5.0). Wild type Fc and Fc 
mutants were eluted using 0.1 M glycine (pH 2.5) and neutralized immediately with 1M 
Tris (pH 8.0). Fc containing fractions were concentrated by ultrafiltration (10 kDa Mw 
cutoff) and purified by gel filtration on a Superdex 200 column (Amersham Pharmacia, 
Piscataway, NJ). 
 
 2.2.4 Preparative expression and purification of IgG  
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Preparative expression was performed by fed-batch fermentation using a 3.3 L jar 
fermentor (New Brunswick Scientific, Edison, NJ) with 1.2 L working volume. Cells 
were grown at 30 oC in R/2 medium (Jeong and Lee, 2003) consisting of: 2 g of 
(NH4)2HPO4, 6.75 g of KH2PO4, 0.93 g of citric acid-H2O, 0.34 g of MgSO4, 20 g of 
glucose, 0.05 g of ampicillin and 5 ml of trace metal solution dissolved in 2 N HCl (10 g 
of FeSO4-7H2O, 2.25 g ZnSO4-7H2O, 1 g of CuSO4-5H2O, 0.35 g of MnSO4-H2O, 0.23 g 
of Na2B4O7-10H2O, 1.5 g of CaCl2, and 0.1 g of (NH4)6Mo7O24 per L). E. coli 
BL21(DE3) (EMD Chemicals, Gibbstown, NJ) harboring pSTJ4-Herceptin IgG1 or 
pSTJ4-Herceptin IgG1-Fc5 were cultured in 500 mL baffled-flask with 120 ml R/2 media 
at 30 oC at 250 rpm for 8 h and used to inoculate the fermentor. The dissolved oxygen 
(DO) concentration was maintained at 40% of air saturation using automatic cascaded 
control by increasing the agitation speed from 100 rpm to 1000 rpm and the air flow rate 
from 1 to 3 SLPM (Standard liquid per minute) and with pure oxygen flow rate from 0 to 
1.5 SLPM when required. Initial pH was adjusted to 6.8 and controlled by the addition of 
30% (v/v) ammonium hydroxide when the pH decreased to less than 6.75, and by the 
supply of either growth feeding solution (700 g/L of glucose and 10 g/L of MgSO4-
7H2O) before induction or production feeding solution (500 g/L glucose, 10 g/L of 
MgSO4-7H2O, and 100 g/L of yeast extract) after induction when the pH increased above 
6.9. When OD600 reached 100, the culture temperature was reduced to 25 oC and 30 min 
later, protein expression was induced with 1 mM of IPTG. The culture broth was 
harvested 7 h after induction. 
Cells were pelleted by centrifugation at 11,000 × g for 30 min, suspended in 1.2 L 
100 mM Tris, 10 mM EDTA (pH 7.4), 4 mg of lysozyme (per g of dry cell weight), 1/5 
  
28
working concentration of protease inhibitor cocktail (complete, EDTA-free, Roche 
Diagnostics, Indianapolis, IN), and 1 mM PMSF and were incubated with shaking at 250 
rpm at 30 oC for 16 h to release periplasmic proteins. After centrifugation at 14,000 × g 
for 30 min, the supernatant was mixed with polyethyleneimine (MP Biomedical, Solon, 
OH) to a final concentration of 0.2% (w/v) recentrifuged at 14,000 × g for 30 min, and 
filtered through 0.2 µm filter. Immobilized Protein A agarose resin pre-equilibrated in 20 
mM sodium phosphate buffer (pH 7.0) was added to the supernatant and incubated at 4 
oC for 16 h. After washing with 200 ml of 20 mM sodium phosphate buffer (pH 7.0) and 
200 ml of 40 mM sodium citrate (pH 5.0), IgG1 was eluted from the resin using 15 ml of 
0.1 M glycine (pH 3.0) and neutralized immediately with 1 M Tris (pH 9.0) solution. The 
eluted samples were concentrated by ultrafiltration through a 10 kDa Mw cutoff 
membrane and the retentate was applied to a Superdex 200 gel filtration column 
developed with PBS (pH 7.4). 
 
 2.2.5 ELISA assays  
50 µl of 4 µg/ml of wild type Fc, Fc mutants, glycosylated IgG1 (Sigma-Aldrich, 
St. Louis, MO) aglycosylated trastuzumab, aglycosylated trastuzumab Fc5 purified from 
E. coli, or glycosylated trastuzumab (Clinical grade, Fox Chase Cancer Center or MD 
Anderson Pharmacy) were diluted in 0.05 M Na2CO3 (pH 9.6) buffer and used to coat 96 
well polystyrene ELISA plate (Corning, Corning, NY) overnight at 4 °C. After blocking 
with 1x PBS (pH 7.4), 0.5% BSA for 2 h at room temperature, the plate was washed 4 
times with PBS containing 0.05% Tween20, and incubated with serially diluted FcγRIIa 
(Berntzen et al., 2005), FcγRIIb (Berntzen et al., 2005), FcγRI (R&D Systems, 
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Minneapolis, MN),  FcγRIIIa (R&D Systems, Minneapolis, MN) or FcγRIIIb (R&D 
Systems, Minneapolis, MN) at room temperature for 1 h. Purified GST fused FcγRIIa and 
FcγRIIb were provided by Dr. Inger Sandlie (University of Oslo, Norway). After washing 
4 times with the same buffer, 1:10000 diluted anti-polyhistidine antibody HRP conjugate 
(Sigma-Aldrich, St. Louis, MO) for FcγRIIIa and FcγRIIIb or 1:5000 diluted anti-GST 
antibody HRP conjugate (Amersham Pharmacia, Piscataway, NJ) for FcγRIIa and 
FcγRIIb was added and plates were washed and developed as described previously 
(Mazor et al., 2007). To determine the binding of IgG to FcRn at pH 7.4, 2 µg/ml of GST 
fused FcRn (Berntzen et al., 2005) (Providied by Dr. Inger Sandlie, University of Oslo, 
Norway) preincubated with 1:5000 diluted Anti-GST-HRP for 1 h as previously 
described (Andersen et al., 2006) was added to plates coated with IgG. To evaluate 
binding at pH 6.0 or 5.5 ELISAs were carried out as above except that the washing buffer 
and sample dilution buffers were adjusted to pH 6.0 or 5.5. 
 
 2.2.6 BIAcore analysis for Fc mutants and Herceptin IgG1 Fc mutants 
Binding of IgG1-Fc domains to the human FcγRI was analyzed by surface 
plasmon resonance using a BIAcore 3000 biosensor (Biacore, Piscataway, NJ). The 
soluble monomeric FcγRI was immobilized on the CM-5 sensor chip by amine coupling 
kit as recommended by the manufacturer. Binding experiments were done in HBS-EP 
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, and 0.005% P20 
surfactant). The soluble human IgG1, wild type aglycosylated IgG1-Fc fragments, and 
isolated aglycosylated Fc mutants (Fc5, Fc49) were injected at a flow rate of 100 ul/min 
for 30 s with dissociation time 300 s. Regeneration of the ligand, FcγRI, was performed 
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by single injection of 100 mM citric acid, pH 3.0. Binding of the soluble monomeric 
FcγRI to IgG1 was determined by injection of IgG1 in duplicate at concentrations of 0, 
40, 60, 80, 100, and 200 nM for 30 s at a flow rate of 100 µl/min over immobilized 
FcγRI. Affinities of FcγRI toward Fc5 and Fc49 were obtained by IgG1 injections of 
IgG1 Fcs in duplicates at concentrations 0, 80, 100, 200, 400, 600 nM and 0, 200, 400, 
600, 800, and 1,000 nM for 30 s at a flow rate of 100 µl/min over immobilized FcγRI, 
respectively. 
Similarly, binding of FcγRI to the full assembled IgG trastuzumab was analyzed 
by immobilizing glycosylated trastuzumab, aglycosylated trastuzumab, and aglycosylated 
trastuzumab-Fc5 individually on the CM5 sensor chip. Binding experiments were done in 
the same HBS-EP buffer. The soluble monomeric FcγRI was injected at a flow rate of 30 
µl/min for 60 s with dissociation time 300 s. Regeneration of the ligand, FcγRI, was 
performed by single injection of 100 mM citric acid, pH 3.0. Binding kinetics of the 
soluble monomeric FcγRI with glycosylated trastuzumab, aglycosylated and trastuzumab, 
trastuzumab Fc5 were measured by injection of soluble FcγRI in duplicate at 
concentrations of 0, 25, 50, 100, 200 nM for 60 s at a flow rate of 30 µl/min over 
immobilized glycosylated trastuzumab, and aglycosylated trastuzumab-Fc5. The binding 
of FcγRI toward wild type aglycosylated trastuzumab was obtained by FcγRI injections 
in duplicates at concentrations 0, 200, 300, 400, 500, and 600 nM for 60 s at a flow rate 
30 µl/min over immobilized aglycosylated trastuzumab. Binding curve at zero 
concentration was subtracted as a blank. Equilibrium dissociation constants (KD) were 
determined by fitting of equilibrium responses to steady-state affinity model provided by 
BIAevaluation 3.0 software. 
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Table 2-1. Plasmids used in this study. 
Plasmids Relevant characteristics Reference or source 
pMoPac1 Cmr, lac promoter, tetA gene, C-terminal 
polyhistidine tag and c-myc tag 
(Hayhurst et al., 2003) 
pMoPac12 Apr, lac promoter, tetA gene, skp gene, C-
terminal polyhistidine tag and c-myc tag 
(Hayhurst et al., 2003) 
pMoPac1-FLAG-
M18 
NlpA fused M18 scFv gene, C-terminal 
FLAG tag in pMoPac1 
(Jung et al., 2007) 
pPelBFLAG Cmr, lac promoter, tetA gene, skp gene, C-
terminal FLAG tag 
This study 
pPelBFLAG-Fc IgG1-Fc gene in pPelBFLAG This study 
pPelBFLAG-M18 
scFv 
M18 scFv gene in pPelBFLAG This study 
pMAZ360-M18.1-
Hum-IgG1 
M18.1 humanized IgG1 gene in pMAZ360 (Mazor et al., 2007) 
pTrc99A Apr, trc promoter, lacIq Amersham Biosci., 
(Piscataway, NJ) 
pTrc99A-DsbA dsbA signal sequence gene in pTrc99A This study 
pTrc99A-DsbA-Fc-
FLAG 
dsbA fused IgG1-Fc gene, C-terminal 
FLAG tag in pTrc99A 
This study 
pSTJ4-Herceptin 
IgG1 
Herceptin IgG1 gene in pMAZ360-M18.1-
Hum-IgG1 
This study 
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Table 2-2. Primers used in this study (Underlining indicates the restriction enzyme sites). 
Primer 
Name Primer nucleotide sequence (5’  3’) 
STJ#16 TTGTGAGCGGATAACAATTTC 
STJ#144 TTTTAGGGGTCGACGACAAAACTCACACATGCCCACCGTG 
STJ#145 TTTAAGGGAAGCTTCTATTAGGCGCGCCCTTTGTCATCG 
STJ#194 CTAGGGAGCCGCGGGAGGAGCAGTACAACNNSNNSNNSNNSNNSNNSNNSNNSNNSNNS
AGCACGTACCGTGTGGTCAGCG 
STJ#195 CTAGAGGAATTCGGCCCCCGAGGCCCCTTTAC 
STJ#196 CGCAGCGAGGCCCAGCCGGCCATGGCG 
STJ#197 CGCAATTCGAATTCGGCCCCCGAGGCCCC 
STJ#220 CAATTTTGTCAGCCGCCTGAGCAGAAG 
STJ#283 CTTCTATCCCAGCGACATCGCCGTGNNSTGGNNSAGCNNSGGGCAGCCGGAGAACAACT
ACAAG 
STJ#284 GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTG 
STJ#285 AGGGAGAGGCTCTTCTGCGTGTAGTGGTTGTGCAGAGCWNNATGWNNCACWNNGCATG
AGAAGACGTTCCCCTGCTG 
STJ#286 AGGGAGAGGCTCTTCTGCGTGTAGTGGTTGTGCAGAGCCTCATGWNNWNNCACGGAGC
ATGAGAAGACGTTCCCCTGCTG 
STJ#287 AGGGAGAGGCTCTTCTGCGTGTAGTGGTTGTGCAGAGCCTCATGWNNWNNWNNCACGG
AGCATGAGAAGACGTTCCCCTGCTG 
STJ#302 GCGGAATTCCCATGGCGGATATTCAAATGACCC 
STJ#303 CAGACGCGCTTAAAGAAGACGGGCTTTGGGTCATTTGAATATCCGCCATG 
STJ#304 CGTCTTCTTTAAGCGCGTCTGTCGGTGATCGCGTGACCATCACGTGTCGT 
STJ#305 AGGCCACCGCCGTATTAACATCTTGGCTCGCACGACACGTGATGGTCACG 
STJ#306 GTTAATACGGCGGTGGCCTGGTATCAACAAAAACCGGGTAAAGCCCCGAA 
STJ#307 GAGTACAGAAAGCTGGCGCTGTAGATTAACAGCTTCGGGGCTTTACCCGG 
STJ#308 CAGCGCCAGCTTTCTGTACTCTGGCGTCCCGAGCCGCTTTTCTGGCAGCC 
STJ#309 TGCTAATGGTCAGCGTGAAGTCCGTACCGCTGCGGCTGCCAGAAAAGCGG 
STJ#310 ACTTCACGCTGACCATTAGCAGCCTGCAGCCGGAGGATTTCGCCACCTAT 
STJ#311 TGGCGGGGTGGTGTAGTGCTGCTGACAATAATAGGTGGCGAAATCCTCCG 
STJ#312 ACTACACCACCCCGCCAACCTTTGGCCAGGGTACGAAAGTGGAGATTAAA 
STJ#313 GACAGATGGTGCGGCCGCCGTGCGTTTAATCTCCACTTTCGTACCCTGG 
STJ#314 ATTGTTATTGCTAGCGGCTCAGCCGGCAATGGCG 
STJ#315 ACCAGACCACCGCCAGATTCCACTAATTGAACCTCCGCCATTGCCGGCTG 
STJ#316 TCTGGCGGTGGTCTGGTGCAGCCAGGCGGTAGCTTACGTCTGAGCTGTGC 
STJ#317 AGGTATCTTTGATGTTGAAGCCAGACGCTGCACAGCTCAGACGTAAGCTA 
STJ#318 TCTGGCTTCAACATCAAAGATACCTACATTCATTGGGTTCGCCAAGCCCC 
STJ#319 ATAGATACGGGCCACCCACTCCAGGCCTTTACCTGGGGCTTGGCGAACCC 
STJ#320 GAGTGGGTGGCCCGTATCTATCCAACCAATGGCTACACGCGTTATGCAGA 
STJ#321 GCGCTAATGGTGAAGCGGCCTTTCACAGAGTCTGCATAACGCGTGTAGCC 
STJ#322 CCGCTTCACCATTAGCGCCGACACCTCTAAGAACACCGCATATTTACAGA 
STJ#323 GTCCTCTGCGCGTAAAGAGTTCATCTGTAAATATGCGGTGTTCTTAGAGG 
STJ#324 AACTCTTTACGCGCAGAGGACACGGCGGTGTACTACTGCTCTCGTTGGGG 
STJ#325 AGTAGTCCATCGCGTAGAAACCGTCACCGCCCCAACGAGAGCAGTAGTAC 
STJ#326 GGTTTCTACGCGATGGACTACTGGGGTCAGGGTACGCTGGTCACGGTCAG 
STJ#327 GCCCTTGAAGCTTGCAGAGCTGACCGTGACCAGCGT 
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2.3 RESULTS 
  2.3.1 Bacterial display of aglycosylated functional homodimeric Fc domains  
A gene encoding the hinge region and Fc domain followed by a FLAG tag and 
preceeded by a PelB signal peptide for secretion into the periplasm was constructed (Fig. 
2-3). E. coli does not have glycosylation machinery, thus the Fc protein secreted into the 
periplasmic space does not have a glycan attached at Asn297. To identify mutations that 
enable aglycosylated Fc to bind to the extracellular domain of FcγRs, it was first 
necessary to develop an E. coli display system suitable for the screening of aglycosylated 
Fc mutant libraries. The E-clonal system developed earlier is well suited for the isolation 
of IgGs with desired antigen specificities. However, it cannot be used to detect binding of 
Fc receptors to the Fc domain because the latter is occupied by the membrane-anchored 
Fc-binding protein which is used to display the IgG on spheroplasts. To overcome this 
problem, we initially attempted to use the fatty acyl chain anchored binding motifs (cJun 
(Kouzarides and Ziff, 1988; Landschulz et al., 1988) or ColE2 mutants (Garinot-
Schneider et al., 1996; Li et al., 2004), respectively) provided by N terminal fusion of 
NlpA(1-6) (Harvey et al., 2004) and the expression of PelB leader peptide fused Fc with 
c-terminal fusion partners (cFos or Im2) for the tethering of Fc domains on spheroplasts 
via interaction of cJun-cFos (Kouzarides and Ziff, 1988; Landschulz et al., 1988) or 
ColE2-Im2 (Garinot-Schneider et al., 1996; Li et al., 2004), Preliminary experiments 
revealed no significantly distinguishable FACS signal compared with negative controls 
that did not express protein fused to the NlpA anchoring motif (data not shown). 
However, in the course of these studies we noticed that spheroplasts generated from cells 
expressing secreted Fc protein that lacked any tethering sequence (Fig 2-2) exhibited 
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slight (2-fold) higher fluorescence upon labeling with Protein A-FITC relative to 
spheroplasts expressing an unrelated protein, namely the M18 scFv that binds to the PA 
subunit of the Bacillus anthracis toxin (Fig 2-4). Similarly, secreted and solubly-
expressed antibody fragments (M.W.>30 kDa), but not smaller proteins (e.g., C-terminal 
polyhistidine-cMyc tagged β2-microglobulin; M.W. 15.24 kDa), were substantially 
retained by spheroplasts, resulting in selective staining of E. coli by fluorescent antigens 
(Fig. 2-2). Spheroplasted cells expressing full length IgG or antibody fragments, M18.1 
humanized (Harvey et al., 2004) scFv, scAb, Fab and IgG and labeled with PA-FITC 
fluorescent antigen displayed fluorescence significantly higher than negative controls 26-
10 (Francisco et al., 1993) scFv, scAb, Fab, and IgG above background (data now 
shown). On the other hand, smaller protein such as C-terminal polyhistidine-cMyc tagged 
β2-microglobulin (M.W. 15.24 kDa) are more thoroughly released upon conversion of 
cells into spheroplasts and thus the respective cells exhibited low fluorescence following 
labeling with FITC-conjugated ligand. The retention of secreted Fc domain proteins by 
spheroplasted cells was highly dependent on growth conditions. Optimal labeling with 
Protein A-FITC was obtained with cells grown at 25 ◦C in the presence of 0.5 M trehalose 
but not with other non-metabolizable sugars such as sucrose or sorbitol. Under these 
conditions spheroplasts expressing the Fc and labeled with Protein A-FITC exhibited 10-
fold higher signal than controls (Fig. 2-4). Western blot analysis revealed that a 
significant fraction of the Fc was retained in cells grown with 0.5 M trehalose (data not 
shown). Secretion of Fc by the signal recognition particle (SRP)-dependent DsbA signal 
sequence (Schierle et al., 2003) did not result in significant protein retention following 
spheroplasting, even in the presence of 0.5 M trehalose. While the precise mechanism for 
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the retention of soluble proteins by spheroplasted cells remains to be determined, the 
fluorescent signal obtained is well suited for library screening purposes. 
 
 
Plac SD FLAGHinge CH2 CH3PelB
 
 
Figure 2-3. Expression cassette for periplasmic display of Fc.  
 
 
 
 
 
 
Figure 2-4. Effect of trehalose on periplasmic display of Fc. Cells expressing either the 
IgG Fc domain or the M18 scFv as a control were grown with or without 0.5 M trehalose, 
spheroplasted and labeled with Protein A-FITC probe for detection. 
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 2.3.2 Isolation of mutants aglycosylated Fc fragments exhibiting FcγRI binding 
Simmons et al. reported that aglycosylated antibodies exhibit negligible binding 
to the FcγRI receptor (Simmons et al., 2002). To isolate mutants of the Fc domain 
capable of binding to the extracellular domain of Fcγ receptors we initially constructed 
libraries composed of: (i) random mutants by error prone PCR (~9.2 × 108 transformants) 
containing 0.49% nt substitutions per gene (as determined by the sequencing of 20 
random clones) and (ii) 10 a.a. random insertions encoded by NNS randomization 
scheme (N any nucleotide, S=C and G) (~2.8 × 107 transformants representing a 
miniscule fraction of the theoretical diversity) into residues 297 or 298 with the intent of 
replacing the glycan that is normally attached to Asn297 with a peptide epitope. 
Transformants from the two libraries were pooled and, following induction of protein 
synthesis, spheroplasts were prepared and labeled with the appropriate FcγR conjugated 
to FITC (Fig. 2-2), and highly fluorescent clones were isolated by flow cytometry. The 
respective genes were rescued by PCR, subcloned, and transformants were subjected to 
additional rounds of FACS sorting. As shown in Figure 2-5, a positive population was 
enriched following screening with fluorescently labeled extracellular domain of FcγRI, 
the high affinity receptor expressed by monocytes, dendritic and to a lesser extent by 
polymorphonuclear cells (Desjarlais et al., 2007). After the 4th round, 50 clones were 
randomly selected and their fluorescence was determined individually. Six clones 
displaying the highest fluorescence (>5x above background) upon labeling with FcγRI-
FITC were isolated (Fig. 2-6) and sequenced (Fig. 2-7). All six clones were derived from 
the error prone PCR Fc library. The isolated clones contained two consensus mutations, 
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E382V and M428I located within the C and F β-strands of CH3 region (Lefranc et al., 
2005) (Fig. 2-8 A and B), respectively. This finding was surprising since these mutations 
are far from the FcγRI binding epitope which is proposed to comprise of the lower hinge 
and the upper part of the CH2 domain (Jefferis et al., 1998). The clone exhibiting the 
highest fluorescence, Fc5, contained only these two substitutions. 
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Figure 2-5. Fluorescence histogram of spheroplasted cells from different rounds of 
sorting labeled with FcγRI-FITC. M: Mean fluorescence intensity. 
 
 
  
38
 
 
 
 
 
Figure 2-6. Fluorescence histogram of spheroplasted cells expressing either wt IgG Fc 
protein or high fluorescence mutants isolated from the fourth round (statistically 
significant high fluorescence; P < 0.001 using unpaired students t test relative to wt IgG 
Fc). M: Mean fluorescence intensity. 
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Figure 2-7. Protein sequences of isolated Fc mutant clones exhibiting high affinity to 
FcγRI. Mean fluorescence values for the respective clones labeled with FcγRI are shown 
in parenthesis. 
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Met428
Val382
CH3
CH2
A B
 
 
Figure 2-8. Location of mutations in isolated aglycosylated Fc domains displayed FcγRI 
binding, in the 3D structure of glycosylated IgG (PBD Code: 1FC1). (A) Isolated 
aglycosylated Fc5 (382E and 428M) represented on the 3D structure of glycosylated 
IgG1 Fc (PBD Code: 1FC1). (B) Two beta sheets including 382E in β-sheet C and 428M 
in β-sheet C of CH3 region represented on the crystal structure of full glycosylated IgG. 
 
Next, additional saturation mutagenesis of: (i) a.a. 380, 382 and 384 in β-sheet C 
of CH3 that makes contact with β-sheet F; (ii) residues 426, 428 and 430 in the F β-sheet, 
(iii) insertional mutagenesis between a.a. 428-429 was performed (Fig. 2-9) and screened 
for binding to FcγRI-FITC. Over 1 × 108 spheroplasts were sorted and in every round the 
top 3% of the population showing the highest fluorescence was isolated (Fig. 2-10). 14 
individual clones isolated from the 4th round of sorting were sequenced. Once again, the 
consensus mutations were E382V and M428I indicating that these amino acid 
substitutions, and especially the introduction of Val at position 382, are critical for 
conferring binding to FcγRI (Fig. 2-11). 
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AVEWESNG---------------------CSVMHEAL
382
AVXWXSXG----------------------CSVXXHEA
AVXWXSXG----------------------CSVXXXHEA
428
AVXWXSXG----------------------CXVXHXA
1 random a.a. insertion
1 a.a. randomize
2 random a.a. insertion
1 a.a. randomize
3 a.a. randomize3 a.a. randomize
3 a.a. randomize
3 a.a. randomize
Plac SD PelB FLAGHinge CH2 CH3
 
 
Figure 2-9. Saturation mutagenesis of a.a. 382 and 428 and adjacent residues in Fc. 
Three sub-libraries in which residues 380, 382, 384 and either (1) 426,428,430; (2) 428 
and following one additional amino acids; or (3) 428 and following two additional amino 
acids were constructed by total gene synthesis and pooled to give a master library of over 
1 × 107 clones. 
 
 
 
Figure 2-10. Screening of the saturation library for high affinity Fcs to FcγRI. 
Fluorescence histogram of spheroplasted cells isolated after different rounds and labeled 
with 30 nM of FcγRI-FITC. M: Mean fluorescence intensity. 
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         Hinge     CH2 
             230     240     250    260     270     280     290    300  
 
FcWT  (16.39) [DKTHTCPPC]PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY 
Fc104 (87.17) [---------]----------------------------------------------------------------------- 
Fc107 (316.58) [---------]----------------------------------------------------------------------- 
Fc101 (521.92) [---------]----------------------------------------------------------------------- 
Fc147 (464.35) [--------R]----------------------------------------------------------------------- 
Fc102 (373.63) [---------]----------------------------------------------------------------------- 
Fc114 (370.26) [---------]----------------------------------------------------------------------- 
Fc117 (390.62) [---------]----------------------------------------------------------------------- 
Fc151 (325.53)  [---------]----------------------------------------------------------------------- 
Fc143 (211.23)  [---------]--------S-------------------------------------------------------------- 
Fc152 (172.61)  [---R-----]----------------------------------------------------------------------- 
Fc149 (139.57)  [---------]----------------------------------------------------------------------- 
Fc106 (268.78) [---------]----------------------------------------------------------------------- 
Fc110 (137.93)  [---------]----------------------------------------------------------------------- 
            
       CH3 
        
             310         320        330        340  350         360        370        380                    
FcWT  (16.39) RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK[GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
Fc104 (87.17) ------------R---------------------------[---------------------------------------- 
Fc107 (316.58) ----------------------------------------[---------------------------------------- 
Fc101 (521.92) ----------------------------------------[---------------------------------------- 
Fc147 (464.35) ----------------------------------------[---------------------------------------- 
Fc102 (373.63) ----------------------------------------[--------------------D------------------- 
Fc114 (370.26) ----------------------------------------[--------------------S------------------- 
Fc117 (390.62) ----------------------------------------[---------------------------------------- 
Fc151 (325.53)  ----------------------------------------[---------------------------------------- 
Fc143 (211.23)  ----------------------------------------[---------------------------------------- 
Fc152 (172.61)  ----------------------------------------[---------------------------------------- 
Fc149 (139.57)  ----------------------------------------[---------------------------------------D 
Fc106 (268.78) ----------------------------------------[---------------------------------------- 
Fc110 (137.93)  ----------------------------------------[---------------------------------------T 
 
 
  390         400       410         420         430        440 
FcWT  (16.39) WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK] 
Fc104 (87.17) -----------------------------------------------I-------------------] 
Fc107 (316.58) -V-----------------------------------------------------------------] 
Fc101 (521.92) -V---------------------------------------------I-------------------] 
Fc147 (464.35) -V---------------------------------------------I-------------------] 
Fc102 (373.63) -V---------------------------------------------I-------------------] 
Fc114 (370.26) -V---------------------------------------------I-------------------] 
Fc117 (390.62) -V---------------------------------------------I-------A-----------] 
Fc151 (325.53) -V-------------------------------------------I-L-S-----------------] 
Fc143 (211.23) -V-------------------------------------------V-L-H-----------------] 
Fc152 (172.61) -V-------------------------------------------T-S-P-----------------] 
Fc149 (139.57) -V-R-----------------------------------------V-L-D-----------------] 
Fc106 (268.78) -T-D-------------------------------------------I-------------------] 
Fc110 (137.93) -M-E---------------------------------------------------------------] 
 
1) Fc101 = Fc103, 111, 115, 116, 125, 136, 141, 146, 148; FACS mean values are indicated in the 
parenthesis 
 
Figure 2-11. Protein sequences of isolated Fc mutants from the saturation library. Mean 
fluorescence values for the respective clones labeled with FcγRI are shown in 
parenthesis. 
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2.3.3 Expression of homodimeric Fc domains in E. coli and characterization of 
affinity to FcγRI  
Aglycosylated (wt) Fc and the mutants Fc5 (E382V, M428I), Fc 11 (E382V) and 
Fc49 (C289R, E382V, M428I) that exhibited the highest fluorescence were expressed 
and purified to near homogeneity. Optimal soluble expression of homodimeric Fc 
fragments was obtained at 30 ºC in E. coli Jude-1 cells in which secretion into the 
periplasm was mediated by the co-translational ssDsbA signal peptide (Schierle et al., 
2003) (Fig. 2-12) that led to a substantially higher amount of correctly assembled Fc both 
in the periplasmic fraction and in the growth medium compared to secretion via the PelB 
signal peptide (Fig. 2-13).  
Following Protein A and gel filtration chromatography, ~ 0.8 mg/L of dimeric Fc 
protein was routinely obtained in shake flask cultures (Fig. 2-14 and 2-15). The affinity 
of the purified homodimeric Fc fragments for FcγRI measured by ELISA (Fig. 2-16) are 
in good correlation with the flow cytometry analysis result for Fc-displaying spheroplasts 
(Fig. 2-6). BIAcore analysis revealed that wt Fc does not bind to FcγRI (KD>30 µM). In 
contrast, Fc5 and Fc49 exhibited KD values of 31 and 92 nM respectively. For 
comparison the equilibrium dissociation constant of commercially available, glycosylated 
IgG was 18 nM. Notably, the aglycosylated Fc5 mutant and the glycosylated human IgG 
exhibited experimentally indistinguishable dissociation rate constants, koff and a 2-fold 
lower association rate constant, kon (Table 2-3). 
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Figure 2-12. Expression cassette for DsbA leader peptide fused aglycosylated Fc. 
 
 
 
 
Figure 2-13. Effect of signal peptide on the soluble expression of Fc proteins. Cells 
expressing Fc secreted via the PelB or DsbA signal peptide were induced at either 25, 30 
or 37 oC, harvested after either 5 or 20 hrs and fractionated into media (M), total soluble 
(S) and periplasmic (P) fractions. Proteins resolved by gel electrophoresis under 
nonreducing conditions and detected by Western blotting using anti-ECS-HRP conjugate.  
 
 
 
 
Figure 2-14. Preparative expression of Fc proteins in shake flasks. Cells expressing Fc 
secreted via the DsbA signal peptide were grown in 500 ml media in shake flasks, 
induced at either 25, 30 or 37 oC, harvested after either 5 hrs or 20 hrs, fractionated into 
media (M), total soluble (S) and periplasmic (P) fractions. Fc proteins were detected as in 
Figure 2-13 above. 
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Figure 2-15. Purified wt Fc and high affinity Fc mutant proteins. Lane 1: M.W. 
standards; Lane 2: Wild type Fc; Lane 3: Fc5; Lane 4: Fc11; Lane 5: Fc49. 
 
 
Figure 2-16. ELISA result of the purified aglycosylated wild type Fc, Fc5, Fc11, and 
Fc49. 
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Table 2-3. Kinetic rates and equilibrium dissociation constants of isolated Fc mutants 
determined by BIACore analysis. 
 
 
 
 
2.3.4 Expression of aglycosylated trastuzumab in E. coli  
Trastuzumab is a highly effective chemotherapeutic antibody specific for 
Her2/neu (Erb2) which is overexpressed in ~30% of breast carcinomas (Liu et al., 2008). 
Extensive evidence indicates that recruitment of innate immune cells via interactions with 
Fcγ receptors plays an important role in the therapeutic action of trastuzumab (Liu et al., 
2008). For preparative production of aglycosylated trastuzumab and trastuzumab-Fc5 in 
E. coli the heavy and light chains were fused to the PelB signal peptide and placed 
downstream from the lac promoter in a dicistronic operon (Fig. 2-17). Briefly, E. coli 
BL21(DE3) cells were grown at 30 ºC to an OD600 of ~100 by fed-batch fermentation in 
pH-stat control mode, protein synthesis was induced, the fermentor was cooled to 25 ºC, 
and cells were harvested 7 hr later at an OD600 of ~130-140 (Fig. 2-18). Under these 
conditions, the yield of aglycosylated tetrameric IgG1 was 40-50 mg/L with >70% 
retained in the periplasmic space. The IgG1 was released from the cell pellet by 
incubation with lysozyme and EDTA for 16 hr at 30 ºC and purified to >80% 
homogeneity by Protein A affinity and size exclusion chromatography (Fig. 2-19). 
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Biacore analysis (Table 2-4 and Fig. 2-20 A-D) revealed that the E. coli expressed 
trastuzumab-Fc5 showed greatly improved binding affinity. Trastuzumab-Fc5 bound to 
FcγRI with similar affinity to commercial-grade glycosylated trastuzumab from CHO 
cells and over 67-fold higher affinity compared with wild type aglycosylated 
trastuzumab. Both glycosylated trastuzumab and aglycosylated trastuzumab-Fc5 
displayed higher affinity for FcγRI compared to isolated Fc domains alone. 
Notably, unlike glycosylated trastuzumab, which binds to all effector human Fcγ 
receptors with physiologically relevant affinities, the aglycosylated trastuzumab-Fc5 
exhibited poor binding for FcγRIIa, FcγRIIb (EC50≥ 1000-fold and 100-fold higher for 
GST fused FcγRIIa and FcγRIIb, respectively, Fig. 2-21 and Fig. 2-22) and FcγRIIIa 
(data not shown). The a.a. substitutions in trastuzumab Fc5 did not affect pH-dependent 
binding (high affinity binding at pH 5.5 and pH 6.0 and low binding at pH 7.4) to the 
neonatal FcRn, which is essential for the prolonged half life of IgG and also for transfer 
of maternal IgG to offspring (Ghetie and Ward, 2000) (Fig. 2-23 A and B). 
 
 
 
Figure 2-17. Map of plasmid pSTJ4-Herceptin IgG1. 
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Figure. 2-18. Example of fed-batch fermentation for the production of aglycosylated 
trastuzumab or aglycosylated trastuzumab-Fc5 in a 3.3 L fermentor. OD600 as a function 
of time after inoculation during the expression of trastuzumab in E. coli. 
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Figure 2-19. Expression and purification of aglycosylated wild type or engineered 
trastuzumab antibodies. SDS-PAGE showing the purified aglycosylated trastuzumab and 
aglycosylated trastuzumab Fc5, Lane 1, 3: Wild type Fc aglycosylated trastuzumab; Lane 
2, 4: aglycosylated trastuzumab Fc5. 
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Table 2.4. Kinetic rates and equilibrium dissociation constants of trastuzumab antibodies 
determined by BIACore analysis. 
1.52.66 x 10-41.77 x 105Glycosylated Herceptin
5.69
382
KD (nM)
1.23 x 10-3
5.02 x 10-2
Koff (sec-1)
1.31 x 105Aglycosylated wild type trastuzumab
2.17 x 105Aglycosylated trastuzumab-Fc5
Kon (M-1 sec-1)
 
 
 
 
 
 
 
Figure 2-20. Biacore sensorgrams for aglycosylated and glycosylated trastuzumab 
antibodies. (A-C) Biacore sensorgrams of (A) wild type aglycosylated trastuzumab, (B) 
aglycosylated trastuzumab-Fc5, and (C) glycosylated trastuzumab for binding to FcγRI. 
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Figure 2-21. ELISA assays for binding to FcγRIIa-GST 
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Figure 2-22. ELISA assays for binding to FcγRIIb-GST. 
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Figure 2-23. ELISA assays for pH dependent binding to FcRn. (A and B) ELISAs at pH 
7.4 and at acidic pH 6.0 (A) or 5.5 (B). Plates were coated with purified aglycosylated 
trastuzumab antibodies, or with commercial glycosylated trastuzumab and the binding of 
FcRn was detected using anti-GST-HRP. 
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2.4 DISCUSSION 
One important mechanism underlying the potency of antibody therapeutics is their 
ability to recruit immune cells for the clearance of target antigens or cells. Thus, the Fc 
region of an antibody is critical for the recruitment of immunological cells and for the 
regulation of antibody dependent cell-mediated cytotoxicity (ADCC). In particular, the 
nature of the ADCC response elicited by antibodies depends on the interaction of the Fc 
region with receptors (FcγRs) located on the surface of a variety of immune cell types. 
The carbohydrate chain attached to the Fc region of glycosylated antibodies 
affects its conformation by packing the space between the two heavy chains in the CH2 
domain and enables the antibody to bind to FcγRs (Krapp et al., 2003). In contrast to 
glycosylated antibodies produced in mammalian cells, aglycosylated antibodies produced 
in bacteria cannot bind to FcγRs and therefore are unable to elicit ADCC. In this chapter 
aglycosylated antibodies were engineered to display high affinity binding to specific 
effector FcγRs, a prerequisite for binding to effector cells and for ADCC. Specifically, in 
this study, we initially developed a new homodimeric Fc display system for the 
engineering aglycosylated Fc domains. Periplasmic expression of PelB leader peptide-
fused Fc fragments cells grown in the presence of high concentrations of trehalose 
allowed the display of the protein onto spheroplasts. The disaccharide trehalose has been 
known to stabilize protein structure and prevent protein aggregation (Nishant Kumar Jain 
et al. 2008 Protein Sci.). Although the mechanism for the effect of trehalose on 
improving the FACS signal intensity and the signal to noise ratio upon display onto 
spheroplasts is not clear, it is possible that its effect is related to the ability of this 
dissacharide to affect the folding stability of proteins. 
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While aglycosylated human antibodies lack the ability to bind effector FcγRs, by 
screening large mutant libraries we isolated aglycosylated Fc domains that can bind to  
FcγRI with high affinity and specificity using the homodimeric Fc display system and 
high throughput flow cytometry. In this work we have focused on aglycosylated IgG1 
that bind to FcγRI with an affinity essentially similar with CHO-derived, glycosylated 
antibodies. However, amino acid substitutions that afford binding to other effector FcγRs, 
or enhanced pH dependent binding to FcRn can also be isolated by this methodology 
from judiciously constructed mutant libraries (S.T.J., S.R., T.H.K., Jan Terje Andersen, 
I.S., P.W. T., G.G., unpublished data). Only two amino acid substitutions in CH3 were 
sufficient to confer full FcγRI binding. All human FcγRs for which crystal structures are 
available, bind to an epitope comprising residues in the hinge and CH2. Biochemical data 
indicate that FcγRI also binds to the same region (Shields et al., 2001). Therefore, it is 
possible that amino acid substitutions in CH3 induce a conformational change in the 
aglycosylated Fc that make the CH2 domains bulge out mimicking the “open” structure 
found in glycosylated IgG (Krapp et al., 2003). Unfortunately, a detailed structural 
interpretation is not possible at the moment, as neither the structure of aglycosylated IgGs 
nor that of FcγRI is available. 
Glycosylated antibodies produced in mammalian cells display binding affinity to 
all effector FcγRs including inhibitory FcγRIIb. In contrast, aglycosylated trastuzumab- 
Fc5 was highly specific only to FcγRI. The binding of an antibody to specific Fc 
receptors determines its ability to recruit other immunological cells and the type of cell 
recruited. Hence, the ability to engineer antibodies that can recruit only certain kinds of 
cells can be critically important for therapy. The aglycosylated antibodies engineered to 
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selectively bind and activate a specific FcγR mediates theareputically relevant and altered 
effector functions as discussed in the following chapter. 
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Chapter 3 
Engineering of Aglycosylated Fc5 for Improved Effector Functions 
3.1 INTRODUCTION 
FcγRI, an integral membrane glycoprotein, is expressed mainly on monocytes 
derived cells including macrophages and dendritic cells. It can be expressed on 
neutrophils and eosinophis by the induction of cytokines such as IFNγ, IL-10, and G-CSF 
(Schmidt and Gessner, 2005). The FcγRI protein is composed of three extracellular 
domains (D1, D2, and D3) and mediates activation signals for ADCC, phagocytosis, and 
cytokine production upon binding to IgG immune complexes (Cohen-Solal et al., 2004). 
The three FcγRI isoforms (FcγRIA, FcγRIB, and FcγRIC) are highly homologous sharing 
over 98% sequence identity at the nucleotide level (van de Winkel and Capel, 1993). In 
contrast to low affinity FcγRs, FcγRII and FcγRIII (Kd = 10-6 ~ 10-7 M), the FcγRI has an 
additional extracellular domain (D3) (Hulett et al., 1991) and exhibits high affinity to 
monomeric IgG (Kd = 10-8 M) (Krapp et al., 2003). FcγRI is important in the early stage 
immune response for low antibody concentration (Kacskovics, 2004).  
For high affinity and specific binding to FcγRI, we isolated Fc engineered 
aglycosylated IgG Fc5 containing 2 mutations in the CH3 region (E382V and M428I). 
The Fc engineered aglycosylated trastuzumab-Fc5 showed similar binding affinity to 
FcγRI with glycosylated trastuzumab and specificity only to FcγRI without increasing 
binding affinities significantly to the other activating or inhibitory FcγRs inclulding 
FcγRIIa, FcγRIIb, and FcγRIIIa. 
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Here we focused on the isolation of aglycosylated IgG that binds exclusively to 
FcγRI. The role of FcγRI in ADCC is much less well understood relative to the other 
activating receptors. It has been suggested that because of its high affinity, FcγRI on 
effector cells is occupied by circulating IgG and therefore it may be involved in ADCC 
only during the early stage immune response when antibody concentration is low (Krapp 
et al., 2003). However, there is increasing evidence that the activation of FcγRI plays an 
important role in the resolution of certain infections and cancer (Bevaart et al., 2006; 
Pfefferkorn and Fanger, 1989; Tillinger et al., 2009). Here we showed that engineered, 
bacterially expressed trastuzumab IgGs potentiate the lysis of Her2 overexpressing SkBr3 
breast cancer cells by monocyte-derived dendritic (mDC) cells. Strikingly, glycosylated, 
clinical grade trastuzumab failed to activate the cytotoxic ability of mDCs. Aglycosylated 
IgGs engineered to display unique FcR binding characteristics may thus be useful for 
elucidating the function of FcγRI and for the selective recruitment of mDCs in cancer 
therapy. 
The high binding affinity of antibodies to human FcRn at slightly acidic pH (5.5 
– 6.0) and the low affinity at neutral pH are critically important for recycling the serum 
antibodies through acidified endosomes leading to longer serum half life of serum 
antibody (Ober et al., 2004a; Ober et al., 2004b; Raghavan and Bjorkman, 1996; 
Rodewald, 1976). In this study, high throughput flow cytometry library screening was 
employed to isolate antibodies exhibiting higher binding affinity to FcγRI than Fc5 and 
similar pH dependent FcRn binding with clinical grade glycosylated trastuzumab. 
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3.2 MATERIALS AND METHODS 
 3.2.1 Error prone PCR library for engineering aglycosylated IgG-Fc5 
All plasmids and primers used in this study are described in Table 3-1 and Table 
3-2. Standard error prone PCR method (Fromant et al., 1995) was employed with the 
template of the pPelBFLAG-Fc5 and two primers (STJ# 196 and STJ#197) synthesized 
from Integrated DNA Technologies (Coralville, IA). The amplified PCR fragments were 
ligated into SfiI digested pPelBFLAG. The resulting plasmids were transformed into E. 
coli Jude-1(F' [Tn10(Tetr) proAB+ lacIq ∆(lacZ)M15] mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80dlacZ∆M15 ∆lacX74 deoR recA1 araD139 ∆(ara leu)7697 galU galK rpsL endA1 
nupG) (Kawarasaki et al., 2003). 
 
 3.2.2 Construction of upper CH2 region randomization library 
4 sub-libraries were constructed as follows: Four parts of upper CH2 region 
(234L-239S, 264V-268H, 297N-299T, 328L-332I) (Kabat et al., 1991) were substituted 
by random amino acids using NNS degenerate codons. For the first sub-library, DNA 
fragments were amplified using the primers (STJ#465 and STJ#220) and the template, 
pPelBFLAG-Fc5. The N-terminal sequence extension of the PCR amplified fragments 
using the primer STJ#473 generated the sub-library replacing 5 amino acids in the region 
234L-239S with random amino acids. Gene assembly PCR products using DNA 
fragments amplified by the primers (STJ#467 and STJ#220) and DNA fragments 
amplified by the primers (STJ#473 and STJ#468) generated the second sub-library that 
randomized 5 amino acid residues for 264V-268H. The third sub-library randomized 
297N-299T was generated using the primer pairs (STJ#473/STJ#470 and 
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STJ#469/STJ#220) and the fourth sub-library (328L-332I) was generated using the 
primer pairs (STJ#473/STJ#470 and STJ#469/STJ#220) using the same PCR template 
plasmid, pPelBFLAG-Fc5. Based on the number of possible mutations, the same amount 
of DNA from three sub-libraries (234L-239S; 264V-268H; 328L-332I) that randomized 5 
amino acid residues were mixed with and 203/205 fold lower amount of DNA from the 
third sub-library (297N-299T) that randomized 3 amino acid residues. Each of the three 
sub-libraries was subcloned into SfiI digested pPelBFLAG. The resulting plasmids were 
transformed into E. coli Jude-1. 
. 
3.2.3 Spheroplasting and flow cytometry screening for affinity maturation of Fc5 
The library cells grown overnight at 37 °C with 250 rpm shaking in Terrific Broth media 
(Becton Dickinson Diagnostic Systems Difco™, Sparks, MD) with 2% (wt/vol) glucose 
and chloramphenicol (50 µg/ml) were diluted 1:50 in fresh TB media containing 0.5 M 
trehalose (Fisher Scientific, Fair Lawn, NJ) and chloramphenicol (50 µg/ml). After 3 h 
incubation at 37 °C with 250 rpm shaking and then 20 min cooling at 25°C, the 
expression of Fc fragments was induced with 1 mM isopropyl-1-thio-β-D-
galactopyranoside (IPTG) and the cells were incubated for 5 hours at 25 °C with 250 rpm 
shaking. 4.5 ml of the culture broth was harvested by centrifugation and washed two 
times in 1 ml of cold 10 mM Tris-HCl (pH 8.0). After centrifugation at 12,000 x g for 1 
min, 1 ml of, the cells resuspened in 1 ml of cold STE solution (0.5 M Sucrose, 10 mM 
Tris-HCl, 10 mM EDTA, pH 8.0) were incubated with rotating mixing at 37°C for 30 
min, pelleted by centrifugation at 12,000 x g for 1 min and washed in 1 ml of cold 
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Solution A (0.5 M Sucrose, 20 mM MgCl2, 10 mM MOPS, pH 6.8). The washed cells 
suspended in 1 ml of Solution A with 1 mg/ml of hen egg lysozyme were incubated at 
37°C for 15 min. After centrifugation at 12,000 × g for 1 min, the resulting spheroplasts 
pellets were resuspended in 1 ml of cold PBS. For library screening, extracellular domain 
of recombinant glycosylated FcγRI/CD64 (R&D Systems, Minneapolis, MN) was labeled 
with FITC using a FITC protein conjugation kit according to the manufacturer’s 
instructions (Invitrogen, Carlsbad, CA). After the conjugation reaction, the affinity of 
FITC-conjugated FcγRI (FcγRI-FITC) for human IgG Fc was confirmed by fluorescent 
ELISA displaying high fluorescence in the Fc glycosylated human IgG-Fc coated wells 
comparing in the BSA coated wells. Spheroplasts were labeled with 30 nM of FcγRI-
FITC. In the subsequent round of sorting, reduced concentration of FcγRI-FITC (10, 3, 
and 1 nM for the 2nd, 3rd, and 4th round sorting, respectively) was used for the labeling of 
spheroplasts for the screening from the error prone PCR library. For the screening 
aglycosylated Fc5 variants from 4 sub-libraries, 10 nM (3 nM for the 2nd round, 1 nM for 
the 3rd round, 0.3 nM for the 4th round) of FcγRI-FITC was used for the labeling. More 
than 4 × 108 spheroplasts per round were sorted by MoFlo (Dako Cytomation, Fort 
Collins, CO) equipped with a 488 nm argon laser for excitation. In each round the top 3% 
of the population showing the highest fluorescence due to FcγRI-FITC labeling was 
isolated by sorting and resorting immediately after the initial sorting. The Fc genes in the 
spheroplasts were rescued by PCR amplification using two specific primers (STJ#16 and 
STJ#220), ligated into pPelBFLAG-Fc using SfiI restriction endonuclease site, and 
transformed in electrocompetent E. coli Jude-1 cells. The resulting transformants were 
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grown on chloramphenicol containing media, and then spheroplasted as above in 
preparation for the next round of sorting. 
 
3.2.4 Expression and purification of aglycosylated trastuzumab antibodies 
For pSTJ4-Herceptin-Fc5-IgG1, pSTJ4-Herceptin-Fc601-IgG1, and pSTJ4-
Herceptin-Fc701-IgG1, Fc5, Fc601, and Fc701 mutant genes were amplified using the 
primers (STJ#290 and STJ#291) and the templates, pPelBFLAG-Fc5, pPelBFLAG-
Fc601, or pPelBFLAG-Fc701 ligated into pSTJ4-Herceptin IgG1 digested using SalI / 
EcoRV. For preparative production of wild type or Fc engineered aglycosylated 
trastuzumab antibodies in E. coli, dicistronic plasmids, pSTJ4-Herceptin-IgG1, pSTJ4-
Herceptin-Fc5-IgG1, pSTJ4-Herceptin-Fc601-IgG1, and pSTJ4-Herceptin-Fc701-IgG1 
were constructed. In these plasmids protein expression is under the control of the lac 
promoter. Heavy and light chains are expressed a dicistronic operon and fused to the 
PelB leader peptide for secretion across the cytoplasmic membrane. After transformation 
of the plasmids into E. coli BL21(DE3) (EMD Chemicals, Gibbstown, NJ), cells grown 
in LB complex medium for overnight were cultured overnight twice for adaptation in R/2 
medium used for high cell density fermentation (Jeong and Lee, 2003). The R/2 medium 
is composed of: 2 g of (NH4)2HPO4, 6.75 g of KH2PO4, 0.93 g of citric acid H2O, 0.34 g 
of MgSO4, 20 g of glucose, 0.05 g of ampicillin and 5 ml of trace metal solution 
dissolved in 2 N HCl (10 g of FeSO4-7H2O, 2.25 g ZnSO4-7H2O, 1 g of CuSO4-5H2O, 
0.35 g of MnSO4-H2O, 0.23 g of Na2B4O7-10H2O, 1.5 g of CaCl2, and 0.1 g of 
(NH4)6Mo7O24 per L). E. coli BL21(DE3) harboring pSTJ4-Herceptin-IgG1, pSTJ4-
Herceptin-IgG1-Fc5, pSTJ4-Herceptin-IgG1-Fc601, or pSTJ4-Herceptin-IgG1-Fc701 
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were cultured in 500 ml baffled-flask with 120 ml R/2 media at 30 °C at 250 rpm for 8 h 
and then inoculated to 3.3L fermentor (BioFlo 310, New Brunswick Scientific Co., 
Edison, NJ) with 1.2 L R/2 medium. Cells were grown at 30 °C by fed-batch 
fermentation with pH-stat glucose feeding strategy. To maintain the dissolved oxygen 
(DO) concentration at 40% of air saturation, the automatic cascade controller increased 
agitation speed from 100 rpm to 1000 rpm, air flow rate from 1 to 3 SLPM (Standard 
liquid per minute) and pure oxygen flow rate from 0 to 1.5 SLPM when needed. The 
initial pH was adjusted to 6.8 and controlled by the addition of 30% (v/v) ammonium 
hydroxide when it decreased to less than 6.75 and by the supply of feeding solutions, 
(700 g/L of glucose and 10 g/L of MgSO4-7H2O; before induction) and (500 g/L glucose, 
10 g/L of MgSO4-7H2O, and 100 g/L of yeast extract; after induction), when it increased 
to more than 6.9. When the OD600 reached about 100, the cells were cooled at 25 °C for 
30 min, and then induced for protein synthesis with 1 mM of isopropyl-1-thio-β-D-
galactopyranoside (IPTG). 7 h later at an OD600 of ~130-140, the culture broth was 
harvested by centrifugation at 11,000 x g for 30 min.  
For the release of periplasmic proteins, cells were suspended in 1.2 L of 100 mM 
Tris, 10 mM EDTA (pH 7.4) solution supplemented with 4 mg of lysozyme (per g of dry 
cell weight) and 1 mM PMSF, and then incubated with shaking at 250 rpm at 30 °C for 
16 h. After centrifugation at 14,000 × g for 30 min, the supernatant was mixed with 
polyethyleneimine (MP Biomedical, Solon, OH) to a final concentration of 0.2% (w/v) 
recentrifuged at 14,000 × g for 30 min, and filtered through 0.2 µm filter. Clear filtrate 
was mixed with Immobilized Protein A agarose resin (Pierce Biotechnology, Rockford, 
IL) pre-equilibrated in 20 mM sodium phosphate buffer (pH 7.0) and incubated at 4 °C 
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for 16 h. After washing with 200 ml of 20 mM sodium phosphate buffer (pH 7.0) and 200 
ml of 40 mM sodium citrate (pH 5.0), wild type aglycosylated trastuzumab, 
aglycosylated trastuzumab-Fc5, aglycosylated trastuzumab-Fc601, and aglycosylated 
trastuzumab-Fc701 were eluted from the resin using 15 ml of 0.1 M glycine (pH 3.0) and 
neutralized immediately with 1M Tris (pH 8.0) solution. The eluted samples were 
concentrated by ultrafiltration through a 10 kDa Mw cutoff membrane and the retentate 
was applied to a Superdex 200 gel filtration column developed with PBS (pH 7.4).  
 
 3.2.5 BIAcore analysis for aglycosylated trastuzumab antibodies to FcγRI 
Glycosylated trastuzumab, trastuzumab, trastuzumab-Fc5, trastuzumab-Fc601, 
and trastuzumab-Fc701 were immobilized on CM5 sensor chip using amine coupling 
method recommened by the manufacturer (Biacore, Piscataway, NJ). The soluble 
monomeric FcγRI in HBS-EP buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM 
EDTA, and 0.005% P20 surfactant) was injected at a flow rate of 30 µl/min for 60 s with 
dissociation time 300 s. The FcγRI ligands were regenerated by single injection of 100 
mM citric acid, pH 3.0. Binding kinetics the soluble monomeric FcγRI with glycosylated 
trastuzumab, aglycosylated trastuzumab, trastuzumab-Fc5, and trastuzumab-Fc601 were 
obtained by injection of soluble FcγRI in duplicate at concentrations of 0, 25, 50, 100, 
200 nM for 60 s at a flow rate of 30 µl/min over immobilized trastuzumab antibodies. 
Binding kinetics for wild type aglycosylated trastuzumab to FcγRI was measured by 
injecting FcγRI in duplicate at concentrations 0, 200, 300, 400, 500, and 600 nM for 60 s 
at a flow rate 30 µl/min over immobilized aglycosylated trastuzumab. Binding curves at 
zero concentration was subtracted as a blank. Fitting of equilibrium responsess to steady-
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state affinity model provided by BIAevaluation 3.0 software generated equilibrium 
dissociation constants (KD). 
 
 3.2.6 ELISA analysis to measure the affinity of trastuzumab antibodies to Fc 
receptors 
50 µl of 4 µg/ml of aglycosylated trastuzumab, trastuzumab-Fc5, trasuzumab-
Fc601, or trasuzumab-Fc701 purified from E. coli, glycosylated IgG trastuzumab were 
diluted in 0.05 M Na2CO3 (pH 9.6) buffer and coated on 96 well polystyrene ELISA 
wells (Corning, Corning, NY) by incubation at 4 °C for 16 hr. The coated wells were 
blocked with 1 × PBS (pH 7.4), 0.5% BSA for 2 hr at room temperature, washed 4 times 
with PBS containing 0.05% Tween20, and incubated with serially diluted FcγRIIa, 
FcγRIIb C-terminally fused to GST (Berntzen et al., 2005), FcγRIIIa (R&D Systems, 
Minneapolis, MN) at room temperature for 1 h. After washing 4 times with the same 
buffer, 1:5,000 diluted anti-GST antibody HRP conjugate (Amersham Pharmacia, 
Piscataway, NJ) for FcγRIIa and FcγRIIb or 1:10,000 diluted anti-polyhistidine antibody 
HRP conjugate (Sigma-Aldrich, St. Louis, MO) for FcγRIIIa was added and plates were 
washed and developed using Ultra-TMB substrate (Pierce Biotechnology, Rockford, IL). 
To determine the binding of IgG to FcRn at pH 7.4, 2 µg/ml of FcRn preincubated in 
PBS (pH 7.4) containing 1:5,000 diluted anti-GST-HRP at room temperature for 1 h as 
previously described (Andersen et al., 2006) was added to plates coated with trastuzumab 
antibodies. To evaluate binding at pH 6.0, ELISAs were carried out as above except 20 
mM MES was added to washing buffer and sample dilution buffers and pH was adjusted 
to 6.0. 
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 3.2.7 Preparation of human monocyte-derived dendritic cells (mDCs)  
Human blood buffy coats collected from healthy donors (Gulf Coast Blood 
Center, Galveston, TX) and added to histopaque solution (Sigma-Aldrich, St. Louis, MO) 
at 1:1 volume, avoiding mixing of the contents. The blood-histopaque solution was 
centrifuged at 1600 rpm for 30 minutes at 23°C without centrifugation braking. The 
PBMC layer was isolated following gradient centrifugation, and washed twice through 
centrifugation with wash buffer (PBS, 2.5% FBS, 1mM EDTA). Cells were then 
resuspended in IMDM (Cambrex, Walkersville, MD) and added to a 24 well plate and 
incubated at 37°C for 2h to allow monocytes to adhere to the plate. Media and non-
adherent cells were then removed by asipration and adherent cells were washed 5 times 
with wash buffer. Cells were then resuspended with 1ml/well of growth media consisting 
of IMDM (Cambrex, Walkersville, MD), 10% FBS (Invitrogen, Carlsbad, CA), and 
cytokines IL-4 (R&D systems, Minneapolis, MN) at 200 ng/ml and granulocyte 
macrophage colony stimulating factor (GM-CSF, R&D systems, Minneapolis, MN) at 
200 ng/ml. IL-4 and GM-CSF were added on day 2 and 5 without changing media. The 
presence of DCs was evaluated by flow cytometry by staining with a fluorescent antibody 
(Anti-CD11c-FITC, eBioscience, San Diego, CA) against the DC-specific surface marker 
CD11c. 
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 3.2.8 ADCC assays 
Target SkBr3 tumor cells were labeled with the isotope Na51CrO4 (Perkin Elmer 
Life Sciences) at 100 uCi/106 cells for 1h at 37°C. Cells were then washed twice with 
PBS, resuspended in RPMI and added to a 96 well plate at 104 cells/well. Engineered Fc 
antibodies and relevant controls were added to the target cells in triplicate wells and 
incubated at 37°C for 1h. The plate was then centrifuged at 2000 rpm for 1 minute and 
washed twice with PBS. Effector cells, either fully differentiated mDCs (day 7) or freshly 
isolated PBMCs, were resuspended in RPMI, 2% low IgG FBS (Invitrogen, Carlsbad, 
CA), LPS (250 ng/106 cells) and added to the wells at various ratios. In blocking 
experiments, the FcγRI blocking antibody 10.1 was added to mDCs at 12 µg/250,000 
cells for 1h at 37°C (eBioscience, San Diego, CA) and then added to target cells. Target 
cells and mDCs were incubated at 37°C for 24h. The isotope levels present in cell media 
were then measured in a liquid scintillation counter. Incubation of target cells with 2% 
SDS was used as a positive control for maximum lysis and incubation with no effector 
cells was used as background lysis.  
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Table 3-1. Plasmids used in this study. 
Plasmids Relevant characteristics Reference or 
source 
pMoPac1 Cmr, lac promoter, tetA gene, C-terminal 
polyhistidine tag and c-myc tag 
(Hayhurst et al., 
2003) 
pMoPac12 Apr, lac promoter, tetA gene, skp gene, C-
terminal polyhistidine tag and c-myc tag 
(Hayhurst et al., 
2003) 
pMoPac1-FLAG-M18 NlpA fused M18 scFv gene, C-terminal 
FLAG tag in pMoPac1 
(Jung et al., 2007) 
pPelBFLAG Cmr, lac promoter, tetA gene, skp gene, 
C-terminal FLAG tag 
This study 
pPelBFLAG-Fc IgG1-Fc gene in pPelBFLAG This study 
pPelBFLAG-Fc5 IgG1-Fc5 gene in pPelBFLAG This study 
pPelBFLAG-Fc601 IgG1-Fc601 gene in pPelBFLAG This study 
pPelBFLAG-Fc701 IgG1-Fc601 gene in pPelBFLAG This study 
pMAZ360-M18.1-
Hum-IgG 
M18.1 humanized IgG1 gene in 
pMAZ360 
(Mazor et al., 
2007) 
pSTJ4-Herceptin IgG1 Herceptin IgG1 gene in pMAZ360-
M18.1-Hum-IgG1 
This study 
pSTJ4-Herceptin-Fc5-
IgG1 
Herceptin IgG1-Fc5 gene in pMAZ360-
M18.1-Hum-IgG1 
This study 
pSTJ4-Herceptin-
Fc601-IgG1 
Herceptin IgG1-601 gene in pMAZ360-
M18.1-Hum-IgG1 
This study 
pSTJ4-Herceptin-
Fc701-IgG1 
Herceptin IgG1-701 gene in pMAZ360-
M18.1-Hum-IgG1 
This study 
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Table 3-2. Primers used in this study. 
Primer 
Name Primer nucleotide sequence (5’  3’) 
STJ#16 TTGTGAGCGGATAACAATTTC 
STJ#196 CGCAGCGAGGCCCAGCCGGCCATGGCG 
STJ#197 CGCAATTCGAATTCGGCCCCCGAGGCCCC 
STJ#220 CAATTTTGTCAGCCGCCTGAGCAGAAG 
STJ#327 GCCCTTGAAGCTTGCAGAGCTGACCGTGACCAGCGT 
STJ#465 CCCACCGTGCCCAGCACCTGAANNSNNSNNSGGANNSNNSGTCTTCCTCTTCCCCCCAAAAC 
CC 
STJ#466 GGGTTTTGGGGGGAAGAGGAAGACSNNSNNTCCSNNSNNSNNTTCAGGTGCTGGGCACGGT 
GGG 
STJ#467 CCTGAGGTCACATGCGTGGTNNSNNSNNSNNSNNSGAAGACCCTGAGGTCAAGTTCAACTG 
G 
STJ#468 CCAGTTGAACTTGACCTCAGGGTCTTCSNNSNNSNNSNNSNNACCACGCATGTGACCTCAGG 
STJ#469 GCCGCGGGAGGAGCAGTACNNSNNSNNSTACCGTGTGGTCAGCGTCCTC 
STJ#470 GAGGACGCTGACCACACGGTASNNSNNSNNGTACTGCTCCTCCCGCGGC 
STJ#471 CAAGTGCAAGGTCTCCAACAAAGCCNNSNNSNNSNNSNNSGAGAAAACCATCTCCAAAGC 
CAAAGGG 
STJ#472 CCCTTTGGCTTTGGAGATGGTTTTCTCSNNSNNSNNSNNSNNGGCTTTGTTGGAGACCTTGCA 
CTTG 
STJ#473 CGCAGCGAGGCCCAGCCGGCCATGGCGGACAAAACTCACACATGCCCACCGTGCCCAGCA 
CCTG 
STJ#471 CAAGTGCAAGGTCTCCAACAAAGCCNNSNNSNNSNNSNNSGAGAAAACCATCTCCAAAGCC 
AAAGGG 
STJ#472 CCCTTTGGCTTTGGAGATGGTTTTCTCSNNSNNSNNSNNSNNGGCTTTGTTGGAGACCTTGC 
ACTTG 
STJ#473 CGCAGCGAGGCCCAGCCGGCCATGGCGGACAAAACTCACACATGCCCACCGTGCCCAGCA 
CCTG 
STJ#474 CGCAGCGAGGCCCAGCCGGCCATGGCGGAGGTTCAATTAGTGGAATCTG 
STJ#475 CGCAGCGAGGCCCAGCCGGCCATGGCGGATATTCAAATGACCCAAAGCCCG 
STJ#476 CGCAATTCGGCCCCCGAGGCCCCGCACTCTCCCCTGTTGAAGCTCTTTG 
STJ#479 GACAAAACTCACACATGCCCACCGTGCC 
STJ#480 GGCACGGTGGGCATGTGTGAGTTTTGTC 
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3.3 RESULTS 
 3.3.1 Isolation of aglycosylated Fc mutants exhibiting higher affinity to FcγRI 
binding compared to Fc5 
For the isolation of IgG1 Fc fragments displaying higher binding affinity to FcγRI 
than the Fc fragment (Fc5; E328V/M428I) (Fig. 3-1 and 3-2) described in chapter 2, the 
Fc5 gene was subjected to random mutagenesis by error prone PCR. The library was 7 × 
108 individual transformats with 0.264% error rate per gene based on the sequence of 20 
library clones randomly selected (Fig. 3-3). 
After the 5th round flow cytometry sorting of over 4 × 108 spheroloplasts labeled 
with FcγRI-FITC, high fluorescent clones were enriched following successive rounds of  
sorting (Fig. 3-4). After the 5th round, 19 individual clones exhibiting higher fluorescence 
than Fc5 were isolated (Fig. 3-5). Sequence analysis showed that all amino acid 
substitutions that contributed to the higher fluorescence signal of the isolated clones were 
located in one of three distinct regions; the upper CH2 region that is likely to directly 
contact FcγRI, the interdomain region connecting the CH2 region F β-sheets and CH3 B 
β-sheets, and the CH3 region that may contribute conformational changes for FcγRI 
binding (Fig. 3-6). Fc601 showed the highest affinity and contained two additional 
mutations K338R, G341V on the G strand of CH2 and A strand of CH3, respectively 
(Fig. 3-7 and 3-8).  
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Figure 3-1. Mutation points of isolated aglycosylated Fc5 (382E and 428M) represented 
on the 3D structure of glycosylated IgG1 Fc (PBD Code: 1FC1). 
CH3 
region 
CH3 region 
Met428 
Val382 
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Figure 3-2.  The location of 382E in β-sheet C and 428M in β-sheet F of CH3 domain 
represented on the crystal structure of glycosylated IgG. (PBD Code: 1FC1). 
CH3 region 
CH3 
Met428 
Val382 
CH2 
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Plac SD PelB FLAGHinge CH2 CH3
Error Prone PCR library (Randomization of Fc5)
Library size: 7 x 108
Error rate:0.264%
 
Figure 3-3. Error prone PCR library for engineering aglycosylated Fc5 domain. 
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Figure 3-4. Fluorescence histogram of spheroplasts labeled with FcγRI-FITC showing 
the enrichment by series rounds of FACS sorting. 
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Figure 3-5. Protein sequences of isolated Fc mutant clones exhibiting higher affinity to 
FcγRI than Fc5. Mean fluorescence values for the respective clones labeled with FcγRI-
FITC are shown in parenthesis. 
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Figure 3-6. Amino acid substitutions in variants Fc601-619 represented on the 3D 
structure of glycosylated IgG1 Fc (PBD Code: 1FC1). 
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Figure 3-7. Fluorescence histogram of spheroplasts expressing wild type Fc, Fc5, or 
Fc601 labeled with 30 nM of FcγRI-FITC. M: Mean fluorescence intensity. 
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Figure 3-8. Amino acid substitutions in Fc601 (K338R, G341V, E382V, M428I) 
represented on the 3D structure of glycosylated IgG1 Fc (PBD Code: 1FC1). 
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 3.3.2 Characterization of aglycosylated trastuzumab-Fc601 in E. coli  
Trastuzumab (Herceptin™) has been clinically utilized for the treatment of breast 
metastatic carcinomas that overexpress HER2/neu (Erb2) (Sergina and Moasser, 2007).  
Trastuzumab recognizes HER2/neu (Erb2) and interacts with surface FcγRs of immune 
cells leading to antibody dependent cell mediated cytotoxicity (ADCC), an important 
mechanism for therapeutic action (Lazar et al., 2006; Sergina and Moasser, 2007). Fc 
fragment genes engineered for high FcγRI affinity were incorporated into full length 
trastuzumab antibodies. For preparative production aglycosylated trastuzumab, 
trastuzumab-Fc5, and trastuzumab-Fc601 in E. coli the heavy and light chains were fused 
to the PelB signal peptide and placed downstream from the lac promoter in a dicistronic 
operon (Figure 3-9). Aglycosylated antibodies were produced by fed-batch fermentation 
of E. coli BL21(DE3) cells with a pH-stat glucose feeding strategy. Subsequently the 
aglycosylated antibodies were purifed from the periplasmic proteins using Protein A 
affinity chromatography followed by gel filtration chromatography as described in 
chapter 2. 
The binding kinetic constants of of full assembled aglycosylated trastuzumab-
Fc601 to FcγRI were measured by BIACore using immobilized trastuzumab-Fc601 on 
the CM5 sensor chip. As shown in Table 3-3 and Figure 3-10, trastuzumab-Fc601 bound 
to FcγRI with similar affinity to that of commercial-grade glycosylated trastuzumab from 
CHO cells and over 130-fold higher affinity compared with wild type aglycosylated 
trastuzumab (Table 3-3 and Fig. 3-10). The affinity of the trastuzumab-Fc601 for the 
extracellular domain of FcγRIIa, FcγRIIb, and FcγRIIIa was analyzed by ELISA. Similar 
to aglycosylated trastuzumab or aglycosylated trastuzumab-Fc5, the aglycosylated 
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tratuzumab exhibited low affinity to FcγRIIa or FcγRIIb (EC50≥ 1000-fold and 100-fold 
higher equilibrium dissociation constant for GST fused to FcγRIIa or FcγRIIb (Fig. 3-11 
and Fig. 3-12), FcγRIIIa (Fig. 3-13). The trastuzumab-Fc601 antibody exhibited only 
slightly higher affinity for FcγRIIb. We examined whether the amino acid substitutions in 
Fc5 and Fc601 affect pH dependent binding to the neonatal FcRn receptor which 
recognizes an epitope located in the CH2-CH3 interface (Martin et al., 2001). 
Aglycosylated trastuzumab-Fc5 showed pH-dependent binding to human FcRn at pH 5.5 
and pH 6.0 and significantly reduced binding at pH 7.4 similar to clinical grade, 
trastuzumab purified from CHO cells. On the other hand, aglycosylated trastuzumab-
Fc601 showed reduced affinity to FcRn binding at pH 6.0 indicating that the additional 
two amino acids substitutions in the CH2-CH3 of Fc601 interfered with binding to the 
neonatal Fc receptor (Fig. 3-14). 
 
 
 
Figure 3-9. Map of plasmid pSTJ4-Herceptin IgG1. 
Plac SD CH2 PelB CH3 CH1 VH1 SD PelB CVL 
pSTJ4-Herceptin IgG1 Fc mutants 
NcoI NheI SalI NotI HindIII EcoRV 
ColE1 ori APr 
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Table 3.3. Kinetic rates and equilibrium dissociation constants obtained by BIACore 
analysis for binding to FcγRI. 
 
 
 
 
 
 
 
Figure 3-10. BIACore sensorgram for aglycosylated trastuzumab (A) and aglycosylated 
trastuzumab-Fc601 (B).  
 
  
79
0
0.5
1
1.5
2
2.5
3
3.5
0.001 0.01 0.1 1 10 100
FcγRIIa-GST concentration (µg/ml)
O
D
45
0
Fc601 aglycosylated Fc5 aglycosylated
Wild type aglycosylated Glycosylated
Blank
 
Figure 3-11. ELISA assays for binding of trastuzumab antibodies to FcγRIIa-GST. 
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Figure 3-12. ELISA assays for binding of trastuzumab antibodies to FcγRIIb-GST. 
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Figure 3-13. ELISA assays for binding of trastuzumab antibodies to FcγRIIIa. 
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Figure 3-14. ELISA assays for pH dependent binding to FcRn at pH 7.4 and 6.0. Plates 
were coated with aglycosylated trastuzumab, trastuzumab-Fc5, trastuzumab-Fc601 or 
commercial glycosylated trastuzumab (Herceptin) and the binding of FcRn was detected 
using anti-GST-HRP. 
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 3.3.3 mDC mediated tumor cells killing by aglycosylated trastuzumab-Fc5 and 
trasutuzumab-Fc601 
Macrophages and immature dendritic cells greatly outnumber the classical killer 
cells (NK and T cells) in tumors (Bonmort et al., 2008). In recent years, the cytotoxic 
properties of various subpopulations of DCs towards cancer cells have attracted 
significant interest (Wesa and Storkus, 2007). Human circulating DCs express FcγRI, 
FcγRIIa, and FcγRIIb, but not FcγRIIIa (Fanger et al., 1996). The expression of FcγRI on 
DCs is largely dependent on the cytokine environment. We found that human mDCs 
isolated from PBMCs following differentiation for 7 days in the presence of IL-4 and 
GM-CSF and activated by exposure to LPS expressed high levels of CD11c (Fig. 3-15) 
and FcγRI (Fig. 3-16). SkBr3 breast carcinoma epithelial cells overexpressing Her-2 were 
incubated either with either clinical grade trastuzumab, aglycosylated trastuzumab-Fc5 or 
aglycosylated trastuzumab-Fc601 at 10 µg/ml. Wild type aglycosylated trastuzumab or 
media without effector cells were used as controls. Activated mDCs were then added at 
either 25:1 or 100:1 ratios and the lysis of the SkBr3 target cells was determined by 
monitoring 51Cr release 24 hours later. No cell lysis above background was detected with 
glycosylated trastuzumab. In contrast, aglycosylated trastuzumab-Fc5 conferred ~40% 
(25:1; E:T ratio) and ~70% (100:1; E:T ratio) tumor cell killing, A comparable degree of 
cell lysis was observed with aglycosylated trastuzumab-Fc601 (Fig. 3-17A). Consistent 
with earlier studies (Lazar et al., 2006; Suzuki et al., 2007), when PBMCs which express 
all FcγRs were used as effector cells, glycosylated trastuzumab showed excellent ADCC 
(Fig. 3-17B). Thus, the highly specific and selective affinity binding of Fc5 or Fc601 to 
FcγRI is able to mediate DC-mediated killing of target tumor cells. 
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Figure 3-15. Flow cytometry histogram showing the expression of CD11c on activated 
DCs. Unlabeled DCs (unshaded); labeled DCs (shaded). 
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Figure 3-16. Flow cytometry histogram showing the expression of FcγRI on activated 
DCs. Unlabeled DCs (unshaded); labeled DCs (shaded). 
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Figure. 3-17. Antibody dependent cellular cytotoxicity (ADCC) induced by engineered 
aglycosylated Fc antibodies. (A) Target Her2 expressing tumor cells (SkBr3) were 
exposed to Her2/neu binding purified aglycosylated or clinical grade glycosylated 
trastuzumab IgG1 antibodies. Effector cells (monocyte derived dendritic cells, mDCs) 
were then introduced and cell lysis was measured by 51Cr release. Trastuzumab-Fc5 and 
Fc601 with high affinity binding to FcγRI induce high levels of ADCC, while 
glycosylated IgGs show very little ADCC activity. (B) SkBr3 cells were exposed to 
engineered IgGs as in A) and exposed to peripheral blood mononuclear cells (PBMCs) as 
effector cells. Glycosylated IgGs show very high ADCC activity while trastuzumab-Fc5 
and Fc601 display reduced levels. (statistical significance using unpaired Student’s t-test 
relative to wt Fc and No Ab controls in (A) and (B), respectively *, P < 0.05 ; **, P < 
0.01).  
B 
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**
**
**
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 3.3.4 Isolation of aglycosylated Fc mutants exhibiting higher affinity to FcγRI 
binding than Fc5 with retaining pH dependent FcRn binding 
Human FcRn has high affinity to human IgG under slightly acidic pH condition 
and low affinity at neutral or basic pH (Ober et al., 2004a; Ober et al., 2004b; Raghavan 
and Bjorkman, 1996; Rodewald, 1976). The FcRn binding sites are located at the 
interface of CH2 and CH3 domains, similar binding sites for staphylococcal Protein A 
(SpA) (Kim et al., 1994; Shields et al., 2001). Fc601 showed improved FcγRI binding 
affinity than Fc5. However, two additional mutations (K338R, G341V) of Fc601 in lower 
CH2 region of IgG1 impaired the pH depended FcRn binding that is critical for the 
regulation of serum IgG concentration by allowing pinocyosed IgGs to make strong IgG-
FcRn complex in acidified endosomes for recycling to blood across vascular endothelial 
cell membrane instead of degradation in lysosomes (Ghetie and Ward, 2000). 
To isolate engineered Fc domains showing higher affinity to FcγRI than Fc5 with 
retaining the pH dependent FcRn binding, new combinatorial libraries consisting of 
random amino acids in upper CH2 region were constructed. The library cells were 
composed of 4 sub-libraries (Figure 3-18) that randomized lower hinge, B/C loop, C’/E 
loop, and F/G loop parts of upper CH2 regions. Spheroplasts were sorted with selectively 
gating the top 3% of the population showing the highest fluorescence due to FcγRI-FITC 
binding. After the 4th round of sorting, 8 individual clones exhibiting higher fluorescence 
than Fc5 were isolated (Fig. 3-19). All of the clones were isolated from the library 
randomized F/G loop of CH2 region and have consensus mutations in L328W and I332Y 
mutations. Also, the amino acid residue 329P was well conserved suggesting the critical 
role of the specific amino acid residue in the binding of FcγRI (Fig. 3-20). The highest 
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fluorescent clone was Fc701 that have L328W, A330V, P331A, I332Y mutations in 
328L-332I region and one additional Q295R mutation (Fig. 3-21 ~ 3-23). 
ELLGGPSV
234 239
VVDVSHE
264 268
YNSTY
297 299
ALPAPIE
328 332
 
 
Figure 3-18. Library for the selection of higher affinity Fc fragments to FcγRI than Fc5 
with pH dependent FcRn binding. 
 
 
 
 
Figure 3-19. DNA sequences of isolated Fc mutant clones exhibiting higher affinity to 
FcγRI than Fc5. Mean fluorescence values for the respective clones labeled with FcγRI 
are shown in parenthesis. 
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Figure 3-20. Summary of mutations in Fc701 – 709. 
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Figure 3-21. Fluorescence histogram of spheroplasted cells for wild type Fc, Fc5, Fc701, 
and Fc702 labeled with 1 nM of FcγRI-FITC. M: Mean fluorescence intensity. 
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Figure 3-22. Fluorescence histogram of spheroplasted cells displaying wild type Fc, Fc5, 
Fc601, and Fc701 after labeling with 1 nM of FcγRI-FITC. M: Mean fluorescence 
intensity. 
 
 
 
Figure 3-23. Mutation points of isolated aglycosylated Fc701 represented on the 3D 
structure of glycosylated IgG1 Fc (PBD Code: 1FC1). 
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 3.3.5 Characterization of aglycosylated trastuzumab-Fc701 
 Full length trastuzumab-Fc701 IgG1 was produced by fed batch fermentation and 
purified using Protein A affinity chromatography followed by gel filtration 
chromatography as described in chapter 2. The kinetic rate constants for the binding of 
full length trastuzumab-Fc701 to FcγRI were measured by BIAcore sensor using 
trastuzumab-Fc701 antibodies immobilized on CM5 sensor chip and soluble FcγRI. 
Trastuzumab-Fc701 bound to FcγRI with similar affinity with trastuzumab Fc601 with 
slightly higher on and off rates than trastuzumab Fc601 (Table 3-4 and Fig. 3-24). 
The pH dependent FcRn binding was analyzed by ELISA at pH 6.0 and at pH 7.4. 
Trastuzumab-Fc601 containing 2 mutations at CH2-CH3 interface did not showed 
significant FcRn binding at pH 6.0. In contrast, trastuzumab Fc701 containing 4 
mutations in F/G loop and one mutation in B/C loop of CH2 region showed strong pH 
dependent binding property with higher affinity binding to FcRn at pH 6.0 than wild type 
aglycosylated or glycosylated trasutuzumab antibodies and no significant binding 
afftinity at pH 7.4 (Fig. 3-25). 
Similary with previsously isolated engineered aglycosylated trastuzumab-Fc5 or –
Fc601, aglycosylated trastuzumab-Fc701 was very specific to FcγRI without showing 
significant binding affinity to effector FcγRIIa (Fig. 3-26), FcγRIIb (Fig. 3-27) and 
FcγRIIIa (Fig. 3-28). 
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Table 3.4. Kinetic rates and equilibrium dissociation constants for trastuzumab 
antibodies obtained by BIACore analysis for binding to FcγRI. 
 
 
 
 
100
RU
80
60
20
0
600
-20
40
R
es
p.
 
D
iff
.
Time
300150 200 250 350 400 450 500 550
s
R
es
p.
 
D
iff
.
 
 
Figure 3-24. BIAcore sensorgrams of aglycosylated trastuzumab-Fc701 antibody with 
binding to FcγRI. 
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Figure 3-25. ELISA assays for pH dependent binding to FcRn at pH 6.0 and 7.4. Plates 
were coated with aglycosylated trastuzumab, trastuzumab-Fc5, trastuzumab-Fc601, 
trasutuzumab-Fc701 or commercial glycosylated trastuzumab and the binding of FcRn 
was detected using anti-GST-HRP. 
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Figure 3-26. ELISA assays for binding of trastuzumab antibodies to FcγRIIa-GST. 
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Figure 3-27. ELISA assays for binding of trastuzumab antibodies to FcγRIIb-GST. 
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Figure 3-28. ELISA assays for binding of trastuzumab antibodies to FcγRIIIa. 
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3.4 DISCUSSION 
In this study, a variety of Fc libraries were used in order to isolate aglycosylated 
antibody Fc mutants exhibiting higher affinity to FcγRI. High throughput screening from 
the error prone PCR library that introduced random amino acid substitutions into the Fc5 
antibody described in chapter 2, generated aglycosylated trastuzumab-Fc601 exhibiting 
130-fold increased affinity to FcγRI compared with the wild type aglycosylated 
trastuzumab. But 2 mutations (K338R, G341V) additionally introduced at the interface of 
CH2 and CH3 regions for Fc5 fragments abolished the binding affinity to human FcRn at 
slightly acidic condition (pH 6.0) that is critically required for maintaining longer serum 
half-life (Ghetie and Ward, 2000). Screening of a saturation library that randomized 
select amino acid residues in upper CH2 of Fc5 resulted in the isolation of trastuzumab-
Fc701 that displayed similar affinity with trastuzumab-Fc601 but also exhibited strong 
pH-dependent FcRn binding, with a slightly higher affinity at pH 6.0 compared to clinical 
grade glycosylated trastuzumab and no significant binding at neutral pH.   
Dendritic cells are professional antigen presentation cells but can mediate tumor 
cells killing directly by a variety of apoptosis and necrosis pathways (Wesa and Storkus, 
2007) or indirectly by stimulating tumor killing cytotoxic by T cells (Rongcun Yang, 
2001) or NK cells (Moretta, 2002; Schmitz et al., 2005). From a subpopulation of 
pheripheral blood DCs (CD64- M-DC8+), Schmitz et al. reported that the trastuzumab 
antibody mediated ADCC of target cells via its interaction with FcγRII and FcγRIII 
(Schmitz et al., 2002). The myeloid-derived DCs used in our study are CD11c+ CD64+ 
and therefore can be categorized as the mature DCs. Schäkel et al. have reported that 
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mature DCs express  a high level of CD33, HLA-DR, CD45RO, and CD83 but not 
CD16 (Schäkel, et al., 1998). Therefore there seems to be an inconsistency between the 
activation of mature DCs via FcγRIIIa (CD16) reported by Schmitz et al. (Schmitz et al., 
2002) and the lack of expression of the receptor reported by Schäkel et al. (Schäkel, et 
al., 1998). Also, in our studies clinical grade tarstuzumab which binds well to the FcRIIa 
receptor on DCs did not mediate ADCC. It appears that the DC subpopulation that 
mediated cytotoxicty in our studies is different from the CD64- M-DC8+ employed by 
Schmitz et al. (Schmitz et al., 2002). Importantly, we showed that trastuzumab-Fc5 and 
trastuzumab-Fc601 exhibited potent DC-mediated lysis of Her2 overexpressing tumor 
cells whereas clinical grade glycosylated tratsuzumab did not. It is likely that the inability 
of glycosylated trastuzumab to induce high levels of DC-mediated ADCC is due to its 
non-discriminate binding to other Fc receptors including the inhibitory FcγRIIb. In 
contrast, aglycosylated trastuzumab-Fc5 and trasutuzmab-Fc601 have selective and high 
affinity binding to FcγRI only. This result is consistent with the previous results for the 
enhanced tumor protection in mice by abrogation of inhibitory FcγRIIb signaling on DCs 
(Kalergis and Ravetch, 2002). The activation of PBMCs by glycosylated trastuzumab 
most likely due to a high concentration of NK cells that express FcγRIIIa; and since the 
levels of circulating immune cells expressing FcγRI is low, it is not surprising that 
trastzumab-Fc5 and trastuzumab-Fc601 showed low PBMC-mediated ADCC. The full 
therapeutic potential of selective activation of FcγRI and DC-mediated ADCC in tumor 
immunotherapy is still unclear. Future studies will need to explore this by determining if 
other relevant DC-mediated functions (i.e., antigen presentation and activation of tumor 
specific T cells) are enhanced by aglycosylated FcγRI binding antibodies. 
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Aglycosylated antibodies engineered for ADCC bypass the need for 
glycoengineering, mammalian expression and problems related to glycan heterogeneity. 
Together with technologies for IgG isolation (Mazor et al., 2007) and commercial level 
expression (Simmons et al., 2002), it is now feasible to carry out the complete 
development of therapeutic antibodies in bacteria. The therapeutic utility of aglycosylated 
antibodies will be further determined by pharmacological parameters, including stability, 
biodistribution and immunogenicity in humans. 
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Chapter 4 
Development of high-throughput antibody screening system for 
immobilized antigen1 
4.1 INTRODUCTION 
 The isolation of antibodies exhibiting high affinity and specificity for target 
antigens is of great importance for numerous aspects of biotechnology, ranging from 
proteomics to the development of therapeutics. Starting in the 1980s, the isolation of useful 
recombinant antibody fragments has been greatly facilitated by the introduction of display 
technologies for the screening of large libraries of antibody genes (Hoogenboom, 2005).  
Antibody display systems rely on the establishment of a physical linkage between an 
antibody gene and the antibody itself. In phage display, the first technique used for 
antibody fragment isolation from repertoire libraries, polypeptides are presented on the 
surface of filamentous bacteriophage via fusion to a phage coat protein (Smith, 1985). 
Numerous antibodies to widely diverse antigens have been isolated from either immune 
repertoires or synthetic libraries by employing sequential rounds of filamentous phage 
panning against immobilized antigen (Bradbury and Marks, 2004). Alternatively, very high 
affinity antibodies can be isolated using display on bacteria (Daugherty et al., 2000a; 
Daugherty et al., 2000b; Georgiou et al., 1997; Lofblom et al., 2005) or yeast (Boder et al., 
                                                 
This chapter appeared as a paper in Jung, S. T., Jeong, K. J., Iverson, B. L. & Georgiou, 
G. (2007) Biotechnol Bioeng 98, 39-47. 
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2000; Boder and Wittrup, 1997; Feldhaus et al., 2003) followed by flow cytometric 
screening for antigen-binding clones (Mattanovich and Borth, 2006). 
 For many applications it is desirable to isolate antibodies to antigens that are bound 
on either synthetic surfaces or on cellular membranes (Binyamin et al., 2006; Linenberger 
et al., 2002). With phage display, antibody libraries can be readily screened for binding to 
either purified membranes in lipid vesicles or to antigens presented on whole cells (Barry et 
al., 1996; Brown, 2000; Du et al., 2006; McGuire et al., 2004). In principle, bacterial and 
yeast display systems can also be employed for the discovery of polypeptides that bind to 
surface immobilized ligands (Dane et al., 2006; Richman et al., 2006; Wang and Shusta, 
2005). However, the larger size and more complex surfaces presented by microbial cells 
relative to filamentous phage could introduce additional complications such as non-specific 
association between other components of the cellular surface. An additional problem with 
libraries displayed on the surface of E. coli is that the lipopolysaccharide layer on the 
external surface of intact outer membrane introduces a negatively charged steric barrier to 
prevent the interaction of displayed proteins and immobilized ligands (Vaara and 
Nurminen, 1999). 
 Recently, we have developed a new E. coli protein display system, called Anchored 
Periplasmic Expression (APEx) (Harvey et al., 2004). In this technology, proteins are not 
displayed on the cell surface but instead they are tethered to the periplasmic side of the 
inner membrane. This is accomplished by fusing the protein of interest to an inner 
membrane anchor such as a transmembrane segment of a native inner membrane protein 
(Jeong et al., 2004), an anchoring motif derived from a lipoprotein which becomes fatty 
acylated during protein translocation and is thus embedded into the lipid bilayer (Pugsley, 
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1993; Sankaran and Wu, 1994), or an exogenous protein such as the M13 phage coat 
protein gp3 known to association with the periplasmic side of the inner membrane (Barbas 
Cf et al., 1991). Spheroplasting using EDTA and lysozyme is then used to remove the outer 
membrane allowing the inner membrane-anchored polypeptide to interact and bind to 
desired ligands. The removal of the outer membrane eliminates the steric barrier presented 
by lipopolysaccharide and surface carbohydrates and facilitates interactions with much 
larger soluble ligands, compared to bacterial surface display (Harvey et al., 2004). 
However, the binding of displayed receptor proteins on spheroplasted E. coli to ligand 
presenting surfaces via specific receptor-ligand interactions has not been investigated 
previously. 
 In this chapter, we show that APEx can be employed to allow the specific binding 
of spheroplasts expressing inner membrane anchored antibodies onto immobilized antigens 
on beads. As model antibodies for this study we used the 26-10 scFv which binds to 
digoxin and related cardiac glycosides such as digoxigenin with low nanomolar affinity 
(Francisco et al., 1993), and the M18 scFv, which binds to the protective antigen (PA) of B. 
anthracis with an affinity of in the low picomolar range (Harvey et al., 2004). Expression 
of GFP in the cytoplasm was employed to render the spheroplasts fluorescent and facilitate 
their detection upon binding onto beads (Fig. 4-1A). Spheroplast binding was shown to be 
mediated by the recognition of the immobilized antigen by the displayed scFv. Protocols 
for the enrichment of spheroplasts binding to immobilized antigen from a large excess of 
spheroplasts expressing unrelated scFvs were developed. These results suggest that APEx 
can be employed for the screening of antibody libraries to immobilized antigens and 
potentially to antigens expressed on cell surfaces. 
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Figure 4-1. Selection of APEx spheroplasts via antibody-antigen interactions. (a) GFP 
expression and display of antibody (scFv) via APEx. (b) Binding of fluorescent 
spheroplasts on antigen-immobilized beads. (c) Selection of highly fluorescent 
spheroplast-bound beads using FC by gating the region defined by the high FL1 signal 
and the distinct scatter of the beads (FSC and SSC).  
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4.2 MATERIALS AND METHODS 
 4.2.1 Reagents 
O Oligonucleotides primers and restriction endonucleases were purchased from 
Integrated DNA Technologies (Coralville, IA) and New England Biolabs (Ipswich, MA), 
respectively. Expanded High Fidelity Polymerase, Digoxigenin-3-O-methyl-carbonyl-e-
aminocaproic acid N-hydroxysuccinimide ester (DIG-NHS-ester), and monoclonal Anti-
Digoxigenin-Fluorescein Fab fragments from sheep were from Roche Diagnostics 
Corporation Biolab (Indianapolis, IN). Digoxigenin-BODIPY (Digoxigenin-4,4-difluoro-
5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl ethtylenediamine) was 
synthesized as described previously (Harvey et al., 2004). PA-FITC was purchased from 
List Biological Laboratories, Inc (Campbell, CA). Amine functionally activated beads 
(D: 10 µm, TentaGel M NH2) were purchased from Rapp Polymere GmbH (Tübingen, 
Germany). N,N,-Dimethylformamide (absolute, over molecular sieves) were from Fluka 
(Buchs, Switzerland). Analytical grades of all other chemical reagents were purchased 
from Sigma-Aldrich (St. Louis, MO) unless stated otherwise. 
 
 4.2.2 Construction of plasmids for anchored antibody and GFP 
All plasmids and primers used in this study are summarized in Table 4-1 and 
Table 4-2. For the expression of the 26-10 scFv and M18 scFv fused to the signal peptide 
and first six N-terminal amino acid residues of NlpA(1-6: CDQSSS), pAPEx1-2610 and 
pAPEx-M18 were digested with SfiI, and the gene fragments containing 26-10 scFv and 
M18 scFv gene were subcloned into SfiI-digested pMoPac1-FLAG in which polyhistidine 
tag and c-myc tag was replaced by FLAG tag (DYKDDDDK) from the pMoPac1 to yield 
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pMoPac1-FLAG-2610 and pMoPac1-FLAG-M18, respectively. For the expression of 26-
10 scFv as MalF(1-175) fusion pTOPO-2610 (Jeong et al., 2004) was modified by the 
addition of a sequence encoding a C-terminal FLAG tag epitope. Similarly, the M18 scFv 
gene was fused to MalF(1-175) by first amplifying the M18 scFv gene with specific 
primers STJ#50 and STJ#51 and subcloning into BglII – HindIII digested pTOPO-
FLAG-2610 to yield pTOPO-FLAG-M18. pAK200-2610 and pAK200-M18 were used to 
express the 26-10 and M18 scFv respectively, fused at the C-terminus to the M13 gp3 
protein. Finally, pBAD30-KmR-GFPmut2 was constructed by amplifying the gfpmut2 
gene (Cormack et al., 1996) with primers STJ#38 and STJ#39 and subcloning it into SacI 
- HindIII digested pBAD30-KmR, a derivative of pBAD30 (Guzman et al., 1995) but the 
Apr gene had been replaced with Kmr gene. All plasmids for antibody expression were 
co-transformed with pBAD30-Kmr-GFPmut2 into E. coli Jude-1(F' [Tn10(Tetr) proAB+ 
lacIq ∆(lacZ)M15] mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 ∆lacX74 deoR recA1 
araD139 ∆(ara leu)7697 galU galK rpsL endA1 nupG) (Kawarasaki et al., 2003). 
 
 4.2.3 Digoxigenin immobilization onto beads 
30 mg of amine functionally activated beads  (TentaGel M NH2) were 
resuspended in 3 ml of N,N,-Dimethylformamide for 1 h then mixed with 5 mg of 
Digoxigenin-3-O-methyl-carbonyl-ε-aminocaproic acid N-hydroxysuccinimide ester 
(DIG-NHS-ester) and incubated overnight. The digoxigenin immobilized beads were 
washed by centrifugation 3000 x g for 1 min and resuspended in 10 ml of PBS 
(Phosphate buffered saline) three times and finally were resuspended in 3 ml PBS. The 
immobilization of digoxigenin on beads was confirmed by FC analysis using a 
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monoclonal Anti-Digoxigenin-Fluorescein Fab conjugate. Specifically, 50 µl of a 1% 
(wt/vol) digoxigenin immobilized beads solution was added to 150 µl of PBS containing 
4 µl of Anti-Digoxigenin-Fluorescein Fab fragments (200 µg/ml). After a 1 hr incubation 
at room temperature with shaking, the immobilized bead solution was diluted 5x in PBS 
and the bead-associated fluorescence was monitored on a BD FACSort through a 530/30 
band pass filter (BD Biosciences, San Jose, CA). 
 
 4.2.4 Culture conditions 
E. coli transformed with pBAD30-KmR-GFPmut2 and plasmids expressing inner 
membrane tethered 26-10 scFv or M18 scFv as appropriate, were grown overnight at 
37°C in Terrific Broth (TB) (Becton Dickinson Diagnostic Systems Difco™, Sparks, 
MD) supplemented with 2% (wt/vol) glucose, chloramphenicol (40 µg/ml) and 
kanamycin (50 µg/ml). After overnight culture, the cells were diluted 1:100 in fresh TB 
medium without glucose, incubated at 37°C for 2 h and then at 25°C. For induction of 
antibody fragments and GFP, 1 mM of isopropyl-1-thio-β-D-galactopyranoside (IPTG) 
and 0.2% (wt/vol) arabinose, respectively, were added when the culture OD600 reached 
approximately 0.6. 
 
 4.2.5 Preparation of spheroplasts and FC analysis 
5 h after induction, an aliquot of the culture equivalent to 4.5 ml/OD600 was 
collected, the cells harvested by centrifugation, washed two times in 1 ml of 10 mM Tris-
HCl (pH 8.0), and resuspended in 1 ml of STE solution (0.5 M Sucrose, 10 mM Tris-
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HCl, 10 mM EDTA, pH 8.0). After incubation with rotating mixing at 37°C for 30 min, 
the cells were pelleted by centrifugation at 12,000 x g for 1 min and washed in 1 ml of 
Solution A (0.5 M Sucrose, 20 mM MgCl2, 10 mM MOPS, pH 6.8). The washed pellet 
was resuspended in 1 ml of Solution A containing 1 mg/ml of hen egg lysozyme and 
incubated at 37°C for 15 min. The resulting suspension was centrifuged at 12,000 x g for 
1 min and the spheroplasts were resuspended in 1 ml of PBS. 300 µl of the spheroplasts 
and 50 µl of the 1% (wt/vol) digoxigenin immobilized beads were mixed in a glass test 
tube and incubated at room temperature for 2 h with shaking and washed in 1 ml of PBS 
to remove unbound spheroplasts by centrifugation at 3,000 rpm for 3 min.  FC analysis 
was performed using a BD FACSort. 
 
 4.2.6 Spheroplast enrichment onto beads with immobilized digoxigenin 
Spheroplasts displaying the 26-10 scFv and the M18 scFv were prepared and 
mixed at 1:100 and 1:1000 ratios. Beads rendered fluorescent by the binding of GFP-
expressing spheroplasts were sorted on a MoFlo droplet deflection FC (Dako 
Cytomation, Fort Collins, Colorado) equipped with a 488 nm Argon laser for excitation.  
Spheroplasts bound on beads were detected through a 530/40 band pass filter (FL1). By 
gating on the populations displaying the distinctive high forward scattering (FSC) and 
side scattering (SSC) of spheroplasted cells as well as the highest ~2.5% FL1 signal, the 
bead-bound spheroplasts were sorted. The scFv genes in the spheroplasts were amplified 
by PCR using two specific primers STJ#16 and STJ#130, cloned into pAK200 vector 
using SfiI cloning sites, and transformed in electrocompetent E. coli Jude-1 cells 
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harboring the plasmid pBAD30-KmR-GFP. The resulting transformants were subjected 
to the second round sorting. To determine sorting efficiency, 40 clones after every round 
sorting were randomly selected and the number of 26-10 scFv clones was confirmed by 
colony PCR using 26-10 scFv specific primers STJ#128 and STJ#129. 
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Table 4-1. Plasmids used in this study. 
Plasmids Relevant characteristics Reference or source 
pMoPac1 Cmr, lac promoter, tetA gene, C-
terminal polyhistidine tag and c-myc 
tag 
(Hayhurst et al., 2003) 
pAPEx1-2610 NlpA fused 26-10 scFv gene in 
pMoPac1 
(Chen et al., 1999) 
pAPEx1-M18 NlpA fused M18 scFv gene in 
pMoPac1 
(Harvey et al., 2004) 
pMoPac1-FLAG-
2610 
NlpA fused 26-10 scFv gene, C-
terminal FLAG in pMoPac1 
This study 
pMoPac1-FLAG-
M18 
NlpA fused M18 scFv gene, C-terminal 
FLAG tag in pMoPac1 
This study 
pTOPO-2610 MalF fragment fused 26-10 scFv gene, 
C-terminal polyhistidine tag in 
pMoPac1 
(Jeong et al., 2004) 
pTOPO-FLAG-
2610 
C-terminal FLAG tag in pTOPO-2610 This study 
pTOPO-FLAG-
M18 
MalF fragment fused M18 scFv gene, 
C-terminal FLAG tag in pTOPO-2610 
This study 
pAK200 Cmr, lac promoter, tetA gene, C-
terminal Gene III fusion 
(Krebber et al., 1997) 
pAK200-2610 26-10 scFv gene in pAK200 (Harvey et al., 2004) 
pAK200-M18 M18 scFv gene in pAK200 (Harvey et al., 2004) 
pBAD30 Apr, BAD promoter (Guzman et al., 1995) 
pBAD30-KmR Kmr, BAD promoter This study 
pGFPmut2 Apr, tac promoter (Cormack et al., 1996) 
pBAD30-KmR-
GFPmut2 
Kmr, BAD promoter, gfpmut2 gene This study 
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Table 4-2. Primers used in this studya. 
Primer 
Name Primer nucleotide sequence (5’  3’) 
STJ#16 TTGTGAGCGGATAACAATTTC 
STJ#38 ACCGGAGCTCTTAAAGAGGAGAAAGGTCATGAGTAAAGGAGAAGAACTTTTCAC 
STJ#39 TTAGGGAAGCTTTTATCATTTGTATAGTTCATCCATGCCATG 
STJ#43 TTTTAGGGCTGCAGCTCAGAATGACTTGGTTGAGTG 
STJ#44 GCGGAATTCGCCGGAAGGGCCCAGTGCTGCAATGATACCG 
STJ#50 GGCTAGATCTGGAGGTGGCAGCGAGGCCCAGCCGGC 
STJ#51 TTAGGGAAGCTTCTATTAGGCGCGCCCTTTGTC 
STJ#128 GGGTACATTTTCACCGACTTCTACATG 
STJ#129 GAACATGCGTAGTTTGGCTACAGTAATATATTG 
STJ#130 GCGTTTGCCATCTTTTCATAATCAAAATCACC 
aUnderlining indicates the restriction enzyme sites 
 
4.3 RESULTS 
 4.3.1 Display of scFv antibodies on E. coli inner membrane 
Three different anchoring domains were employed for the display of the scFv 
antibodies (26-10 scFv and M18 scFv) onto the periplasmic side of the inner membrane 
(Fig. 5-2A). First, the signal peptide and the 6 N-terminal amino acid residues of the 
mature E. coli lipoprotein NlpA were fused to the scFv antibodies. The resulting proteins, 
NlpA(1-6)-scFvs, become fatty acylated at the N-terminal Cys residue. Upon 
translocation into the periplasmic space, the lipid tail anchors the constructs on the 
periplasmic side of the inner membrane. Second, we constructed fusions containing aa 1-
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175 of MalF encoding the three N-terminal transmembrane α-helices followed by 93 
amino acid residues presumed to be located within a long periplasmic loop (Tapia et al., 
1999). In these fusions, it is anticipated that the transmembrane α-helices serve as the 
membrane anchor whereas aa 82-175 serve as a linker to remove spatially the antibody 
binding site from the surface of the inner membrane and potentially facilitate binding to 
immobilized antigens. Also, we reasoned that integral membrane proteins such as MalF 
might be localized at different sites than lipoproteins on the inner membrane, and such 
differences in localization of the fusion might affect antigen binding. Finally, C-terminal 
anchoring was achieved by fusing the 3’ of the scFv genes to the gp3 protein of M13, 
which is localized on the inner surface of the inner membrane until the later stages of 
filamentous phage assembly (Barbas Cf et al., 1991). All scFv fusions were expressed 
from the lac promoter. 
The display of the anchored scFvs on spheroplasts via NlpA(1-6), MalF(1-175) or 
gp3 fusions was evaluated by flow cytometry (FC), following labeling with digoxigenin-
BODIPY (for 26-10 scFv fusions) and PA-FITC (for M18 scFv fusions) respectively 
(Fig. 4-2B). To aid the visualization of spheroplasts by FC, the cells were also 
transformed with pBAD30-KmR-GFPmut2, a plasmid encoding the mut2 version of GFP 
(Cormack et al., 1996), which fluoresces approximately 100 times more intensely than 
wild-type GFP and also has highly red shifted maximum excitation wavelength suitable 
for FACS applications using standard FITC emission filters. As expected, upon induction 
of GFPmut2 expression with arabinose the cells became brightly fluorescent. 
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Figure 4-2. Inner Membrane anchoring of scFvs display. (A) scFv antibodies were fused 
to the NlpA signal peptide followed by six amino acid residues (CDQSSS) from the 
mature protein, the E. coli MalF 1-175, or the filamentous phage gp3 protein. The first 
two result in N-terminal display whereas with the latter the scFv is displayed from its C-
terminus. (B) Fluorescence histograms showing spheroplasts displaying 26-10 scFv (peak 
a) and M18 scFv (peak b) fused to NlpA(1-6), MalF (1-175), or gp3 and incubated with 
either soluble PA-FITC or soluble Digoxigenin-BODIPY. M: Mean fluorescence 
intensity. 
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 4.3.2 Binding of spheroplasts on the antigen immobilized beads 
Digoxigenin was immobilized via an amide linkage onto amine functionally 
activated beads as described in Materials and Methods. FC analysis confirmed the 
efficient immobilization of digoxigenin on beads (Fig. 4-3A). The binding between 
digoxigenin-derivatized beads and spheroplasts expressing the 26-10 or the M18 anti-PA 
scFv fused to either NlpA(1-6), MalF(1-175) or gp3 was evaluated by FC analysis. An 
FC gate was set up based on the side and forward scatter (SSC and FSC, respectively) of 
the beads, which is clearly distinct from that of the cells (Fig. 4-3C). Fluorescence with 
both the 26-10 and M18 antibodies would be indicative of non-specific binding of the 
spheroplasts onto the beads, whereas fluorescence with only one or more of the 26-10 
scFv expressing constructs would indicate a specific interaction.  
As can be seen in Figure 4-3B, the highest fluorescence was observed in 
spheroplasts expressing the 26-10 scFv-gp3 fusion where the antibody fragment is 
tethered to the inner membrane via its C-terminus. The FACS data presented in Figure 5-
3 indicate that spheroplasts can bind specifically onto a solid surface by virtue of the 
interaction between an inner membrane tethered antibody and the immobilized antigen.  
Binding of the 26-10 scFv-gp3 onto digoxigenin-derivatized beads was also confirmed by 
fluorescence microscopy (data not shown). By comparison, the fluorescence of beads 
incubated with spheroplasts expressing either NlpA(1-6)-26-10 scFv or MalF(1-175)-26-
10 sc Fv was about 3-fold lower than that of spheroplasts expressing 26-10 scFv-gp3 and 
did not show specific binding. 
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Figure 4-3. FC analysis of spheroplasts with beads containing immobilized antigen. (A) 
Detection of immobilized digoxigenin using Anti-Digoxigenin-Fluorescein Fab 
fragments. The fluorescent histogram of beads in the absence of immobilization is also 
shown. (B) Histograms for digoxigenin immobilized beads incubated with spheroplasts 
displaying 26-10 scFv and M18 scFv as fusions to NlpA(1-6), MalF (1-175) or gp3. M: 
Mean fluorescence intensity. 
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 4.3.3 Enrichment of 26-10 scFv anchoring spheroplasts 
As a prerequisite for the screening of libraries of spheroplast-anchored scFvs 
onto antigen-immobilized beads, we optimized conditions for the enrichment of 
spheroplasts on the basis of antibody-immobilized antigen binding. Spheroplasts 
expressing the 26-10 scFv were mixed with either 100-fold or 1,000-fold excess of M18 
scFv clones. The resulting mixture was incubated with digoxigenin-immobilized beads 
and spheroplast-bound beads were sorted by FC selectively gating for high GFP 
fluorescence in the scattering region of the beads. When the M18 scFv was present in a 
100-fold excess, sorting resulted in the collection of 1,772 beads out of an input of 5.6 x 
106. The DNA encoding the scFv genes associated with the collected beads was rescued 
by PCR and subcloned into pAK200. Following transformation and plating onto selective 
media, colony PCR revealed that 9/40 clones picked at random contained the 26-10 scFv 
indicating a 22.5-fold enrichment per round. Next, we examined the degree of enrichment 
obtained in the presence of 1,000-fold excess of spheroplasts expressing the M18 scFv. 
Fluorescent beads were sorted as above, the rescued scFv genes were subcloned into 
pAK200 and the ligation mixture was transformed into cells that were used as the input 
for the next round of sorting. Following three rounds of enrichment, which took 
approximately two weeks, FC analysis revealed a clear increase in the fluorescence signal 
of the sorted population (Fig. 4-4). 38/40 third round colonies picked at random 
contained the 26-10 scFv gene indicating that a 950-overall enrichment had been 
achieved over three rounds. 
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Table 4-3. Enrichment obtained by sorting of 26-10 and M18 scFv mixture (1:1,000). 
Round of 
Sorting 
Number of 26-
10 scFv clonesa 
Number of M18 
scFv clonesa % positives 
Enrichment 
from Presort 
Presort 1 1,000 0.1 - 
First round 0 40 - - 
Second round 2 38 5.0 50 
Third round 38 2 95.0 950 
aDetermined by colony PCR of randomly selected colonies after each round of sorting. 
 
 
 
 
 
Figure 4-4. Enrichment of 26-10 scFv clones from a 1,000 excess of M18 scFv-gp3 by 
binding to beads with immobilized digoxigenin. FC histograms represent the mean 
fluorescence intensity (M) of the spheroplast population after each round of sorting.  
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4.4 DISCUSSION 
In this chapter, we demonstrated that spheroplasts expressing scFv antibodies 
displayed on the periplasmic side of the inner membrane could bind to immobilized 
antigens. To facilitate the detection of spheroplasts bound onto beads, we co-expressed 
GFP in the cytoplasm. FACS and fluorescent microscopy analyses clearly showed the 
selective binding of spheroplasts expressing scFv onto beads decorated with antigen (Fig. 
5-3 and data not shown). Interestingly, the recognition of immobilized antigen by 
spheroplasts was critically dependent on how the scFv is anchored onto the inner 
membrane. In earlier studies we had employed the leader peptide and the 6 amino acid 
residues that comprise the fatty acylation motif in the E. coli protein NlpA to anchor 
successfully various scFvs and other proteins onto the inner membrane. NlpA(1-6)-scFv 
fusions were shown to recognize fluorescent soluble antigens up to at least 250 kDa 
M.W. However, spheroplasts displaying the anti-digoxin 26-10 scFv as an NlpA(1-6) 
fusion failed to bind to beads decorated with immobilized hapten. We reasoned that lack 
of binding to the immobilized antigen might be due to the close proximity of the scFv N-
terminus to the lipid bilayer. To circumvent this problem, antibody fragments were 
anchored onto the membrane by fusion to the first three transmembrane domains and the 
large periplasmic loop of MalF. In this construct the scFv is fused to amino acids 1-175 
of MalF that is thought to be periplasmically exposed and should be able to serve as a 
spacer to distance the antibody fragment from the inner membrane. Nonetheless, MalF(1-
175)-scFv fusions also failed to mediate the binding of spheroplasts onto antigen 
immobilized on beads.  
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The gp3 protein of the filamentous bacteriophages becomes associated with the 
inner membrane prior to its incorporation into the growing virion. The ability of gp3 to 
tolerate polypeptides fused to its N-terminus has been widely exploited for phage display. 
Similarly, scFv-gp3 fusions are suitable for APEx and antigen binding can be detected by 
FACS following spheroplasting. In scFv-gp3 fusions, the C-terminus of the antibody 
fragment is covalently linked to the gp3 protein. Although the fusion junction is in close 
proximity to the VH CDR3 region that plays an important role in antigen recognition, it 
does not affect the binding of soluble antigens. Moreover, we show here that scFv-gp3 
display allows the binding of spheroplasts to antigens immobilized on beads. The precise 
molecular mechanism responsible for the higher accessibility of scFv anchored on 
spheroplasts as C-terminal fusions compared to N-terminal fusions are not clear at the 
moment. It is well established that the orientation of proteins immobilized on  solid 
surfaces is critical to function and to their interaction with other molecules (Cha et al., 
2005; Seong and Choi, 2003). Analogous orientation effects may be important in this 
instance as well. Alternatively, it is possible that the different anchoring domains localize 
to distinct sites in the inner membrane which are more or less accessible following 
spheroplasting. Recent studies in Gram-positive bacteria have revealed that the leader 
peptide can direct secreted polypeptides either to the septum or the poles (Carlsson et al., 
2006). By analogy, it is possible that a gp3 fusion is directed to an inner membrane site 
distinct from the location where NlpA or MalF reside, meaning that the different fusions 
are in distinct local environments that may influence surface binding. Whatever the 
explanation, the data presented in this chapter clearly show that gp3 fusions are suitable 
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for mediating the binding of spheroplasts onto immobilized antigens via antibody-antigen 
interactions. 
We have demonstrated that spheroplasted cells expressing scFv-gp3 fusions can 
be enriched by binding to beads with immobilized antigen (Table 4-1, Fig. 4-4). 
Experiments using 100-fold and 1,000-fold excess of spheroplasts expressing a scFv-gp3 
fusion of unrelated specificity revealed that the degree of enrichment per round is 
relatively low, of the order of 20-25-fold per round. As a result, 3 rounds of sorting were 
required to enrich 26-10 scFv-gp3 expressing spheroplasts present in a 1:1,000 mixture. 
As can be seen in Figure 4-4, the enhancement of the fluorescent signal is low in 
the initial rounds but increases significantly in round 3. There may be a relatively 
straightforward and general explanation for this finding: In the flow cytometric 
enrichment of cells via binding to soluble fluorescent molecules, the ligand is present in a 
large stoichiometric excess relative to the number of receptors per cell. As a result, cells 
that bind to the ligand become highly fluorescent by binding many fluorescent antigen 
molecules, so that binders can be enriched from the overall population with high 
efficiency. In contrast, when the ligand is immobilized on particles such as beads or, by 
analogy, the surface of mammalian cells, the number of spheroplasts expressing ligand-
binding proteins is much lower than the number of antigen containing particles. The 
positive, ligand-binding spheroplasts will, on average, end up distributed onto different 
beads. With only one spheroplast per bead, the fluorescence due to the expression of GFP 
is low resulting in a low initial enrichment. The degree of enrichment increases in 
subsequent rounds as the ratio of positive spheroplasts to the number of beads becomes 
higher.  
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In summary, the experiments described here indicate that APEx can be employed 
for the binding of E. coli to immobilized antigens and is suitable for the library screening 
of antibodies recognizing insoluble ligands including receptors or antigens on whole 
mammalian cells and is further extended to the proteomic research to find interacting 
proteins that activate specific cells. Recently, we have succeeded in displaying full length 
IgG antibodies on spheroplasts and have demonstrated the isolation of specific antibodies 
from very complex libraries (Mazor et al., 2007). The APEx display of bivalent IgGs 
could be exploited for the isolation of weak binders that are better represented in 
repertoire libraries and may thus facilitate the selection of IgGs specific to insoluble 
antigens from large repertoire libraries. 
  
116
Chapter 5 
Conclusion and Recommendations 
5.1 CONCLUSION 
 The work presented in this dissertation describes the development of screening 
systems for the engineering of aglycosylated antibody Fc region, the isolation of 
aglycosylated antibodies displaying highly selective binding to Fc receptors and 
conferring unique effector functions in ADCC, and finally, a new high-throughput 
screening method for the isolation of antibodies specific to insoluble antigens. 
 For the engineering of aglycosylated antibody Fc domains with altered binding 
affinity to Fc binding ligands, we have developed a new bacterial display system. In this 
system, the Fc polypeptide was secreted with the PelB leader peptide and properly folded 
and dimerized in the E. coli periplasmic space. Spheroplasted cells after cultivation at 
optimized condition retained a significant fraction of Fc protein that was accessible to Fc 
binding ligands. Using this display system and flow cytometry screening upon labeling 
with fluorescently labeled FcγRI, aglycosylated Fc variants showing high affinity to 
FcγRI were isolated from a large error prone PCR library. Among the isolated Fc mutant 
domains, the Fc5 mutant exhibiting high affinity to FcγRI was found to contain only two 
mutations (E382V and M428I) located within the CH3 C and F β-sheets that are distal 
from the reported FcγRs binding site. Notably, E. coli-expressed engineered anti-Her2 
IgG1 antibody (trastuzumab) containing these 2 mutations was highly specific to FcγRI 
with negligible binding affinity to other effector FcγRs including the inhibitory FcγRIIb. 
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The pH dependent human FcRn binding that is critical for the homeostasis of serum IgG 
molecules with intracellular trafficking and recycling was not significantly affected by 
the two mutations in CH3 region.  
 High-throughput FACS screening from a new library randomized from Fc5 
generated Fc mutants displaying higher affinities relative to the parental Fc5 protein 
towards FcγRI. Among them, Fc601 containing the mutations, K338R and G341V in 
addition to Fc5 (E382V and M428I), showed the highest affinity for FcγRI. Following 
expression in E. coli and purification for the Fc engineered aglycosylated trastuzumab 
antibodies possessing the isolated mutant domains, either Fc5 or Fc601, effector function 
and ADCC were evaluated by measuring the cytotoxicity of Her2 overexpressing tumor 
cells using monocyte-derived dendritic cells. Remarkably, E. coli-expressed 
aglycosylated IgG variants (Fc5 and Fc601) that are highly specific to FcγRI, but not 
clinical grade glycosylated trastuzumab (Herceptin) that is non-specific to all FcγRs, was 
able to potentiate the killing of the cells. These results show that aglycosylated antibodies 
showing complete loss of ADCC can be engineered for highly selective binding affinity 
to an FcγR and for unique ADCC that nonselective FcγR binding glycosylated antibodies 
cannot elicit. To isolate Fc domains displaying higher affinity to FcγRI than Fc5 without 
abrogating pH-dependent human FcRn binding, FACS screening was employed using 
libraries that randomized the lower hinge and upper CH2 region. The isolated 
trastuzumab-Fc701 that has mutations in CH2 region F/G loop (L328W, A330V, P331A, 
I332Y) and one additional mutation (Q295R) showed higher affinity to FcγRI than 
trastuzumab-Fc5 and also higher binding affinity to FcRn at pH 6.0 than the clinical 
grade trastuzumab. 
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 Finally, we showed that the APEx system previously developed for the screening 
of high affinity proteins to soluble binding ligands is suitable for the discovery of proteins 
that bind to cell surface molecules or antigens immobilized on synthetic surface. In this 
study, scFv antibodies specific for the cardiac digoxin or for the PA antigens of Bacillus 
anthracis were expressed in E. coli as fusions to either N-terminal or C-terminal 
membrane anchoring domains. Upon spheroplasting at optimized condition, only the C-
terminally anchored scFv-gp3 fusions enabled specific binding to the antigens 
immobilized on beads. From spheroplasts expressing anti-digoxin (26-10) scFvs in a 
large excess (1000-fold) of spheroplasts expressing unrelated anti-PA (M18) scFv, three 
rounds FACS screening allowed 950 fold enrichment of the insoluble antigen specific 
spheroplasts. These results demonstrate the utility of the APEx display system for the 
isolation of antibodies specific to insoluble biomarkers on cell surfaces or solid surfaces. 
 
5.2 RECOMMENDATIONS 
 Currently, we have no structural information for the wild type aglycosylated Fc 
domain, the Fc5 mutant domain, or the extracellular domain of FcγRI. Structural analysis 
of the aglycosylated Fc domains and FcγRI by X-ray crystallography could provide 
information how the two mutations (E382V and M428I) in CH3 domain allow highly 
selective binding of the aglycosylated antibody to FcγRI. In using monocyte-derived 
dendritic cells as effector cells, aglycosylated antibodies (Fc5 or Fc601), could potentiate 
the killing of tumor cells. On the other hand, clinical grade glycosylated trastuzumab 
showed only background level cytotoxicity. We hypothesize that the selective 
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engagement of the engineered aglycosylated antibodies to FcγRI enables the high 
cytotoxicity of tumor cells in contrast to the glycosylated antibodies that bind 
nonspecifically to all effector FcγRs. To elucidate this mechanism, blocking the binding 
of engineered aglycosylated antibodies to FcγRI on the effector monocyte-derived 
dendritic cells can be used. Preliminary blocking experiment using commercially 
available FcγRI blocking antibodies was not successful due to the much lower affinity of 
these blocking antibodies relative to the binding affinity of the engineered aglycosylated 
antibodies containing either Fc5 or Fc601 domains to FcγRI. However, we can try to 
block the FcγRI mediated signaling by antisense FcγRI siRNA. If we can isolate a new 
FcγRI blocking antibody clone with higher affinity than the interaction between FcγRI 
and engineered aglycosylated antibodies containing either Fc5 or Fc601, it can be useful 
for investigating the mechanism about our proposed FcγRI mediated effector function.  
 In this work, we focused on the binding to FcγRI among effector FcγRs and 
isolated aglycosylated antibodies showing highly selective binding affinity to FcγRI and 
a unique effector function that their glycosylated counterpart antibodies could not exhibit. 
However, aglycosylated Fc engineered antibodies that bind to other activating FcγRs 
including FcγRIIa or FcγRIIIa can be also isolated using either homodimeric Fc display 
system described in chapter 2 or covalently inner membrane anchored full length IgG 
display system described in appendix 2. Since IgG binding to FcγRIIb down-regulates the 
recruitment of immune cells and immunological functions, screening of aglycosylated 
antibodies exhibiting high affinity to FcγRIIa and FcγRIIIa relative to FcγRIIb can be 
utilized for the isolation of aglycosylated antibodies with improved ADCC in 
immunotherapy. Additionally, the screening of IgG variants for better pH dependent 
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hFcRn binding can be employed to isolate antibodies with enhanced serum stability. To 
determine the therapeutic utility of the aglycosylated antibodies, pharmacokinetic study 
in mice or primate animals and immunogenicity in humans should be followed.  
 Finally, we demonstrated the successful binding and enrichment of spheroplasts 
displaying insoluble antigen specific scFv using C-terminally fused APEx format and 
antigen immobilized Tenta-Gel beads. The methodology developed in chapter 4 can be 
applied for the isolation of antibodies binding to membrane bound or cell surface 
antigens from large library screening. 
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Appendix 1 
Bacterally Expressed Aglycosylated Fc Receptors 
A1.1 INTRODUCTION 
Fc receptors are surface glycoproteins expressed on leukocytes that play a critical 
role in the human immune system by mediating humoral and cellular immunity. To 
deeply investigate the interaction of IgG Fc and Fc receptors as well as to use them in 
library screening for high affinity Fc, an efficient production and purification system for 
large amount of Fc receptors is required. In addition, the effect of glycosylation of Fc 
receptors on function and the binding of IgG has not been extensively studied. So far 
FcγRIIa, FcγRIIb, and FcγRIIIb have been successfully expressed in E. coli and used for 
structural analysis by crystallography (Galon et al., 1997; Sondermann et al., 1999; 
Sondermann et al., 2000; Sondermann and Jacob, 1999). However, efficient processes for 
the expression of large amounts of these proteins are not available. Additionally FcγRI 
has not yet been expressed in any significant amount. In an earlier study, Paetz et al. 
reported the production of only 40ng/ g pellet or 17 µg/L culture (Paetz et al., 2005) in 
bacteria. 
In this study, we have optimized the expression of extracellular domain of FcγRs 
(FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa) in E. coli. The proteins have been purified and 
refolded from E. coli inclusion bodies. In ELISA assays using the purified FcγRs on the 
plate coated glycosylated IgG1, all the refolded proteins showed affinity to the 
glycosylated IgG1. 
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A1.2 MATERIAS AND METHOD 
 A1.2.1 Construction of plasmids for the expression of FcγRs 
Human FcγRs cDNAs were purchased from ATCC (Manassas, VA). DNA 
fragments encoding FcγRI were PCR amplified using the primers (STJ#266 and 
STJ#267) using the template plasmid, pCMV-SPORT6 (ATCC: MGC-45021), digested 
with NdeI / HindIII endonucleases, ligated into pET21a (EMD Chemicals, Gibbstown, 
NJ) digested using the same restriction enzymes to generate pET21a-FcγRI. PCR 
amplification using the primers (STJ#199 and STJ#200) from the template plasmid, 
pDNR-LIB (ATCC: MGC-23887), ligation into NdeI / HindIII digested pET21a 
generated pET21a-FcγRIIa. pET21a-FcγRIIb was constructed by PCR amplification 
using the primers (STJ#294 and STJ#295) and the template plasmid, pCMV-
SPORT6.ccdb (ATCC: MGC-21364), and ligation into pET21a digested with NdeI / 
HindIII. For pET21a-FcγRIIIa, DNA fragments were amplified using the primers 
(STJ#296 and STJ#297) and the template pCMV-SPORT6 (ATCC: MGC-45020) and 
ligated into NdeI / HindIII digested pET21a. 
DNA fragments encoding E. coli codon optimized FcγRI was synthesized using 
gene assembly PCR using the primers (STJ#148 ~ STJ#173, STJ#241 and STJ#242) for 
FcγRI, the primers (STJ#201 ~ STJ#218) for FcγRIIa, the primers (STJ#247 ~ STJ#264) 
for FcγRIIb, the primers (STJ#174 ~ STJ#193, STJ#243 and STJ#244) for FcγRIIIa were 
ligated into NdeI / HindIII digested pET21a to generate E. coli codon optimized FcγR 
expression plasmids, pET21a-FcγRI-opt, pET21a-FcγRIIa-opt, pET21a-FcγRIIb-opt, 
pET21a-FcγRIIIa-opt. The resulting plasmids were transformed into E. coli BL21(DE3) 
(EMD Chemicals, Gibbstown, NJ). 
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 A1.2.2 Expression and purification of of FcγRs 
E. coli BL21(DE3) cells harboring FcγR expression plasmids were cultured in 
500 ml of LB medium supplemented with 50 µg/ml of ampicillin at 37 °C with 250 rpm 
shaking. Protein expression was induced by adding 1 mM of isopropyl-1-thio-β-D-
galactopyranoside (IPTG) when OD600 of culture reached 0.6. Cells were harvested by 
centrifuging at 7,000g for 20 min after 5 h of induction. FcγRs expressed as inclusion 
bodies were solubilized in 8M urea solution, purfied using Ni-NTA agarose resin 
(Qiagen, Valencia, CA), and refolded as described in the previous study (Jung et al., 
2003). 
 
 A1.2.3 ELISA analysis 
50 µl of 4 µg/ml of glycosylated serum human IgG1 (Sigma-Aldrich, St. Louis, 
MO) were diluted in 0.05 M Na2CO3 (pH 9.6) buffer and used to coat 96 well polystyrene 
ELISA wells (Corning, Corning, NY) for 16 h at 4 °C. After blocking with 1 × PBS (pH 
7.4), 0.5% BSA for 2 h at room temperature, the plate was washed 4 times with PBS 
containing 0.05% Tween20, and incubated with serially diluted FcγRs at room 
temperature for 1 h. After washing 4 times with the same buffer, 1:10,000 diluted anti-
polyhistidine HRP conjugate (Sigma-Aldrich, St. Louis, MO) was added and plates were 
washed and developed using Ultra-TMB substrate (Pierce Biotechnology, Rockford, IL). 
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Table A1-1. Plasmids used in this study. 
Plasmids Relevant characteristics Reference or 
source 
pCMV-SPORT6-
FcrRI 
ATCC: MGC-45021 ATCC  
(Manassas, VA) 
pDNR-LIB-FcrRIIa ATCC: MGC-23887 ATCC 
(Manassas, VA) 
pCMV-
SPORT6.ccdb-
FcrRIIb 
ATCC: MGC-21364 ATCC 
(Manassas, VA) 
pCMV-SPORT6-
FcrRIIIa 
ATCC: MGC-45020 ATCC 
(Manassas, VA) 
pET21a Apr, T7 promoter, lacIq EMD Chemicals  
( Gibbstown, NJ) 
pET21a-FcγRI FcγRI gene in pET21a This study 
pET21a-FcγRIIa FcγRIIa gene in pET21a This study 
pET21a-FcγRIIb FcγRIIb gene in pET21a This study 
pET21a-FcγRIIIa FcγRIIIa gene in pET21a This study 
pET21a-FcγRI-opt E. coli codon optimized FcγRI gene in 
pET21a 
This study 
pET21a-FcγRIIa-opt E. coli codon optimized FcγRIIa gene 
in pET21a 
This study 
pET21a-FcγRIIb-opt E. coli codon optimized FcγRIIb gene 
in pET21a 
This study 
pET21a-FcγRIIIa-opt E. coli codon optimized FcγRIIIa gene 
in pET21a 
This study 
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Table A1-2. Primers used in this study. 
Primer 
Name Primer nucleotide sequence (5’  3’) 
STJ#148 CGCAGCGAGGCCCAGCCGGCCATGGCGCAGGTGGATACC 
STJ#149 CACCCACGGCGGCTGAAGGGTAATCACCGCTTTGGTGGTATCCACCTGCGCCAT 
STJ#150 CAGCCGCCGTGGGTGAGCGTGTTTCAGGAAGAAACCGTAACGCTTCATTGCGAG 
STJ#151 ACTGGGTGCTAGAGGACCCCGGCAGATGCAGCACCTCGCAATGAAGCGTTACGG 
STJ#152 GGGTCCTCTAGCACCCAGTGGTTTCTGAACGGCACCGCGACCCAGACCTCAACC 
STJ#153 ATCATTCACGCTCGCGCTAGTAATACGATAGCTCGGGGTTGAGGTCTGGGTCGC 
STJ#154 TAGCGCGAGCGTGAATGATTCAGGGGAATACCGTTGTCAGCGTGGTCTGAGCGG 
STJ#155 GCCACGATGAATTTCCAGCTGAATTGGATCGCTACGGCCGCTCAGACCACGCTG 
STJ#156 CAGCTGGAAATTCATCGTGGCTGGCTGCTTCTGCAGGTGTCTAGCCGGGTGTTT 
STJ#157 GCATGGCAACGCAACGCTAACGGTTCGCCTTCGGTAAACACCCGGCTAGACACC 
STJ#158 GCGTTGCGTTGCCATGCGTGGAAAGATAAACTTGTGTATAATGTGCTGTATTAT 
STJ#159 AACTTAAACGCTTTGCCATTACGATAATACAGCACATTATACACAAGTTTATCT 
STJ#160 CGTAATGGCAAAGCGTTTAAGTTTTTCCATTGGAATTCGAACCTGACCATTCTG 
STJ#161 GATACGTTCCATTATGGCTAATATTGGTTTTCAGAATGGTCAGGTTCGAATTCC 
STJ#162 CCAATATTAGCCATAATGGAACGTATCATTGTAGCGGAATGGGCAAACATCGTT 
STJ#163 TCTTTCACTGTCACGCTAATGCCTGCGCTGGTGTAACGATGTTTGCCCATTCCG  
STJ#164 GCATTAGCGTGACAGTGAAAGAACTTTTTCCGGCTCCGGTGTTGAATGCCAGTG 
STJ#165 GGTCACCAGATTGCCTTCCAACAGCGGGCTAGTCACACTGGCATTCAACACCGG 
STJ#166 TGGAAGGCAATCTGGTGACCCTGAGCTGCGAAACCAAACTGTTACTGCAGCGCC 
STJ#167 CCCATATAGAAGCTAAAATACAGTTGCAGCCCTGGGCGCTGCAGTAACAGTTTG 
STJ#168 GCAACTGTATTTTAGCTTCTATATGGGCAGCAAAACCCTGCGTGGCCGGAACAC 
STJ#169 TTCACGACGCGCGGTCAGAATCTGATATTCACTAGAGGTGTTCCGGCCACGCAG 
STJ#170 GACCGCGCGTCGTGAAGATAGCGGCCTGTATTGGTGCGAAGCGGCGACCGAAGA 
STJ#171 CAGTTCCAGTTCCGGGCTACGTTTCAATACATTACCATCTTCGGTCGCCGCTTC 
STJ#172 GTAGCCCGGAACTGGAACTGCAAGTGTTAGGCCTGCAGCTTCCGACACCAGGGG  
STJ#173 CGCAATTCGGCCCCCGAGGCCCCTGGTGTCGGAAGC 
STJ#174 CGCAGCGAGGCCCAG 
STJ#175 TTTGGGCAGATCTTCGGTACGCATGCCCGCCATGGCCGGCTGGGCCTCGCTGCG 
STJ#176 CGTACCGAAGATCTGCCCAAAGCGGTGGTGTTTCTGGAACCGCAGTGGTATCGT 
STJ#177 TGGCATTTCAGTGTGACGCTATCTTTCTCCAGCACACGATACCACTGCGGTTCC 
STJ#178 TAGCGTCACACTGAAATGCCAGGGCGCGTATAGCCCTGAGGATAATTCTACCCA 
STJ#179 GGCTGCTAATCAGGCTTTCATTATGAAACCACTGGGTAGAATTATCCTCAGGGC 
STJ#180 ATGAAAGCCTGATTAGCAGCCAGGCGAGCTCTTACTTTATCGATGCGGCGACCG 
STJ#181 AGATTGGTCTGACAACGATATTCGCCGCTGTCATCCACGGTCGCCGCATCGATA 
STJ#182 CGAATATCGTTGTCAGACCAATCTGAGCACCTTGAGCGATCCGGTGCAGTTAGA 
STJ#183 GAGGCGCTTGCAGCAGTAACCAGCCAATATGCACTTCTAACTGCACCGGATCGC 
STJ#184 ACTGCTGCAAGCGCCTCGTTGGGTGTTTAAAGAAGAAGATCCGATTCATCTGCG 
STJ#185 ATGCAGCGCGGTATTTTTCCAGCTATGGCAACGCAGATGAATCGGATCTTCTTC 
STJ#186 GGAAAAATACCGCGCTGCATAAAGTGACCTATTTACAGAATGGCAAAGGCCGTA 
STJ#187 GAATATAGAAATCGCTATTATGATGAAAATACTTACGGCCTTTGCCATTCTGTA 
STJ#188 AGTATTTTCATCATAATAGCGATTTCTATATTCCGAAAGCGACCTTGAAGGATT 
STJ#189 TTCCGACAAGCCCACGACAGAAATAGCTGCCAGAATCCTTCAAGGTCGCTTTCG 
STJ#190 GTCGTGGGCTTGTCGGAAGCAAAAATGTGAGCAGCGAAACCGTGAATATTACCA 
STJ#191 CTTATGGTGCTAACGCTCAGGCCCTGGGTAATGGTAATATTCACGGTTTCGCTG 
STJ#192 CCTGAGCGTTAGCACCATAAGCAGCTTTTTTCCTCCGGGGTATCAGGGGGCCTC 
STJ#193 CGCAATTCGGCCCCCGAGGCCCCCTGATACCCC  
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STJ#199 GCGGAATTCCATATGCAAGCTGCTCCCCCAAAGGCTGTG 
STJ#200 TTAGGGAAGCTTAATGACCCCCATTGGTGAAGAGCTGC 
STJ#201 GCGGAATTCCATATGCAGGCTGC 
STJ#202 GGCGGTTCCAGTTTCAGCACGGCTTTCGGTGGGGCAGCCTGCATATGGAATTCC 
STJ#203 TGCTGAAACTGGAACCGCCGTGGATTAATGTGTTGCAGGAAGATAGCGTGACCC 
STJ#204 TCGCTTTCAGGGCTACGCGCTCCCTGACAGGTCAGGGTCACGCTATCTTCCTGC 
STJ#205 GCGTAGCCCTGAAAGCGATTCTATTCAGTGGTTTCACAATGGAAATCTGATTCC 
STJ#206 TAAAACGATAGCTCGGCTGGGTATGGGTCGGAATCAGATTTCCATTGTGAAACC 
STJ#207 CCCAGCCGAGCTATCGTTTTAAAGCGAACAATAATGATAGCGGCGAATACACCT 
STJ#208 CCGGATCGCTCAGGCTGGTCTGGCCCGTCTGGCAGGTGTATTCGCCGCTATCAT 
STJ#209 CAGCCTGAGCGATCCGGTGCATCTGACCGTGCTTAGCGAATGGCTGGTGCTGCA  
STJ#210 ATGGTTTCGCCTTCCTGAAATTCCAGATGCGGGGTTTGCAGCACCAGCCATTCG  
STJ#211 AATTTCAGGAAGGCGAAACCATTATGCTGCGTTGCCATAGCTGGAAAGATAAAC 
STJ#212 CATTCTGAAAAAAGGTCACTTTCACCAGCGGTTTATCTTTCCAGCTATGGCAAC 
STJ#213 GGTGAAAGTGACCTTTTTTCAGAATGGCAAAAGCCAGAAATTTTCTCACCTGGA 
STJ#214 AATGATTCGCCTGCGGAATGCTAAAGGTCGGATCCAGGTGAGAAAATTTCTGGC 
STJ#215 CATTCCGCAGGCGAATCATTCTCACTCCGGCGATTACCATTGTACCGGCAATAT 
STJ#216 ACCGGTTTGCTGCTAAACAGGGTATAGCCTATATTGCCGGTACAATGGTAATCG 
STJ#217 CTGTTTAGCAGCAAACCGGTGACAATTACCGTGCAGGTGCCGAGCATGGGCAGC 
STJ#218 TAAGGGAAGCTTAATCACGCCCATCGGTGAGCTGCTGCCCATGCTCGGC 
STJ#241 GCGGAATTCCATATGCAGGTGGATACCACCAAAGCGGTG 
STJ#242 TTAGGGAAGCTTTGGTGTCGGAAGCTGCAGGCC 
STJ#243 GCGGAATTCCATATGGGCATGCGTACCGAAGATCTGCC 
STJ#244 TTAGGGAAGCTTCTGATACCCCGGAGGAAAAAAGCTGC 
STJ#247 GCGGAATTCCATATGGGCACACCTGCGGCACCTC 
STJ#248 TTAATCCACTGCGGTTCCAGTTTCAGCACCGCTTTTGGAGGTGCCGCAGGTGTG 
STJ#249 ACTGGAACCGCAGTGGATTAATGTGTTACAGGAAGATAGCGTTACCCTGACCTG 
STJ#250 ATACTATCGCTTTCCGGGCTATGGGTGCCACGGCAGGTCAGGGTAACGCTATCT 
STJ#251 TAGCCCGGAAAGCGATAGTATTCAGTGGTTTCATAACGGCAATCTGATTCCGAC 
STJ#252 TCGCTTTAAAACGATAGCTCGGCTGGGTATGGGTCGGAATCAGATTGCCGTTAT 
STJ#253 CCGAGCTATCGTTTTAAAGCGAATAACAACGACTCTGGCGAATACACGTGCCAG 
STJ#254 AGATGCACCGGGTCGCTCAGGCTCGTCTGGCCGGTCTGGCACGTGTATTCGCCA 
STJ#255 AGCGACCCGGTGCATCTGACCGTGCTGAGTGAATGGCTGGTGCTGCAGACCCCG 
STJ#256 CGCAGCACAATGGTTTCGCCTTCCTGAAATTCCAGATGCGGGGTCTGCAGCACC 
STJ#257 GCGAAACCATTGTGCTGCGTTGCCATAGCTGGAAAGATAAACCGCTGGTGAAAG 
STJ#258 TTTTTGCTTTTGCCATTCTGAAAAAAGGTCACTTTCACCAGCGGTTTATCTTTC 
STJ#259 TTTTTCAGAATGGCAAAAGCAAAAAGTTTAGCCGTTCCGATCCGAATTTTAGCA 
STJ#260 ATCGCCGCTGTGGCTATGATTCGCCTGCGGAATGCTAAAATTCGGATCGGAACG 
STJ#261 CATAGCCACAGCGGCGATTATCATTGTACCGGCAACATCGGCTATACTCTGTAT 
STJ#262 CCTGCACGGTGATGGTCACCGGTTTGCTGCTATACAGAGTATAGCCGATGTTGC 
STJ#263 TGACCATCACCGTGCAGGCGCCGAGCAGCAGCCCGATGGGCATTATCAAGCTTC 
STJ#264 TTAGGGAAGCTTGATAATGCCCATCGG 
STJ#266 GCGGAATTCCATATGCAAGTGGACACCACAAAGGCAGTGATC 
STJ#267 TTAGGGAAGCTTAGGAGTTGGTAACTGGAGGCCAAGCAC 
STJ#294 GCGGAATTCCATATGGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTG 
STJ#295 TTAGGGAAGCTTAATGATCCCCATCGGTGAAGAGCTGGGAGCTTGGACAGTGATGGTCAC 
STJ#296 GCGGAATTCCATATGGGCATGCGGACTGAAGATCTCCC 
STJ#297 TTAGGGAAGCTTTTGGTACCCAGGTGGAAAGAATG 
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A1.3 RESULTS 
 A1.3.1 Expression of aglycosylated FcγRs in E. coli 
For the expression of aglycosylated human FcγRs, human FcγR cDNAs were 
subcloned into pET21a plasmids under the control of T7 promoter (Fig. A1-1). Synthetic 
genes encoding FcγRs optimized for E. coli codon usage and overlapping 
oligonucleotides for the amplification of the synthetic genes were designed by the online 
program DNAWorks (http://helixweb.nih.gov/dnaworks) (Hoover and Lubkowski, 2002). 
The expression levels of FcγRIIa and FcγRIIb were improved by using the synthetic 
genes through codon optimization for full coding sequences (Fig. A1-2). As expected, the 
overexpressed proteins (FcγRIIa, FcγRIIb, and FcγRIIIa) were localized entirely in the 
inclusion body fraction. The expression level of FcγRI was extremely low and could not 
be detected on the Western blot even after the codon optimization. One possible 
explanation for the lack of protein expression was that stable RNA structures at the 5’ 
could have prevented ribosome binding and/or translation initiation (De Smit et al., 
1990). Indeed the RNAStructure software (Ver. 3.71) indicated a strong propensity for 
the formation of stable structures in the mRNA. To increase translation efficiency, a C-
terminal polyhistidine tag was fused to the N-terminal of both the codon optimized 
synthetic FcγRI gene and the wild type FcγRI gene. The expression level could be 
significantly increased by adding the polyhistidine tag at the N-terminus. However, 
significant degradation was observed by Western blotting. To further increase expression 
level and reduce degradation products, expression in a variety of DE3 lysogen E. coli 
strains such as BL21(DE3), BLR(DE3), HMS174(DE3), Tuner(DE3), (DE3), 
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Rosetta2(DE3), Rosetta-gami(DE3), Rosetta-gami B(DE3), Orgami (DE3), and Orgami 
B(DE3) were attempted. Also, to reduce C-terminal degradation, a C-terminal FLAG was 
introduced in addition to the N-terminal polyhistidine tag. By using dual tags, namely N-
terminal polyhistidine tag and C-terminal FLAG tag, the FcγRI protein could be 
successfully overexpressed in Rosetta-gami (DE3) cells (Fig. A1-3). 
 
 A1.3.2 Purification and refolding of FcγRs 
For the purification of FcγRs, inclusion bodies were collected, washed, 
solubilized in 8 M urea buffer, and further purified using immobilized metal affinity 
chromatography (IMAC) column. The purified FcγRs were refolded by the previously 
published stepwise dialysis method (Jung et al., 2003). The yields were over 20 mg / L 
culture for FcγRIIa, FcγRIIb, and FcγRIIIa. The yield of FcγRI was 1.74 mg / L (Fig. A1-
4). 
 
 
Figure A1-1. Gene casettes for the expression of FcγRIIa, FcγRIIb, and FcγRIIIa. 
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Figure A1-2. Expression of FcγRIIa, FcγRIIb, and FcγRIIIa. Lane1: wild type FcγRIIa-
His; Lane 2: codon optimized FcγRIIa-His; Lane 3: wild type FcγRIIb-His; Lane 4: 
codon optimized FcγRIIb-His; Lane 5: wild type FcγRIIIa-His; Lane 6: codon optimized 
FcγRIIIa-His. 
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Figure A1-3. Western blot showing the expression of FcγRI depending on the codon 
optimization, the terminal tag location, and the various DE3 lysogen containing E. coli 
strains. Lane 1: BL21(DE3) harboring human FcγRI cDNA with C-terminal 6xHis tag; 
Lane 2: BL21(DE3) harboring FcγRI gene optimized for E. coli codon usage with C-
terminal 6xHis tag; Lane 3: BL21(DE3) harboring human FcγRI cDNA with N-terminal 
6xHis tag; Lane 4: BL21(DE3) harboring FcγRI gene optimized for E. coli codon usage 
with N-terminal 6xHis tag; Lane 5: Rosetta gami(DE3) harboring FcγRI gene optimized 
for E. coli codon usage with N-terminal 6xHis tag; Lane 6: Rosetta gami(DE3) harboring 
FcγRI gene optimized for E. coli codon usage with both N-terminal 6xHis and C-terminal 
FLAG tags. 
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Figure A1-4. SDS-PAGE showing the purified Fc receptors. Lane1: FcγRI-His; Lane 2: 
FcγRIIa-His; Lane 3: FcγRIIb-His; Lane 4: FcγRIIIa-His. 
 
 A1.3.3 Affinity of aglycosylated FcγRs 
The activity of the purified FcγRs was analyzed by ELISA. Plates were coated 
with glycosylated serum human IgG1 and binding of the purified FcγRs was detected 
using anti-His antibody HRP conjugate. FcγRI FcγRIIa, FcγRIIb, and FcγRIIIa all 
showed affinity to human IgG1 relative to the negative control (BSA) (Fig. A1-5). 
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Figure A1-5. ELISA assays for purified FcγRs (FcγRI, FcγRIIa, FcγRIIb, and FcγRIIIa). 
ELISA plate was coated with 4 µg/ml of glycosylated human IgG1 (Sigma-Aldrich, St. 
Louis, MO) and binding of purified FcγRs was detected by anti-polyhistidine-HRP 
conjugate (Sigma-Aldrich, St. Louis, MO). 
 
A1.4 DISCUSSION 
Human effector FcγRs are expressed in most immune cells (van de Winkel and 
Capel, 1993) and play essential roles in linking antibody associated humoral and cellular 
immune responses by binding to the Fc domain of IgG (Berken and Benacerraf, 1966; 
Ravetch and Bolland, 2001). In this chapter, we expressed the aglycosylated extracellular 
domains of FcγRs in E. coli. Use of E. coli codon optimized synthetic genes and, in the 
case of FcγRI, minimization of 5’ mRNA secondary structure by fusion to a gene 
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encoding an N-terminal 6xHis sequence could increase expression level. The FcγRs were 
expressed as inclusion bodies and soluble active protein was obtained by refolding. 
The kinetic constants for the binding of IgG to aglycosylated FcγRIIa, FcγRIIb, 
and FcγRIIIb have been reported (Maenaka et al., 2001). However, the binding kinetics 
of aglycosylated FcγRI and FcγRIIIa are not available. To elucidate questions about the 
effect of glycosylation on the binding affinity of Fc receptors to IgG, the quantitative 
kinetic analysis of the purified aglycosylated FcγRI and FcγRIIIa needs to be performed 
and the results will be compared with the published values for glycosylated recombinant 
FcγRs. Also, it will be interesting to investigate the specificity of FcγRs for the various 
IgG subclasses (IgG1, IgG2, IgG3, and IgG4). Finally the purified functional FcγRs may 
be used for the screening of antibodies for improved effector functions or the study on the 
interaction between IgG and FcγRs. 
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Appendix 2 
Development of a covalently anchored full length IgG display system 
A2.1 INTRODUCTION 
 Phage display, the oldest and the most widely used technique for library 
screening, relies on the presentation of diverse polypeptides on the surface of filamentous 
bacteriophage via fusion to a phage coat protein (Smith, 1985). It has been successfully 
used for the discovery of antigen specific antibody fragments from immune or 
nonimmune library (Bradbury and Marks, 2004). Compared with phage display, cell 
surface display systems using bacteria (Daugherty et al., 2000a; Daugherty et al., 2000b; 
Georgiou et al., 1997; Lofblom et al., 2005) or yeast (Boder et al., 2000; Boder and 
Wittrup, 1997; Feldhaus et al., 2003) are attractive since their relatively large size of cells 
allows high-throughput screening by flow cytometry (FC) with real-time optimization of 
quantitative multi-parameter and sorting (Mattanovich and Borth, 2006). Cell surface 
display approaches in Escherichia coli are attractive because of the rapid cell growth, 
high transformation efficiency, simple gene manipulation, and efficient production of 
target proteins of the bacteria (Daugherty et al., 2000a; Daugherty et al., 2000b; Georgiou 
et al., 1997). However, E coli cell surface display can be limited by the reduction of 
library diversity resulting from protein export to outer membrane and complications in 
screening caused by interfering biomolecules on the surface of outer membrane (Chen et 
al., 2001). In addition to cell surface display in E. coli, display in the periplasmic space 
has been developed for the screening of antigen specific proteins (Chen et al., 2001). 
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  The anchored periplasmic expression (APEx) system was developed in our group 
(Harvey et al., 2004). In this system, fusion to lipoprotein (NlpA) or the Gene III protein 
(gp3) of bacteriophage M13, are employed to target and anchor proteins to the 
periplasmic face of the inner membrane (Harvey et al., 2004). Osmotic shock and 
chemical/enzyme treatment of E. coli is used to remove the outer membrane and most of 
the peptidoglycan layer to generate spheroplasts. For the screening of high affinity 
antibody/proteins, the spheroplasts expressing antibody/protein tethered onto the inner 
membrane are mixed with a fluorescently labeled antigen/ligand and fluorescent cells are 
collected by FACS. 
While APEx system has been successfully used for the screening of high affinity 
antibody fragments for soluble antigens (Harvey et al., 2004; Harvey et al., 2006), it 
cannot be directly used for the display of multimeric proteins such as dimeric Fc protein 
or full length IgG. Also, the E-clonal system developed earlier for the isolation of IgGs 
with desired antigen specificities (Mazor et al., 2007) cannot be used to detect binding of 
Fc binding ligands to the Fc domain because the latter is occupied by the membrane-
anchored Fc-binding protein which is used to display the IgG on spheroplasts. Here we 
report a new covalent full length IgG display and screening system. In this system, IgG 
light chains (VL-Ck) are designed for soluble periplasmic expression and covalent 
anchoring onto inner membrane. Tetrameric assembly of homodimeric IgG heavy chains 
(VH-CH1-Hinge-CH2-CH3) with both soluble and inner membrane anchored IgG light 
chains (VL-Ck) generates covalent anchored full length IgG for the engineering of Fc 
domains in full length IgG. 
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A2.2 MATERIALS AND METHODS 
A2.2.1 Solube expression and purification of homodimeric wild type Fc and Fc2a 
fragments 
All primers and plasmids used in this study are described in Table A2-1 and Table 
A2-2. Fc2a is an aglycosylated antibody variant optimized for FcγRIIa binding by two 
mutations (S298G/T299A) in the upper CH2 region; it has been reported that IgG 
containing Fc2a displays FcγRIIa binding (Sazinsky et al., 2008). For the expression of 
correctly assembled, homodimeric wild type Fc and FcγRIIa binding Fc (Fc2a, 
S298G/T299A) in the periplasmic space of E. coli, the plasmids pDsbA-Fc-FLAG and 
pDsbA-Fc2a-FLAG were constructed for the export of Fc via the DsbA signal peptide. 
Cleavage of pTrc99A (Amersham Pharmacia) with FatI restriction endonuclease which is 
compatible with the NcoI and also with SalI followed by ligating synthetic DNA 
fragment encoding the 53 bp DsbA signal peptide gene generated pDsbA. The parental 
Fc genes were amplified using he primers STJ#144 and STJ#145, ligated into pDsbA 
plasmid using SalI and HindIII restriction enzyme sites giving rise to pDsbA-Fc-FLAG. 
The Fc2a mutant gene was amplified using the primers (STJ#422 and STJ#147) and the 
template (pDsbA-Fc-FLAG), ligated into SacII / HindIII digested pDsbA-Fc-FLAG to 
generate pDsbA-Fc2a-FLAG. pDsbA-Fc5-FLAG was constructed by ligating Fc5 
(E382V / M428I) fragments using the primers (STJ#290 and STJ#220) digested with SalI 
/ EcoRI into pDsbA-Fc-FLAG using the same restriction sites.  
For the expression of wild type and Fc2a Fc fragments, E. coli Jude-1 cells 
harboring pDsbA-Fc-FLAG or pDsbA-Fc2a-FLAG were cultured in 2L flasks with 500 
ml working volume. The culture supernatant from the induced cells was separated by 
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centrifugation at 7,000 rpm for 30 min. The supernatant was filtered through 0.22 µm 
bottle top filters (Corning, Corning NY) and loaded onto a column packed with 1 ml of 
Immobilized Protein A agarose (Pierce, Rockford, IL). After loading of 400 ml of 
supernatants by gravity flow, the columns were washed with 75 ml of 20 mM sodium 
phosphate buffer (pH 7.0) and with 50 ml of 40 mM sodium citrate (pH 5.0). Wild type 
Fc and mutant Fc2a fragments were eluted using 0.1M glycine (pH 2.5) and immediately 
neutralized with 1M Tris (pH 8.0) solution. 
 
 A2.2.2 Production and purification of full length aglycosylated trastuzumab and 
aglycosylated trastuzumab-Fc2a 
For pSTJ4-Herceptin-Fc2a-IgG1 or pSTJ4-Herceptin-Fc5-IgG1, Fc5 or Fc2a 
mutant genes were amplified using the primers (STJ#290 and STJ#291) and the 
templates, pDsbA-Fc5-FLAG for Fc5 fragments or pDsbA-Fc2a-FLAG for Fc2a 
fragments, respectively. The amplified PCR fragments were ligated into SalI / EcoRV 
digested pSTJ4-Hercepin IgG1 to make pSTJ4-Herceptin-Fc5-IgG1 or pSTJ4-Herceptin-
Fc2a-IgG1. The plasmids for full length wild type trastuzumab and mutant trastuzumab-
Fc2a are under the control of lac promter in a dicistronic operon with PelB leader peptide 
fusions to both heavy and light chains.  
After transformation of the plasmids into E. coli BL21(DE3) (EMD Chemicals, 
Gibbstown, NJ), cells were grown in LB complex medium overnight and then 
subcultured overnight twice for adaptation in R/2 medium (Jeong and Lee, 2003). E. coli 
BL21(DE3) harboring pSTJ4-Herceptin-IgG1 or pSTJ4-Herceptin-IgG1-Fc2a were 
cultured in 500 ml baffled-flask with 120 ml R/2 media at 30 °C for 8 h with 250 rpm 
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shaking and then inoculated to 3.3L BioFlo 310 fermentor (New Brunswick Scientific 
Co., Edison, NJ) with 1.2L R/2 medium. Fed-batch fermentations were performed at 30 
°C using a pH-stat glucose feeding strategy. The dissolved oxygen (DO) concentration 
was monitored and maintained at 40% of air saturation using automatic cascade control 
that increases agitation speed from 100 rpm to 1,000 rpm, air flow rate from 1 to 3 SLPM 
(Standard liquid per minute) and pure oxygen flow rate from 0 to 1.5 SLPM when 
needed. The initial pH was adjusted to 6.8 and controlled by the addition of 30% (v/v) 
ammonium hydroxide when it decreased to less than 6.75 and by the supply of feeding 
solutions, (700 g/L of glucose and 10 g/L of MgSO4-7H2O; before induction) and (500 
g/L glucose, 10 g/L of MgSO4-7H2O, and 100 g/L of yeast extract; after induction), when 
it increased to more than 6.9. When the OD600 reached 100, the culture temperature was 
set to 25 °C and 30 min later, protein synthesis was induced with 1 mM of isopropyl-1-
thio-β-D-galactopyranoside (IPTG). 7 h after induction at OD600 of ~130-140, the 
culture broth was harvested. 
Cells were harvested by centrifugation at 11,000 × g for 30 min and resuspended 
in 1.2 L solution containing 100 mM Tris, 10 mM EDTA (pH 7.4) supplemented with 4 
mg of lysozyme (per g of dry cell weight) and 1 mM PMSF. Periplasmic proteins were 
released by the incubation of the suspended solution with shaking at 250 rpm at 30 °C for 
16 h. After centrifugation at 14,000 × g for 30 min, polyethyleneimine (MP Biomedical, 
Solon, OH) was added dropwise to the supernatant until its concentration reaches 0.2 % 
(w/v). Large amount of nucleic acids complexed with cationic polyethyleneimine 
polymers were removed by centrifugation at 14,000 × g for 30 min followd by filtration 
through 0.2 µm filter. The clear filtrate was mixed with Immobilized Protein A agarose 
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resin pre-equilibrated in 20 mM sodium phosphate buffer (pH 7.0) and incubated at 4 °C 
for 16 h. After washing with 200 ml of 20 mM sodium phosphate buffer (pH 7.0) and 200 
ml of 40 mM sodium citrate (pH 5.0), wild type aglycosylated trastuzumab or 
trastuzumab-Fc2a were eluted from the Protein A resin using 15 ml of 0.1 M glycine (pH 
3.0) and neutralized immediately with 1M Tris (pH 8.0) solution. The eluted samples 
were concentrated by ultrafiltration through a 10 kDa Mw cutoff membrane and the 
retentate was further purified using a Superdex 200 gel filtration column developed with 
PBS (pH 7.4). 
 
A2.2.3 ELISA analysis 
96 well polystyrene ELISA plates (Corning, Corning, NY) were coated with 50 µl 
of 4 µg/ml of aglycosylated trastuzumab, aglycosylated trastuzumab-Fc2a, or clinical 
grade glycosylated IgG trastuzumab diluted in 0.05 M Na2CO3 (pH 9.6) buffer for 16 hr 
at 4 °C. The plate was blocked with 1 × PBS (pH 7.4), 0.5% BSA for 2 hr at room 
temperature, washed 4 times with PBS containing 0.05% Tween20, and incubated with 
serially diluted FcγRIIa-GST fusion proteins (Berntzen et al., 2005) at room temperature 
for 1 h. After washing 4 times with the same buffer, addition of 1:5,000 diluted anti-GST 
antibody HRP conjugate (Amersham Pharmacia, Piscataway, NJ), washing 4 times again, 
the plates were developed using Ultra-TMB substrate (Pierce, Rockford, IL). 
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 A2.2.4. Construction of plasmids for covalently anchored full length IgG display 
system  
Ligation of PCR-amplified and SfiI-digested Fc gene encoding human IgG1-Fc 
fragment, hinge, CH2 and CH3 region of human IgG1 heavy chain (GeneBank Accession 
No. AF237583) into pPelBFLAG digested with SfiI generated pPelBFLAG-Fc. 
pBADNlpAHis-M18 was constructed by ligating XbaI / HindIII digested NlpA-fused 
M18 scFv gene from pMoPac1-FLAG-M18 into pBAD30-KmR digested with same 
restriction endonucleases. Subcloning of SfiI digested trastuzumab VL-Ck amplified 
using the primers (STJ#475 and STJ#476) and the template, pSTJ4-Herceptin IgG1 into 
SfiI digested pBADNlpAHis-M18 generated pBADNlpA-VL-Ck-His. PelB leader 
peptide fused trastuzumab VL-Ck was amplified using the primers (STJ#16 and 
STJ#340) and the template (pSTJ4-Herceptin IgG1), digesteted by XbaI / HindIII 
endonucleases and ligated into pBAD-NlpA-VL-Ck-His using the same restriction 
enzyme sites to generate pBADPelB-VL-Ck. pBADPelB-VL-Ck-NlpA-VL-Ck-His was 
constructed by ligating XbaI digested PCR fragments amplified using the primers 
(STJ#70 and STJ#332) and the template (pBADPelB-VL-Ck) into pBADNlpA-VL-Ck-
His digested using the same endonuclease. Trastuzumab heavy chains were amplified 
using the primers (STJ#474 and STJ#67) and the template pSTJ4-Herceptin IgG1 for 
pPelB-Herceptin(H)-FLAG, pPelB-Hercepin(H)-Fc5-FLAG, and pPelB-Herceptin(H)-
Fc2a-FLAG, respectively. For the expression of correctly assembled, homodimeric wild 
type Fc and Fc2a in the periplasmic space of E. coli, the plasmids pDsbA-Fc-FLAG and 
pDsbA-Fc2a-FLAG were constructed for the export of Fc via the DsbA signal peptide. 
The PCR amplified fragments were digested with SfiI, ligated into pPelBFLAG digested 
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with the same endonuclease to generate pPelB-Herceptin(H)-FLAG, pPelB-
Herceptin(H)-Fc5-FLAG and pPelB-Herceptin(H)-Fc2a-FLAG. 
  
 A2.2.5 Preparation of spheroplasts and FACS analysis  
Two plasmids, pBADPelB-VL-Ck-NlpA-VL-Ck-His and pPelB-Herceptin(H)-
FLAG, were co-transformed into E. coli Jude-1 (F' [ Tn10(Tetr) proAB+ lacIq 
∆(lacZ)M15] mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 ∆lacX74 deoR recA1 
araD139 ∆(ara leu)7697 galU galK rpsL endA1 nupG) (Kawarasaki et al., 2003) for the 
display of aglycosylated trastuzumab full length IgG1. Co-trasnformation of E. coli Jude-
1 with pBADPelB-VL-Ck-NlpA-VL-Ck-His and pPelB-Herceptin(H)-Fc5-FLAG were 
performed for the display aglycosylated trastuzumab-Fc5 full length IgG1. To display 
display aglycosylated trastuzumab-Fc2a full length IgG1, Jude-1 cells were co-
transformed with the plasmids, pBADPelB-VL-Ck-NlpA-VL-Ck-His and pPelB-
Herceptin(H)-Fc2a-FLAG. The transformed E. coli cells were cultured overnight at 250 
rpm at 37 °C in Terrific Broth (Becton Dickinson Diagnostic Systems Difco™, Sparks, 
MD) with 2% (wt/vol) glucose supplemented with chloramphenicol (50 µg/ml) and 
kanamycin (50 µg/ml). The overnight cultured cells were diluted 1:100 in fresh 7 ml of 
TB medium with chloramphenicol (50 µg/ml) and kanamycin (50 µg/ml) in 125 ml 
Erlenmeyer flasks. After incubation at 37°C for 2 h and cooling at 25°C for 20 min with 
250 rpm shaking, protein expression was induced with 1 mM of isopropyl-1-thio-D-
galactopyranoside (IPTG) and 0,2 % arabinose.  
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20 h after IPTG induction, 6 ml of the culture broth was harvested by 
centrifugation and washed two times in 1 ml of cold 10 mM Tris-HCl (pH 8.0). Cells 
were resuspended in 1 ml of cold STE solution (0.5 M Sucrose, 10 mM Tris-HCl, 10 mM 
EDTA, pH 8.0), incubated with rotating mixing at 37°C for 30 min, pelleted by 
centrifugation at 12,000 x g for 1 min and washed in 1 ml of cold Solution A (0.5 M 
Sucrose, 20 mM MgCl2, 10 mM MOPS, pH 6.8). The washed cells were incubated in 1 
ml Solution A with 1 mg/ml of hen egg lysozyme at 37°C for 15 min. After 
centrifugation at 12,000 x g for 1 min the resulting spheroplast pellets were resuspended 
in 1 ml of cold PBS. 300 µl of the spheroplasts were further diluted in 700 µl of PBS was 
labeled with 30 nM FcγRI-FITC to analyze the binding of FcγRI. For the FACS analysis 
of FcγRIIa binding, spheroplasts were incubated with 90 nM FcγRIIa C-terminal fused to 
GST (Berntzen et al., 2005), washed in 1 ml of PBS, and labeled with polyclonal goat 
anti-GST-FITC (Abcam, Cambridge, MA) diluted 1:200 in 1 ml of PBS. After incubation 
for 1 h with vigorous shaking at 25°C in dark condition, the mixture was pelleted by 
centrifugation at centrifuged at 12,000 x g for 1 min and resuspended in 1 ml of PBS. The 
fluorescently labeled spheroplasts were diluted in 2.5 ml of PBS and analyzed on BD 
FACSCalibur (BD Bioscience, San Jose, CA).  
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Table A2-1. Primers used in this study.  
Primer 
Name Primer nucleotide sequence (5’  3’) 
STJ#16 TTGTGAGCGGATAACAATTTC 
STJ#67 AATTCGGCCCCCGAGGCCCCTTTACCCGGGGACAGGGAGAGGCTCTTCTGCGTG 
STJ#70 CTACCTGACGCTTTTTATCGC 
STJ#144 TTTTAGGGGTCGACGACAAAACTCACACATGCCCACCGTG 
STJ#145 TTTAAGGGAAGCTTCTATTAGGCGCGCCCTTTGTCATCG 
STJ#147 GGCAAATTCTGTTTTATCAGACCGCTTCTG 
STJ#220 CAATTTTGTCAGCCGCCTGAGCAGAAG 
STJ#290 TTTTAGGGGTCGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCA 
CCG 
STJ#291 GGCCACCGGATATCTTATTATTTACCCGGGGACAGGGAGAGG 
STJ#332 GGGAATTCTAGACTATTAGCACTCTCCCCTGTTGAAGCTCTTTG 
STJ#340 TTTAAGGGAAGCTTCTATTAGCACTCTCCCCTGTTGAAGCTCTTTG 
STJ#422 CTAGGGAGCCGCGGGAGGAGCAGTACAACGGCGCGTACCGTGTGGTCAGCGTCCTC 
STJ#474 CGCAGCGAGGCCCAGCCGGCCATGGCGGAGGTTCAATTAGTGGAATCTG 
STJ#475 CGCAGCGAGGCCCAGCCGGCCATGGCGGATATTCAAATGACCCAAAGCCCG 
STJ#476 CGCAATTCGGCCCCCGAGGCCCCGCACTCTCCCCTGTTGAAGCTCTTTG 
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Table A2-2. Plasmids used in this study. 
Plasmids Relevant characteristics Reference or 
source 
pMoPac1 Cmr, lac promoter, tetA gene, C-terminal 
polyhistidine tag and c-myc tag 
(Hayhurst et al., 
2003) 
pMoPac12 Apr, lac promoter, tetA gene, skp gene, C-terminal 
polyhistidine tag and c-myc tag 
(Hayhurst et al., 
2003) 
pMoPac1-FLAG-M18 NlpA fused M18 scFv gene, C-terminal FLAG tag 
in pMoPac1 
(Jung et al., 2007) 
pPelBFLAG-M18 Cmr, lac promoter, tetA gene, skp gene, C-terminal 
FLAG tag 
This study 
pPelBFLAG-Fc IgG1-Fc gene in pPelBFLAG This study 
pPelBFLAG-Fc5 IgG1-Fc5 gene in pPelBFLAG This study 
pPelBFLAG-Fc2a IgG1-Fc2a gene in pPelBFLAG This study 
pMAZ360-M18.1-Hum-IgG M18.1 humanized IgG1 gene in pMAZ360 (Mazor et al., 
2007) 
pSTJ4-Herceptin IgG1 Trastuzumab IgG1 gene in pMAZ360-M18.1-
Hum-IgG1 
This study 
pSTJ4-Herceptin IgG1-Fc5 Trastuzumab IgG1-Fc5 gene in pMAZ360-M18.1-
Hum-IgG1 
This study 
pSTJ4-Herceptin IgG1-Fc2a Trastuzumab IgG1-Fc2a gene in pMAZ360-
M18.1-Hum-IgG1 
This study 
pPelB-Herceptin(H)- FLAG IgG1 heavy chain gene in pPelBFLAG This study 
pPelB-Herceptin(H)-Fc5-
FLAG 
IgG1-Fc5 heavy chain gene in pPelBFLAG This study 
pPelB-Herceptin(H)-Fc2a-
FLAG 
IgG1-Fc2a heavy chain gene in pPelBFLAG This study 
pDsbA DsbA signal sequence gene in pTrc99A This study 
pDsbA-Fc-FLAG DsbA fused IgG1-Fc gene, C-terminal FLAG tag in 
pTrc99A 
This study 
pDsbA-Fc5-FLAG DsbA fused IgG1-Fc5 gene, C-terminal FLAG tag 
in pTrc99A 
This study 
pDsbA-Fc2a-FLAG DsbA fused IgG1-Fc2a gene, C-terminal FLAG tag 
in pTrc99A 
This study 
pBAD30 Apr, BAD promoter (Guzman et al., 
1995) 
pBAD30-KmR Kmr, BAD promoter (Jung et al., 2007) 
pBADNlpAHis-M18 
 
NlpA fused M18 scFv, C-terminal polyhistidine tag 
in pBAD30 
This study 
pBAD-PelB-VL-Ck-His PelB fused trastuzumab VL-Ck domain, C-
terminal polyhistidine tag and c-myc tag in 
pBAD30-KmR 
This study 
pBAD-PelB-VL-Ck-NlpA-
VL-Ck-His 
PelB fused trastuzumab VL-Ck domain and NlpA 
fused trastuzumab VL-Ck-His in pBAD30-KmR 
This study 
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A2.3 RESULTS 
A2.3.1 Binding of Fc2a (S298G/T299A) and trastuzumab-Fc2a to human FcγRIIa 
DsbA leader peptide fused wild type Fc and Fc2a fragments were purified using 
Protein A affinity chromatography. Most of the purified wild type Fc and Fc2a were 
dimeric forms. (Fig. A2-1). For preparative production of aglycosylated trastuzumab and 
trastuzumab-Fc2a in E. coli, dicistronic plasmids, pSTJ4-Herceptin-IgG1 and pSTJ4-
Herceptin-Fc2a-IgG1, were constructed. Using the Fed-batch fermentation with pH-stat 
glucose feeding strategy, full length aglycsoylated wild type trastuzumab or trastuzumab-
Fc2a antibodies were produced. The trastumab antibodies produced in E. coli periplasmic 
space were released with incubation in the solution containing lysozyme and EDTA, and 
purified using Protein A affinity chromatography followed by size exclusion 
chromatography. The binding affinity of purified homodimeric mutant Fc fragments 
(Fc2a) or aglycosylated trastuzumab-Fc2a to extracellular domain of FcγRIIa was 
analyzed by ELISA. As expected, the aglycosylated Fc mutant full length tratuzumab 
(S298G/T299A) exhibited similar high binding affinity to FcγRIIa with glycosylated full 
length trastuzumab. In contrast, purified homodimeric Fc fragments engineered for 
FcγRIIa (S298G/T299A) did not show binding affinity to extracellular domain of 
FcγRIIa (Fig. A2-2) suggesting the structural and functional roles of Fab arms for the 
binding of the FcγRIIa receptor proteins. 
  
146
M
25
50
100
37.5
20
1
15
10
2
250
150
75
 
 
Figure A2-1. Purified wild type Fc and Fc2a proteins. Lane M: M.W. standards; Lane 
1: Wild type Fc; Lane 2; Fc2a (S298G/T299A). 
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Figure A2-2. ELISA assays showing the affinity of aglycosylated Fc fragment (Fc2a) 
and aglycosylated full length trastuzumab-Fc2a to FcγRIIa. 
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 A2.3.2 FACS analysis for the covalently anchored full length IgG display system to 
engineer IgG heavy chain 
To use bacterial full length IgG display system for library screening, four factors 
should be considered. Firstly, IgG heavy chains and light chains must be well expressed. 
Secondly, the heavy and light chains should be assembled well in E. coli. Thirdly, 
binding ligands should be accessible to the full length IgG in bacterial cells. Finally, the 
anchoring of the displayed full length IgG should be robust during library screening. Two 
plasmids co-expression system was used for stable and covalent anchoring of full length 
IgG (Fig. A2-3). 
 
Cytoplasm
Full length IgG
CDQSSS
Plac
HisPBAD SD
CH2 CH3CH1VH1SD PelB FLAG
PelB CκVL NlpA CκVL
 
Figure A2-3. Covalently anchored full length IgG display system. 
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The pBADPelB-VL-Ck-NlpA-VL-Ck-His plasmid enables the expression of the 
NlpA leader peptide fused IgG light chain (VL-Ck) and the PelB leader peptide fused 
IgG light chain (VL-Ck). Thus a portion of the light chain becomes anchored on the 
periplasmic side of the inner membrane where it associates with heavy chain to produce 
tetrameric full length, IgG. pPelB-Herceptin(H)-FLAG is a high copy number plasmid 
encoding the IgG heavy chain under the control of the lac promoter. 
For affinity maturation using FACS sorting method based on gating selective 
fluorescence and scattering regions, it is required to get distinguishable high or low 
fluorescence signal comparing a negative control with low coefficient of variation (CV = 
[Standard Deviation/Mean Value] × 100). For full length trastuzumab antibodies, the 
fluorescense profile of spheroplasts expressing inner membrane anchored IgG (via the 
NlpA-VL-Ck polypeptide) and spheroplasts expressing soluble IgG from a dicistronic 
vector system (Mazor et al., 2007) were compared. The 2 plasmids anchored full length 
IgG display system clearly exhibited dramatically improved signal intensity and CV 
value upon labeling with FcγRI-FITC. The fluorescence signal for the anchored full 
length IgG display system was tested with cells cultured at 12 °C or 25 °C in TB. 
Spheroplasts generated from trastuzumab-Fc5 displaying cells using the 2 plasmids 
covalently anchored full length IgG display system cultured at 25 °C exhibited much 
higher fluorescence and improved CV upon labeling with FcγRI-FITC relative to 
spheroplasts expressing a wild type trastuzumab (Fig A2-4). Also, in the FACS analysis 
to measure the affinity of spheroplasts for FcγRIIa-GST (Fig. A2-5), 2 plasmids 
covalently anchored full length IgG display system cultured at 25 °C in TB showed 
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surprisingly improved signal intensity and CV providing a selective display system for 
real affinity maturation of full length IgG (Fig. A2-6 and Fig. A2-7).  
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Figure A2-4. Fluorescence histograms showing the binding of FcγRI using either the 2- 
plasmid system or the dicistronic system. Trastuzumab full length IgG was expressed 
using either the 2 plasmid anchored full length IgG display system or the dicistronic full 
length IgG display system. Spheroplasts were incubated with 30 nM FcγRI-FITC probe 
for detection. M: Mean fluorescence intensity. 
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Figure A2-5. Fluorescence histograms showing the binding of FcγRIIa using either the 
2-plasmid system or the dicistronic system. Trastuzumab full length IgG was expressed 
using either the 2 plasmid anchored full length IgG display system or dicistronic full 
length IgG display system. Spheroplasts were incubated with 30 nM FcγRIIa-GST and 
labeled with polyclonal anti-GST-FITC (1:200) probe for detection. M: Mean 
fluorescence intensity. 
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Figure A2-6. FACS analysis of cells displaying covalently anchored full length IgG 
expressed by 2 plasmids and bound by FcγRI. Spheroplasts expressing trastuzumab full 
length IgGs were incubated with 30 nM FcγRI-FITC probe for detection. M: Mean 
fluorescence intensity. 
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Figure A2-7. FACS analysis of cells displaying covalently anchored full length IgG 
expressed by 2 plasmids and bound by FcγRIIa. Spheroplasts expressing trastuzumab full 
length IgGs were incubated with incubated with 30 nM FcγRIIa-GST and labeled with 
polyclonal anti-GST-FITC (1:200) probe for detection. M: Mean fluorescence intensity. 
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A2.4 DISCUSSION 
Spheroplasts displaying homodimeric Fc fragments were unable to bind to 
FcγRIIa and therefore not sutible for library screening purposes. While antibodies 
engineered to bind to FcRIIa in the absence glycosylation behaved as reported, the 
respective Fc domains did not display any binding. Consequently it was determined that a 
system for the display of full length IgG needs to be developed in order to isolate mutants 
that bind the low affinity receptors with biologically relevant affinities. For the display of 
full length IgG, a 2-plasmid system was employed. In the low copy number dicistonic 
expression system, antibody light chains (VL-Ck) were expressed with PelB leader 
peptide for soluble expression and NlpA leader petide for inner membrane anchoring by 
the lipidation of cystein followed by the NlpA signal sequence. Antibody heavy chains 
were fused to N-terminal PelB leader peptide and were expressed from the high copy 
number plasmids pMopac12 also containing the gene for the Skp chaperone which can 
assist the folding of many antibodies. Tetrameric full length IgG is formed by the 
covalent disulfide bonds between two heavy chains and between heavy chain and light 
chain in oxidized E. coli periplasmic space. Under optimized culture conditions, 
spheroplasts displaying aglycosylated full length trastuzumab-Fc5 (which binds to FcγRI) 
or trastuzumab-Fc2a (which binds to FcγRIIa) generated excellent FACS signal relative 
to spheroplasts displaying wild type trastuzumab upon labeling with FcγRI-FITC or 
FcγRIIa-GST followed by GST specific fluorescent secondary antibodies.  
It has been known that FcγRs bind to lower hinge region and upper CH2 region 
(Jefferis et al., 1998). Thus, homodimeric Fc fragments should be capable of binding to 
FcγRs. However, we found that, in the case of aglycosylated antibodies, the presence of 
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the antigen binding fragments (Fab) also contributes significantly to binding to FcγRs. 
One possibility is that the Fab arms might affect the flexibility of Fc hinge region or the 
conformation of hinge-CH2 region leading to a change the affinity towards FcγRs.  
The E. coli anchored full-length IgG display system described in this Appendix 
allows the interaction between full length IgG and IgG binding ligands including FcγRs. 
This system could be exploited for the screening of aglycosylated full length IgG 
exhibiting altered binding affinity to Fc receptors (FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, 
and FcRn) with novel or improved effector functions.  
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Appendix 3 
E. coli 2 Hybrid Systems for Engineering of Aglycosylated Antibody Fc 
A3.1 INTRODUCTION 
 To identify mutations that allow aglycosylated Fc to bind to the extracellular 
domain of Fcγ receptors, C1q, or FcRn, it was necessary to develop an E. coli display 
system suitable for the screening of Fc combinatorial libraries. For the bacterial display 
of dimeric antibody Fc domains three factors should be considered: Firstly, the Fc 
domain of antibody should be encoded by single gene to prevent the formation of 
heterodimers. Secondly, the Fc proteins should be expressed in a cellular compartment 
that enables correct folding and assembly. In E. coli the periplasmic space provides an 
oxidative environment for the formation of disulfide bonds and is suitable for the 
production of correctly folded and dimerized heterologous protein (Georgiou and 
Segatori, 2005). Finally, for the efficient isolation of cells displaying high affinity 
variants, the Fc proteins should stably be anchored to the cells. Proteins that are weakly 
bound onto spheroplasts are not suitable for screening purposes because they can 
contaminate other cells displaying different varainrs and reduce the efficiency of 
enrichment of positive clones. Here we attempted to develop a 2 hybrid display system 
for aglycosylated homodimeric Fc domains. 
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A3.2. MATERIALS AND METHODS 
 A3.2.1 Reagents 
Oligonucleotides primers and restriction endonucleases were obtained from 
Integrated DNA Technologies (Coralville, IA) and New England Biolabs (Ipswich, MA), 
respectively. Taq Polymerase and FITC protein labeling kit were from Invitrogen 
(Carlsbad, CA). Recombinant human FcγRI/CD64 was purchased from R&D Systems 
(Minneapolis, MN). Trehalose was obtained from Fisher Scientific (Fair Lawn, NJ).   
Human IgG-Fc and Rabbit anti-ECS antibody peroxidase conjugated were from Bethyl 
Laboratories (Montgomery, TX). Digoxigenin-BODIPY (Digoxigenin-4,4-difluoro-5,7-
dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl ethtylenediamine) was synthesized 
as described previously (1). PA-FITC was obtained from List Biological Laboratories 
(Campbell, CA). Protein A-FITC and analytical grades of all other chemical reagents 
were purchased from Sigma-Aldrich (St. Louis, MO) unless stated otherwise. 
 
A3.2.2 Construction of plasmids for the display of homodimeric IgG-Fc 
All plasmids and primers used in this study are described in Table A3-1 and 
TableA3-2. Plasmid pPelBHis was generated by ligating BamHI-HindIII digested skp 
gene from pMopac12 into pMopac1 digested with the same restriction endonucleases. 
pPelBFLAG was derived from pPelBHis in which polyhistidine tag and c-myc tag were 
replaced by FLAG tag (DYKDDDDK). Subcloning of PCR amplified and SfiI digested 
Fc gene encoding human IgG1-Fc fragment, hinge, CH2 and CH3 region of human IgG1 
heavy chain (GeneBank Accession No. AF237583) into SfiI digested pPelBHis and 
  
156
pPelBFLAG generated pPelBHis-Fc and pPelBFLAG-Fc, respectively. pPelBHis-beta 2 
microglobulin was constructed by subcloning soluble mature human beta 2 microglobulin 
gene synthesized from overlap PCR amplification using 10 primers including 2 external 
primers (STJ#78 and STJ#84) and 8 internal primers (STJ#86-93) into pPelBHis using 
SfiI restriction endonuclease site. pPelBHis-FcγRIIa was generated by introducing SfiI 
digested soluble mature human FcγRIIa gene (GeneBank Accession No. P12318) (2) 
amplified from pDNR-LIB-FcrRIIa (ATCC: MGC-23887) using primers STJ#74 and 
STJ#80 into pPelBHis. SfiI digested genes from pMoPac1-FLAG-M18 and pMoPac1-
FLAG-2610 for M18 scFv (3) and 26-10 scFv (4) specific for the PA antigen of Bacillus 
anthracis and cardiac glycoside digoxin, respectively, were introduced to pPelBFLAG to 
generate pPelBFLAG-M18 scFv and pPelB-2610 scFv. 
pNlpAFLAG-M18 was constructed by ligating XbaI–HindIII digested fragments 
for NlpA and 6 amino acid residues (CDQSSS) fused M18 scFv gene from pMopac1-
FLAG-M18 into pPelBFLAG-M18. pNlpAHis-Fc was generated by subcloning SfiI 
digested Fc gene into pNlpAFLAG-M18 and by replacing FLAG with polyhistidine tag 
and c-myc tag. pBADNlpAFLAG-M18 and pBADNlpAHis-Fc were generated by 
ligating XbaI–HindIII digested M18 scFv gene and Fc gene from pNlpAFLAG-M18 and 
pNlpAHis-Fc, respectively, into pBAD30 digested with same restriction endonucleases.  
To display Fc domain using the leucine zipper pair of cJun-cFos, NotI–SalI 
digested cFos fragments amplified using two primers (STJ#68 and STJ#69) and the 
cFos(Cys) fragments encoding additional three amino acids including internal two Gly 
residues and external Cys residue at both ends of C-terminus and N-terminus amplified 
using two primers (STJ#96 and STJ#97) were cloned into pPelBHis-Fc to make 
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pPelBHis-Fc-cFos for non-covalent bonding of cJun-cFos interaction pair and pPelBHis-
Fc-cFos(Cys) for covalent disulfide bonding of both N terminal and C terminal ends of 
cJun-cFos pair in E. coli periplasmic space. For anchoring periplasmic expressed Fc 
domain fused to cFos or cFos(Cys), pBADNlpAFLAG-cJun and pBADNlpAFLAG-
cJun(Cys) were generated by subcloning SfiI digested cJun fragments amplified with 
primers (STJ#58 and STJ#59) and cJun(Cys) fragments amplified with primers (STJ#94 
and STJ#95) into SfiI digested pBADNlpAFLAG-M18. 
For the display of Fc using tight ColE2–Im2 interaction, Im2 gene that is PCR 
amplified using two primers (ST#116 and STJ#117) and template E. coli WTZ1011 
ColE2 harboring plasmid ColE2-P9 (The Coli Genetic Stock Center, Yale Univ. CGSC  
No. 8203) (5) was NotI-SalI digested and ligated into pPelBFLAG-Fc, pPelBFLAG-M18, 
and pPelBFLAG-2610 to generate pPelBFLAG-Fc-Im2, pPelBFLAG-M18-Im2, and 
pPelbFLAG-2610-Im2. To construct plasmids encoding NlpA-fused ColE2 mutants 
binding to Im2 with strong protein protein interaction, the catalytic domains of three 
ColE2 mutants were amplified by overlap PCR with the template plasmid used for Im2 
gene amplification and with four primers including two common external primers 
(STJ#114 and STJ#115) and two internal reverse primers (STJ#120 and STJ#121) for 
ColE2(H574A), internal primers (STJ#118 and STJ#119) for ColE2(H578A), and  
internal primers (STJ#122 and STJ#123) for ColE2(H574A/H578A), respectively. The 
amplified PCR products were SfiI digested and introduced into pBADNlpAHis to 
generate pBADNlpAHis-ColE2(H574A), pBADNlpAHis-ColE2(H578A), and 
pBADNlpAHis-ColE2(H574A/H578A). 
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Subcloning of SfiI digested M18.1 hum scFv (1) and 26-10 scFv gene into 
pMopac12 generated pMopac12-M18.1 hum scFv and pMopac12-2610 scFv. Also, 
subcloning of the SfiI digested M18.1 hum scFv and 26-10 scFv into pMopac16 
generated pMopac16-M18 scAb and pMopac16-2610 scAb. For pTrcdsabAHis-Fc and 
pTrcdsbAHis-FcγRIIa, Fc and FcγRIIa gene fragments were PCR amplified using  
primers (STJ#144 and STJ#139) with the templates pPelBHis-Fc for Fc gene and  
primers (STJ# 136 and STJ#139) with the template pPelB-FcγRIIa for FcγRIIa gene, 
respectively, SalI-HindIII digested, and ligated into dsbA signal sequence (6) inserted 
into pTrc99A. All plasmids were transformed into E. coli Jude-1(F' [Tn10(Tetr) proAB+ 
lacIq ∆(lacZ)M15] mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 ∆lacX74 deoR recA1 
araD139 ∆(ara leu)7697 galU galK rpsL endA1 nupG) (Kawarasaki et al., 2003). 
 
A2.2.3 Culture conditions for two plasmids system 
For the periplasmic display using leucine zippers, cJun-cFos, pPelBHis-Fc-cFos 
and pPelBHis-Fc-cFos(Cys) were co-transformed with pBADNlpAFLAG-cJun or 
pBADNlpAFLAG-cJun(Cys) into E. coli Jude-1. To display Fc using the interaction of 
ColE2-Im2, plasmids pPelBFLAG-Fc-Im2, pPelB-M18 scFv-Im2, or pPelBFLAG-2610 
scFv-Im2 were co-transformed with either pBADNlpAHis-ColE2(H574A), 
pBADNlpAHis-ColE2(H578A), or pBADNlpAHis-ColE2(H574/578) respectively 
containing single or double mutations at C-terminal ColE2 DNase catalytic domain. The 
transformants harboring two plasmids were grown overnight at 37°C with 250 rpm 
shaking in Terrific Broth (TB) (Becton Dickinson Diagnostic Systems DIFCO™, Sparks, 
MD) supplemented with 2% (wt/vol) glucose, chloramphenicol (40 µg/ml) and ampicillin 
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(50 µg/ml). After overnight culture, the cells were diluted 1:100 in fresh TB medium 
without glucose, incubated at 37 °C for 2 h and then cooled at 25°C for 20 min. Firstly, 
PelB signal sequence fused proteins were induced with 1 mM of isopropyl-1-thio-β-D-
galactopyranoside (IPTG) to allow time for correct folding in periplasmic space prior to 
binding to inner membrane anchored ColE2 mutants. And 2 h after IPTG induction, 0.2% 
(wt/vol) arabinose was added to induce expression of inner membrane anchored cJun, 
cJun(Cys), ColE2(H574A), ColE2(H578A), or ColE2(H574A/H578A). 
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Table A3-1. Plasmids used in this study. 
Plasmids Relevant characteristics Reference or 
source 
pMoPac1 Cmr, lac promoter, tetA gene, C-terminal polyhistidine tag 
and c-myc tag 
(Hayhurst et al., 
2003) 
pMoPac12 Apr, lac promoter, tetA gene, skp gene, C-terminal 
polyhistidine tag and c-myc tag 
(Hayhurst et al., 
2003) 
pMoPac16 Apr, lac promoter, tetA gene, HuCκ gene, skp gene, C-
terminal polyhistidine tag and c-myc tag 
(Hayhurst et al., 
2003) 
pMoPac1-FLAG-M18 NlpA fused M18 scFv gene, C-terminal FLAG tag in 
pMoPac1 
(Jung et al., 2007) 
pMoPac1-FLAG-2610 NlpA fused 26-10 scFv gene, C-terminal FLAG in 
pMoPac1 
(Jung et al., 2007) 
pPelBHis Cmr, lac promoter, tetA gene, skp gene, C-terminal 
polyhistidine tag and c-myc tag 
This study 
pPelBHis-Fc IgG1-Fc gene in pPelBHis This study 
pPelBHis-beta 2 microglobulin Human beta 2 microglobulin gene in pPelBHis This study 
pPelBHis-FcγRIIa FcγRIIa gene in pPelBHis This study 
pPelBHis-Fc-cFos IgG1-Fc gene fused to C-terminal cFos gene in pPelBHis This study 
pPelBHis-Fc-cFos(Cys) IgG1-Fc gene fused to C-terminal cFos(Cys) gene in 
pPelBHis 
This study 
pPelBFLAG Cmr, lac promoter, tetA gene, skp gene, C-terminal FLAG 
tag 
This study 
pPelBFLAG-Fc IgG1-Fc gene in pPelBFLAG This study 
pPelBFLAG-M18 scFv M18 scFv gene in pPelBFLAG This study 
pPelBFLAG-2610 scFv 26-10 scFv gene in pPelBFLAG This study 
pPelBFLAG-Fc-Im2 IgG1-Fc gene fused to C-terminal Im2 gene in pPelBFLAG This study 
pPelBFLAG-M18 scFv-Im2 M18 scFv gene fused to C-terminal Im2 gene in 
pPelBFLAG 
This study 
pPelBFLAG-2610 scFv-Im2 26-10 scFv gene fused to C-terminal Im2 gene in 
pPelBFLAG 
This study 
pMopac12-M18.1 hum scFv M18.1 humanized scFv gene in pMoPac12 This study 
pMopac12-2610 scFv 26-10 scFv gene in pMoPac12 This study 
pMopac16-M18.1 hum scab M18.1 humanized scAb gene in pMoPac16 This study 
pMopac16-2610 scAb 26-10 scAb gene in pMoPac16 This study 
pMAZ360-M18.1-Hum-IgG M18.1 humanized IgG1 gene in pMAZ360 (Mazor et al., 2007) 
pMAZ360-26.10 IgG 26-10 IgG1 gene in pMAZ360 (Mazor et al., 2007) 
pNlpAFLAG-M18 NlpA fused M18 scFv gene in pPelBFLAG This study 
pNlpAHis-Fc NlpA fused IgG-Fc gene in pPelBHis This study 
pBAD30 Apr, BAD promoter (Guzman et al., 1995) 
pBADNlpAFLAG-M18 NlpA fused M18 scFv gene, C-terminal FLAG tag in 
pBAD30 
This study 
pBADNlpAFLAG-cJun NlpA fused cJun gene, C-terminal FLAG tag in pBAD30 This study 
pBADNlpAFLAG-cJun(Cys) NlpA fused cJun(Cys) gene, C-terminal FLAG in pBAD30 This study 
pBADNlpAHis-Fc NlpA fused IgG-Fc gene, C-terminal polyhistidine tag in 
pBAD30 
This study 
pBADNlpAHis-ColE2(H574A) NlpA fused ColE2(H574A) gene, C-terminal polyhistidine 
tag in pBAD30 
This study 
pBADNlpAHis-ColE2(H578A) NlpA fused ColE2(H578A) gene, C-terminal polyhistidine 
tag in pBAD30 
This study 
pBADNlpAHis-
ColE2(H574A/H578A) 
NlpA fused ColE2(H574A/H578A) gene, C-terminal 
polyhistidine tag in pBAD30 
This study 
pTrc99A Apr, trc promoter, lacIq Amersham Biosci., 
(Piscataway, NJ) 
pTrcdsbAHis-Fc dsbA fused IgG-Fc gene, C-terminal FLAG tag in pTrc99A This study 
pTrcdsbAHis-FcγRIIa dsbA fused FcγRIIa gene, C-terminal polyhistidine tag in 
pTrc99A 
This study 
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Table A3-2. Primers used in this study. (Underlining indicates the restriction enzyme 
sites) 
Primer 
Name Primer nucleotide sequence (5’  3’) 
STJ#16 TTGTGAGCGGATAACAATTTC 
STJ#58 CGAACTGGCCCAGCCGGCCATCGCCCGGCTAGAGGAAAAAG 
STJ#59 CGAACTGGCCCCCGAGGCCCGGTGGTTCATGACTTTCTGTTTAAG 
STJ#68 GATATCGCGGCCGCACTGACCGACACCCTGCAGG 
STJ#69 TTTTAGGGGTCGACTGCGGCGTGTGCCGCCAGGATGAAC 
STJ#74 CGCAGCGAGGCCCAGCCGGCCATGGCGCAAGCTGCTCCCCCAAAGGC 
STJ#78 CGCAGCGAGGCCCAGCCGGCCATGGCGATCCAGCGTACTCCAAAGATTC 
STJ#80 CGCAATTCGGCCCCCGAGGCCCCAATGACCCCCATTGGTGAAGAG 
STJ#84 CGCAATTCGGCCCCCGAGGCCCCCATGTCTCGATCCCACTTAAC 
STJ#86 CAGCGTACTCCAAAGATTCAGGTTTACTCACGTCATCCAGCAGAGAATGGAAAG 
STJ#87 CAGCAGAGAATGGAAAGTCAAATTTCCTGAATTGCTATGTGTCTGGGTTTCATC 
STJ#88 CTATGTGTCTGGGTTTCATCCATCCGACATTGAAGTTGACTTACTGAAGAATGG 
STJ#89 GTTGACTTACTGAAGAATGGAGAGAGAATTGAAAAAGTGGAGCATTCAGACTTG 
STJ#90 GTACAAGAGATAGAAAGACCAGTCCTTGCTGAAAGACAAGTCTGAATGCTCCAC 
STJ#91 ACTCATCTTTTTCAGTGGGGGTGAATTCAGTGTAGTACAAGAGATAGAAAGACC 
STJ#92 CTGTGACAAAGTCACATGGTTCACACGGCAGGCATACTCATCTTTTTCAGTGGG 
STJ#93 CATGTCTCGATCCCACTTAACTATCTTGGGCTGTGACAAAGTCACATGG 
STJ#94 CGAACTGGCCCAGCCGGCCATGGCGTGCGGCGGCATCGCCCGGCTAGAGGAAAA 
STJ#95 CGAACTGGCCCCCGAGGCCCGGCAGCCGCCGTGGTTCATGACTTTCTGTTTAAG 
STJ#96 GATATCGCGGCCGCATGCGGCGGCCTGACCGACACCCTGCAGG 
STJ#97 TTTTAGGGGTCGACTGCGGCGCAGCGCCGTGTGCCGCCAGGATGAAC 
STJ#114 GACGAACTGGCCCAGCCGGCCATGGCGGAGAGTAAACGGAATAAGCCAGGGAAG 
STJ#115 GCGAACTGGCCCCCGAGGCCCCCTTACCCCGATGAATATCAATATGTCGCTTAG 
STJ#116 CGAGATATCGCGGCCGCAATGGAACTGAAACATAGTATTAGTGATTATACCGAG 
STJ#117 GTTTTAGGGGTCGACTGCGGCGCCCTGTTTAAATCCTGACTTACCGTTAGC 
STJ#118 CTTACCCCGATGAATATCAATCGCTCGCTTAGGTGTGGTCACTCTGATATTATT 
STJ#119 GCGAACTGGCCCCCGAGGCCCCCTTACCCCGATGAATATCAATCGCTCGCTTAG 
STJ#120 CTTACCCCGCGCAATATCAATATGTCGCTTAGGTGTGGTCACTC 
STJ#121 GCGAACTGGCCCCCGAGGCCCCCTTACCCCGCGCAATATCAATATGTCGCTTAG 
STJ#122 CTTACCCCGCGCAATATCAATCGCTCGCTTAGGTGTGGTCACTCTGATATTATT 
STJ#123 GCGAACTGGCCCCCGAGGCCCCCTTACCCCGCGCAATATCAATCGCTCGCTTAG 
STJ#136 TTTTAGGGGTCGACCAAGCTGCTCCCCCAAAGGCTG 
STJ#139 TTTAAGGGAAGCTTCTATCAATGGTGGTGGTGGTGGTGGTGATG 
STJ#144 TTTTAGGGGTCGACGACAAAACTCACACATGCCCACCGTG 
STJ#194 CTAGGGAGCCGCGGGAGGAGCAGTACAACNNSNNSNNSNNSNNSNNSNNSNNSNNSNNS 
AGCACGTACCGTGTGGTCAGCG 
STJ#195 CTAGAGGAATTCGGCCCCCGAGGCCCCTTTAC 
STJ#196 CGCAGCGAGGCCCAGCCGGCCATGGCG 
STJ#197 CGCAATTCGAATTCGGCCCCCGAGGCCCC 
STJ#220 CAATTTTGTCAGCCGCCTGAGCAGAAG 
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A3.3 RESULTS 
Initially, display of Fc was attempted using the leucine zipper interaction between 
cJun and cFos interaction for tethering onto the inner membrane. The repetitive leucine 
residues at every seven amino acid of cJun and cFos allow for a strong non-covalent 
interaction between the two proteins (Kouzarides and Ziff, 1988; Landschulz et al., 
1988). Expression of cFos-fused Fc from pPelBHis-Fc-cFos was induced first and 
followed by induction of protein synthesis from the pBADNlpAFLAG-cJun encoding a 
fusion between the cJun domain and the NlpA leader sequence and six amino acid 
residues (CDQSSS) (Fig. A3-1). In separate studies, to ensure covalent attachment 
between cJun and cFos three amino acid residues including one external Cys and two 
internal Gly were introduced to the N and C terminal ends of both cJun and cFos. The 
resulting cJun(Cys)–cFos(Cys) allows the formation of a disulfide bond between the two 
leucine zippers in the periplasmic space (de Kruif and Logtenberg, 1996). With the APEx 
displayed pNlpAHis-Fc as a positive control and the pNlpAFLAG-cJun(Cys) not 
anchoring Fc domains as a negative control, the two Fc display systems were analyzed by 
flow cytometry after spheroplasting and incubation with Protein A-FITC (Fig. A3-2A). 
As expected, the periplasmic Fc display system employing engineered cJun(Cys)–
cFos(Cys) showed higher fluorescence signal compared with native cJun–cFos 
suggesting improved anchoring of the Fc domain to inner membrane. However, when the 
system was compared with other negative controls that express only periplasmic Fc 
domains without co-expression of anchoring partner cJun or cJun(Cys), it did not show a 
high signal selectively. Additionally, the spheroplasts harboring pPelBFLAG-Fc for 
expression of soluble periplasmic Fc secreted via the PelB leader peptide without an 
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additional inner membrane anchoring motif showed very high fluorescence signal 
suggesting that periplasmically expressed Fc proteins remain bound to the cells without 
an inner membrane anchoring motif even after spheroplasting (Fig. A3-2B). 
To achieve a stronger tethering of Fc onto spheroplasts, display using stronger 
protein-protein interaction pairs compared to leucine zippers was also considered. The 
ColE2–Im2 protein interaction pair, represents one of the tightest protein-protein 
interactionw in nature (KD= 10-15) (Li et al., 2004). To display homodimeric Fc using the 
ColE2-Im2 interaction, Im2 fused-Fc was firstly induced for periplasmic Fc assembly and 
then the expression of ColE2 mutants fused to the NlpA leader sequence and six amino 
acids (CDQSSS) was induced for inner membrane anchoring (Fig. A3-3). To prevent 
autodegradation of host DNA, the zinc binding histidines (H574, H578) were substituted 
to Ala by site directed mutagenesis (Garinot-Schneider et al., 1996). The resulting three 
mutants (H574A, H578A, or H574A/H578A) could inhibit host DNase activity while 
retaining Im2 binding (data not shown). Of the three ColE2 mutants, the single mutant, 
ColE2 (H578A) showed the best result for the display of Im2 fused 26-10 scFv on the 
FACS analysis detected by digoxin BODIPY (data not shown). The utility of the display 
system using the ColE2 (H578A)–Im2 interaction was further investigated with M18 
scFv, 26-10 scFv, and also with homodimeric Fc. Im2 fused antibodies, M18 scFv-Im2 
and 26-10 scFv-Im2 showed selectively higher fluorescence signal compared with 
negative controls, M18 scFv and 26-10 scFv not fused to Im2, respectively. However, the 
higher signals appeared to be due to differences in expression levels. When ColE2 was 
not expressed, M18 scFv, 26.10 scFv, and Fc were well expressed. However, the 
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expression of ColE2 with Im2 or without Im2 inhibited the expression of M18 scFv, 26-
10 scFv and of Fc partially or completely, respectively (Fig. A3-4). 
 
 
 
 
 
Figure A3-1. Two plasmids system for the periplasmic display of Fc using cJun-cFos or 
cJun(Cys)-cFos(Cys) interaction. 
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B
 
 
Figure A3-2. FACS analysis results of periplasmic displayed Fc homodimer using cJun-
cFos and cJun(Cys)-cFos(Cys) interaction pairs. (A) FACS signals of periplasmic 
displayed Fc using cJun-cFos and cJun(Cys)-cFos(Cys) were compared with a positive 
and a negative controls. (B) FACS signals of periplasmic displayed Fc using cJun-cFos 
and cJun(Cys)-cFos(Cys) were compared with one plasmid systems not co-expressing 
NlpA and 6 amino acid residues (CDQSSS) fused cJun or cJun(Cys). Spheroplasts were 
incubated with Protein A-FITC probe for detection. Mn: Mean fluorescence intensity. 
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Figure A3-3. Two plasmids system for the periplasmic display of Fc using ColE2-Im2 
interaction. 
 
 
 
 
 
 
Figure A3-4. Effect of ColE2 on the expression of target proteins, M18 scFv (Lane 1-3), 
26-10 scFv (Lane 4-6), and Fc (Lane 7-9). In lane 1, 4 and 7, Im2 fused proteins were co-
expressed with APEx displayed ColE2(H578A). In lane 2, 5 and 7, Im2 fused proteins 
were expressed without APEx displayed ColE2(H578A). In lane 3, 6 and 9, proteins 
without Im2 fusions were co-expressed APEx displayed ColE2(H578A). Anti-FLAG 
antibody peroxidase conjugated was used as a detection antibody for Western blot. 
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A3.4 DISCUSSION 
In this study, two different 2 hybrid systems were constructed and employed for 
the display system of homodimeric IgG Fc domains onto spheroplasted E.coli. Secreted 
Fc domains were fused to heterodimerization domains (cFos or Im2) and co-expressed 
with heterodimerziation partners (cJun (Kouzarides and Ziff, 1988; Landschulz et al., 
1988) or ColE2 (Garinot-Schneider et al., 1996; Li et al., 2004), respectively), N-
terminally fused to the inner membrane anchor NlpA(1-6) (Harvey et al., 2004). The 
fluorescence signal to noise ratio obtained following labeling with Protein A-FITC was 
not suitable for library screening purposes. However, in the course of these studies, we 
found that the retention of soluble, secreted Fc domain proteins onto spheroplasted cells 
was highly dependent on the growth conditions. Optimal specific labeling with Protein 
A-FITC was obtained in cells expressing Fc secreted with a PelB leader peptide and 
grown at 25 ºC in the presence of 0.5 M treaholose, as discussed in chapter 2. Under 
these conditions spheroplasts expressing the Fc protein exhibited 10 fold higher 
fluorescence than the control. Under the optimized conditions, a library encoding Fc 
mutant domains followed by a FLAG tag and preceded by a PelB signal peptide for 
secretion into the periplasm was constructed. E. coli cells expressing high affinity Fc 
domain to Fc binding ligands could be sorted by flow cytometry after spheroplasting and 
labeling with fluorophore-conjugated Fc domain binding ligands. 
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